BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08399 A2

(51) International Patent Classification[7]: C12N 9/00

(21) International Application Number: PCT/US01/23092

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/220,038	21 July 2000 (21.07.2000)	US
60/222;112	28 July 2000 (28.07.2000)	US
60/222,831	4 August 2000 (04.08.2000)	US
60/224,729	11 August 2000 (11.08.2000)	US

(71) Applicant *(for all designated States except US)*: **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(71) Applicant and
(72) Inventor: **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **KHAN, Farrah, A.** [IN/US]; 3617 Central Road #102, Glenview, IL 60025 (US). **GURURAJAN, Rajagopal** [IN/US]; 5591 Dent Avenue, San Jose, CA 95118 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street #205, San Leandro, CA 94577 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue, #1, Menlo Park, CA 94025 (US). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **TRIBOULEY, Catherine, M.** [US/US]; 1121 Tennessee Street, #5, San Francisco, CA 94107 (US). **BANDMAN, Olga** [US/US]; 366 Anna Avenue, MT. View, CA 94043 (US). **NGUYEN, Danniel, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **BURFORD, Neil** [US/US]; 105 Wildwood Circle, Durham, CT 06422 (US). **LAL, Preeti** [US/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **DING, Li** [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). **RECIPON, Shirley, A.** [US/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). **KEARNEY, Liam** [IE/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **GREENWALD, Sara, R.** [US/US]; 21 Bucareli Drive, San Francisco, CA 94132 (US). **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **XU, Yuming** [US/US]; 1739 Walnut Drive, Mountain View, CA 94040 (US). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB). **GIETZEN, Kimberly, J.** [US/US]; 691 Los Huecos Drive, San Jose, CA 95123 (US). **YANG, Junming** [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). **HILLMAN, Jennifer, L.** [US/US]; 230 Monroe Drive, #17, Mountain View, CA 94040 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associatedd withd abberant expression of PKIN.

WO 02/08399 A2

HUMAN KINASES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human kinases and to the use of these sequences in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

BACKGROUND OF THE INVENTION

Kinases comprise the largest known enzyme superfamily and vary widely in their target molecules. Kinases catalyze the transfer of high energy phosphate groups from a phosphate donor to a phosphate acceptor. Nucleotides usually serve as the phosphate donor in these reactions, with most kinases utilizing adenosine triphosphate (ATP). The phosphate acceptor can be any of a variety of molecules, including nucleosides, nucleotides, lipids, carbohydrates, and proteins. Proteins are phosphorylated on hydroxyamino acids. Addition of a phosphate group alters the local charge on the acceptor molecule, causing internal conformational changes and potentially influencing intermolecular contacts. Reversible protein phosphorylation is the primary method for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors. The activated proteins initiate the cell's intracellular response by way of intracellular signaling pathways and second messenger molecules such as cyclic nucleotides, calcium-calmodulin, inositol, and various mitogens, that regulate protein phosphorylation.

Kinases are involved in all aspects of a cell's function, from basic metabolic processes, such as glycolysis, to cell-cycle regulation, differentiation, and communication with the extracellular environment through signal transduction cascades. Inappropriate phosphorylation of proteins in cells has been linked to changes in cell cycle progression and cell differentiation. Changes in the cell cycle have been linked to induction of apoptosis or cancer. Changes in cell differentiation have been linked to diseases and disorders of the reproductive system, immune system, and skeletal muscle.

There are two classes of protein kinases. One class, protein tyrosine kinases (PTKs), phosphorylates tyrosine residues, and the other class, protein serine/threonine kinases (STKs), phosphorylates serine and threonine residues. Some PTKs and STKs possess structural characteristics of both families and have dual specificity for both tyrosine and serine/threonine

residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain containing specific residues and sequence motifs characteristic of the kinase family. The protein kinase catalytic domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VI-XI bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a tyrosine, serine, or threonine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI through IX comprise the highly conserved catalytic core. PTKs and STKs also contain distinct sequence motifs in subdomains VI and VIII which may confer hydroxyamino acid specificity.

In addition, kinases may also be classified by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and S. Hanks (1995) The Protein Kinase Facts Book, Vol I, pp. 17-20 Academic Press, San Diego CA.). In particular, two protein kinase signature sequences have been identified in the kinase domain, the first containing an active site lysine residue involved in ATP binding, and the second containing an aspartate residue important for catalytic activity. If a protein analyzed includes the two protein kinase signatures, the probability of that protein being a protein kinase is close to 100% (PROSITE: PDOC00100, November 1995).

Protein Tyrosine Kinases

Protein tyrosine kinases (PTKs) may be classified as either transmembrane, receptor PTKs or nontransmembrane, nonreceptor PTK proteins. Transmembrane tyrosine kinases function as receptors for most growth factors. Growth factors bind to the receptor tyrosine kinase (RTK), which causes the receptor to phosphorylate itself (autophosphorylation) and specific intracellular second messenger proteins. Growth factors (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Nontransmembrane, nonreceptor PTKs lack transmembrane regions and, instead, form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that function through non-receptor PTKs include those for cytokines and hormones (growth hormone and prolactin), and antigen-specific receptors on T and B lymphocytes.

Many PTKs were first identified as oncogene products in cancer cells in which PTK

activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and N.K. Tonks (1992) Annu. Rev. Cell Biol. 8:463-493). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Substrates for tyrosine kinases can be identified using anti-phosphotyrosine antibodies to screen tyrosine-phosphorylated cDNA expression libraries. Fish, so named for tyrosine-phosphorylated in Src-transfromed fibroblast, is a tyrosine kinase substrate which has been identified by such a technique. Fish has five SH3 domains and a phox homology (PX) domain. Fish is suggested to be involved in signalling by tyrosine kinases and have a role in the actin cytoskeleton (Lock,P. et al (1998) EMBO J. 17:4346-4357).

SHP-2, an SH2-domain-containing phosphotyrosine phosphatase, is a positive signal transducer for several receptor tyrosine kinases (RTKs) and cytokine receptors. Phosphotyrosine phosphatases are critical positive and negative regulators in the intraellular signalling pathways that result in growth-factor-specific cell responses such as mitosis, migration, differentiation, transformation, survival or death. Signal-regulatory proteins (SIRPs) comprise a new gene family of at least 15 members, consisting of two subtypes distinguished by the presence or absence of a cytoplasmic SHP-2-binding domain. The SIRP-alpha subfamily members have a cytoplasmic SHP2-binding domain and includes SIRP-alpha-1, a transmembrane protein, a substrate of activated RTKs and which binds to SH2 domains. SIRPs have a high degree of homology with immune antigen recognition molecules. The SIRP-beta subfamily lacks the cytoplasmic tail. The SIRP-beta-1 gene encodes a polypeptide of 398 amino acids. SIRP family members are generally involved in regulation of signals which define differnet physiological and pathological process (Kharitonenkov,A. et al (1997) Nature 386:181-186). Two possible areas of regulation include determination of brain diversity and genetic individuality (Sano,S et al (1999) Biochem. J. 344 Pt 3:667-675) and recognition of self which fails in diseases such as hemolytic anemia (Oldenborg,P.-A et al (2000) Science 288:2051-2054).

Protein Serine/Threonine Kinases

Protein serine/threonine kinases (STKs) are nontransmembrane proteins. A subclass of STKs are known as ERKs (extracellular signal regulated kinases) or MAPs (mitogen-activated protein kinases) and are activated after cell stimulation by a variety of hormones and growth factors. Cell stimulation induces a signaling cascade leading to phosphorylation of MEK (MAP/ERK kinase) which, in turn, activates ERK via serine and threonine phosphorylation. A varied number of proteins represent the downstream effectors for the active ERK and implicate it in the control of cell

proliferation and differentiation, as well as regulation of the cytoskeleton. Activation of ERK is normally transient, and cells possess dual specificity phosphatases that are responsible for its down-regulation. Also, numerous studies have shown that elevated ERK activity is associated with some cancers. Other STKs include the second messenger dependent protein kinases such as the cyclic-AMP dependent protein kinases (PKA), calcium-calmodulin (CaM) dependent protein kinases, and the mitogen-activated protein kinases (MAP); the cyclin-dependent protein kinases; checkpoint and cell cycle kinases; Numb-associated kinase (Nak); human Fused (hFu); proliferation-related kinases; 5'-AMP-activated protein kinases; and kinases involved in apoptosis.

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic ADP ribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The PKAs are involved in mediating hormone-induced cellular responses and are activated by cAMP produced within the cell in response to hormone stimulation. cAMP is an intracellular mediator of hormone action in all animal cells that have been studied. Hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cAMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York NY, pp. 416-431, 1887).

The casein kinase I (CKI) gene family is another subfamily of serine/threonine protein kinases. This continuously expanding group of kinases have been implicated in the regulation of numerous cytoplasmic and nuclear processes, including cell metabolism, and DNA replication and repair. CKI enzymes are present in the membranes, nucleus, cytoplasm and cytoskeleton of eukaryotic cells, and on the mitotic spindles of mammalian cells (Fish, K.J. et al. (1995) J. Biol. Chem. 270:14875-14883).

The CKI family members all have a short amino-terminal domain of 9-76 amino acids, a highly conserved kinase domain of 284 amino acids, and a variable carboxyl-terminal domain that ranges from 24 to over 200 amino acids in length (Cegielska, A. et al. (1998) J. Biol. Chem. 273:1357-1364). The CKI family is comprised of highly related proteins, as seen by the identification of isoforms of casein kinase I from a variety of sources. There are at least five mammalian isoforms, α, β, γ, δ, and ε. Fish et al., identified CKI-epsilon from a human placenta cDNA library. It is a basic protein of 416 amino acids and is closest to CKI-delta. Through recombinant expression, it was determined to

phosphorylate known CKI substrates and was inhibited by the CKI-specific inhibitor CKI-7. The human gene for CKI-epsilon was able to rescue yeast with a slow-growth phenotype caused by deletion of the yeast CKI locus, HRR250 (Fish et al., supra).

The mammalian circadian mutation tau was found to be a semidominant autosomal allele of CKI-epsilon that markedly shortens period length of circadian rhythms in Syrian hamsters. The tau locus is encoded by casein kinase I-epsilon, which is also a homolog of the Drosophila circadian gene double-time. Studies of both the wildtype and tau mutant CKI-epsilon enzyme indicated that the mutant enzyme has a noticeable reduction in the maximum velocity and autophosphorylation state. Further, *in vitro,* CKI-epsilon is able to interact with mammalian PERIOD proteins, while the mutant enzyme is deficient in its ability to phosphorylate PERIOD. Lowrey et al., have proposed that CKI-epsilon plays a major role in delaying the negative feedback signal within the transcription-translation-based autoregulatory loop that composes the core of the circadian mechanism. Therefore the CKI-epsilon enzyme is an ideal target for pharmaceutical compounds influencing circadian rhythms, jet-lag and sleep, in addition to other physiologic and metabolic processes under circadian regulation (Lowrey, P.L. et al. (2000) Science 288:483-491).

Homeodomain-interacting protein kinases (HIPKs) are serine/threonine kinases and novel members of the DYRK kinase subfamily (Hofmann, T.G. et al. (2000) Biochimie 82:1123-1127). HIPKs contain a conserved protein kinase domain separated from a domain that interacts with homeoproteins. HIPKs are nuclear kinases, and HIPK2 is highly expressed in neuronal tissue (Kim, Y.H. et al. (1998) J. Biol. Chem. 273:25875-25879; Wang, Y. et al. (2001) Biochim. Biophys. Acta 1518:168-172). HIPKs act as corepressors for homeodomian transcription factors. This corepressor activity is seen in posttranslational modifications such as ubiquitination and phosphorylation, each of which are important in the regulation of cellular protein function (Kim, Y.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96:12350-12355).

The murine homology to *Caenorhabditis elegans* UNC51, a serine/threonine kinase, has been determined to be required to signal the program of gene expression leading to axon formation from granule cells of the cerebellar cortex (Tomoda, T. et al (1999) Neuron 24:833-346. The human homolog of UNC-51, ULK1, for UNC-51 (C. elegans)-like kinase 1, is composed of 1050 amino acids, has a calculated MV of 112.6 kDa and a pI of 8.80. ULK1 has 41% overall sequence similarity to UNC-51 and is highly convserved among vertebrates including mammals, birds, reptiles, amphibians, and fish. By Northern blot analysis, Kuroyanagi et al have shown ULK1 to be ubiquitously expressed in adult tissues, including skeletal muscle, heart, pancreas, brain, placenta, liver, kidney, and lung while UNC-51 has been specifically located in the nervous system of C. elegans. Fish and RH mapping

confirmed the localization of ULK1 to human chromosome 12q24.3. (Kuroyanagi, H. et al (1998) Genomics 51:76-85.

Calcium-Calmodulin Dependent Protein Kinases

Calcium-calmodulin dependent (CaM) kinases are involved in regulation of smooth muscle contraction, glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM dependent protein kinases are activated by calmodulin, an intracellular calcium receptor, in response to the concentration of free calcium in the cell. Many CaM kinases are also activated by phosphorylation. Some CaM kinases are also activated by autophosphorylation or by other regulatory kinases. CaM kinase I phosphorylates a variety of substrates including the neurotransmitter-related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. et al. (1995) EMBO J. 14:3679-3686). CaM kinase II also phosphorylates synapsin at different sites and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. CaM kinase II controls the synthesis of catecholamines and seratonin, through phosphorylation/activation of tyrosine hydroxylase and tryptophan hydroxylase, respectively (Fujisawa, H. (1990) BioEssays 12:27-29). The mRNA encoding a calmodulin-binding protein kinase-like protein was found to be enriched in mammalian forebrain. This protein is associated with vesicles in both axons and dendrites and accumulates largely postnatally. The amino acid sequence of this protein is similar to CaM-dependent STKs, and the protein binds calmodulin in the presence of calcium (Godbout, M. et al. (1994) J. Neurosci. 14:1-13).

Mitogen-Activated Protein Kinases

The mitogen-activated protein kinases (MAP) which mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades are another STK family that regulates intracellular signaling pathways. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S.E. and R.A. Weinberg (1993) Nature 365:781-783). There are 3-kinase modules comprising the MAP kinase cascade: MAPK (MAP), MAPK kinase (MAP2K, MAPKK, or MKK), and MKK kinase (MAP3K, MAPKKK, OR MEKK) (Wang,X.S. et al (1998) Biochem. Biophys. Res. Commun. 253:33-37). The extracellular-regulated kinase (ERK) pathway is activated by growth factors and mitogens, for example, epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS). The closely related though distinct parallel pathways, the c-Jun N-terminal kinase (JNK), or stress-activated kinase (SAPK) pathway, and the p38 kinase pathway are activated by stress stimuli and proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1

(IL-1). Altered MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.. MAP kinase signaling pathways are present in mammalian cells as well as in yeast.

MAPKKK6 (MAP3K6) is one of numerous MAP3Ks identified. Isolated from skeletal muscle, MAP3K6 is 1,280 amino acids in length with 11 kinase subdomains and is detected in several tissues. The highest expression has been found in heart and skeletal muscle. MAP3K6 has 45% amino acid sequence identity with MAP3K5, while their catalytic domains share 82% identity. MAP3K6 interaction with MAP3K5 *in vivo* was confirmed by coimmunoprecipitation. Recombinant MAP3K6 has been shown to weakly activate the JNK but not the p38 kinase or ERK pathways (Wang,X.S. et al. *supra)*

Cyclin-Dependent Protein Kinases

The cyclin-dependent protein kinases (CDKs) are STKs that control the progression of cells through the cell cycle. The entry and exit of a cell from mitosis are regulated by the synthesis and destruction of a family of activating proteins called cyclins. Cyclins are small regulatory proteins that bind to and activate CDKs, which then phosphorylate and activate selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to cyclin binding, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue on the CDK.

Another family of STKs associated with the cell cycle are the NIMA (never in mitosis)-related kinases (Neks). Both CDKs and Neks are involved in duplication, maturation, and separation of the microtubule organizing center, the centrosome, in animal cells (Fry, A.M. et al. (1998) EMBO J. 17:470-481).

Checkpoint and Cell Cycle Kinases

In the process of cell division, the order and timing of cell cycle transitions are under control of cell cycle checkpoints, which ensure that critical events such as DNA replication and chromosome segregation are carried out with precision. If DNA is damaged, e.g. by radiation, a checkpoint pathway is activated that arrests the cell cycle to provide time for repair. If the damage is extensive, apoptosis is induced. In the absence of such checkpoints, the damaged DNA is inherited by aberrant cells which may cause proliferative disorders such as cancer. Protein kinases play an important role in this process. For example, a specific kinase, checkpoint kinase 1 (Chk1), has been identified in yeast and mammals, and is activated by DNA damage in yeast. Activation of Chk1 leads to the arrest of the cell at the G2/M transition (Sanchez, Y. et al. (1997) Science 277:1497-1501). Specifically, Chk1 phosphorylates the cell division cycle phosphatase CDC25, inhibiting its normal function which is

to dephosphorylate and activate the cyclin-dependent kinase Cdc2. Cdc2 activation controls the entry of cells into mitosis (Peng, C.-Y. et al. (1997) Science 277:1501-1505). Thus, activation of Chk1 prevents the damaged cell from entering mitosis. A similar deficiency in a checkpoint kinase, such as Chk1, may also contribute to cancer by failure to arrest cells with damaged DNA at other checkpoints such as G2/M.

Proliferation-Related Kinases

Proliferation-related kinase is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakarocytic cells (Li, B. et al. (1996) J. Biol. Chem. 271:19402-19408). Proliferation-related kinase is related to the polo (derived from Drosophila polo gene) family of STKs implicated in cell division. Proliferation-related kinase is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation.

5'-AMP-activated protein kinase

A ligand-activated STK protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. et al. (1996) J. Biol Chem. 271:8675-8681). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

Kinases in Apoptosis

Apoptosis is a highly regulated signaling pathway leading to cell death that plays a crucial role in tissue development and homeostasis. Deregulation of this process is associated with the pathogenesis of a number of diseases including autoimmune disease, neurodegenerative disorders, and cancer. Various STKs play key roles in this process. ZIP kinase is an STK containing a C-terminal leucine zipper domain in addition to its N-terminal protein kinase domain. This C-terminal domain appears to mediate homodimerization and activation of the kinase as well as interactions with transcription factors such as activating transcription factor, ATF4, a member of the cyclic-AMP responsive element binding protein (ATF/CREB) family of transcriptional factors (Sanjo, H. et al. (1998) J. Biol. Chem. 273:29066-29071). DRAK1 and DRAK2 are STKs that share homology with the death-associated protein kinases (DAP kinases), known to function in interferon-γ induced

apoptosis (Sanjo et al., supra). Like ZIP kinase, DAP kinases contain a C-terminal protein-protein interaction domain, in the form of ankyrin repeats, in addition to the N-terminal kinase domain. ZIP, DAP, and DRAK kinases induce morphological changes associated with apoptosis when transfected into NIH3T3 cells (Sanjo et al., supra). However, deletion of either the N-terminal kinase catalytic domain or the C-terminal domain of these proteins abolishes apoptosis activity, indicating that in addition to the kinase activity, activity in the C-terminal domain is also necessary for apoptosis, possibly as an interacting domain with a regulator or a specific substrate.

RICK is another STK recently identified as mediating a specific apoptotic pathway involving the death receptor, CD95 (Inohara, N. et al. (1998) J. Biol. Chem. 273:12296-12300). CD95 is a member of the tumor necrosis factor receptor superfamily and plays a critical role in the regulation and homeostasis of the immune system (Nagata, S. (1997) Cell 88:355-365). The CD95 receptor signaling pathway involves recruitment of various intracellular molecules to a receptor complex following ligand binding. This process includes recruitment of the cysteine protease caspase-8 which, in turn, activates a caspase cascade leading to cell death. RICK is composed of an N-terminal kinase catalytic domain and a C-terminal "caspase-recruitment" domain that interacts with caspase-like domains, indicating that RICK plays a role in the recruitment of caspase-8. This interpretation is supported by the fact that the expression of RICK in human 293T cells promotes activation of caspase-8 and potentiates the induction of apoptosis by various proteins involved in the CD95 apoptosis pathway (Inohara et al., supra).

Mitochondrial Protein Kinases

A novel class of eukaryotic kinases, related by sequence to prokaryotic histidine protein kinases, are the mitochondrial protein kinases (MPKs) which seem to have no sequence similarity with other eukaryotic protein kinases. These protein kinases are located exclusively in the mitochondrial matrix space and may have evolved from genes originally present in respiration-dependent bacteria which were endocytosed by primitive eukaryotic cells. MPKs are responsible for phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase and pyruvate dehydrogenase complexes (Harris, R.A. et al. (1995) Adv. Enzyme Regul. 34:147-162). Five MPKs have been identified. Four members correspond to pyruvate dehydrogenase kinase isozymes, regulating the activity of the pyruvate dehydrogenase complex, which is an important regulatory enzyme at the interface between glycolysis and the citric acid cycle. The fifth member corresponds to a branched-chain alpha-ketoacid dehydrogenase kinase, important in the regulation of the pathway for the disposal of branched-chain amino acids. (Harris, R.A. et al. (1997) Adv. Enzyme Regul. 37:271-293). Both starvation and the diabetic state are known to result in a great increase in the activity of the pyruvate

dehydrogenase kinase in the liver, heart and muscle of the rat. This increase contributes in both disease states to the phosphorylation and inactivation of the pyruvate dehydrogenase complex and conservation of pyruvate and lactate for gluconeogenesis (Harris (1995) supra).

KINASES WITH NON-PROTEIN SUBSTRATES

Lipid and Inositol kinases

Lipid kinases phosphorylate hydroxyl residues on lipid head groups. A family of kinases involved in phosphorylation of phosphatidylinositol (PI) has been described, each member phosphorylating a specific carbon on the inositol ring (Leevers, S.J. et al. (1999) Curr. Opin. Cell. Biol. 11:219-225). The phosphorylation of phosphatidylinositol is involved in activation of the protein kinase C signaling pathway. The inositol phospholipids (phosphoinositides) intracellular signaling pathway begins with binding of a signaling molecule to a G-protein linked receptor in the plasma membrane. This leads to the phosphorylation of phosphatidylinositol (PI) residues on the inner side of the plasma membrane by inositol kinases, thus converting PI residues to the biphosphate state (PIP_2). PIP_2 is then cleaved into inositol triphosphate (IP_3) and diacylglycerol. These two products act as mediators for separate signaling pathways. Cellular responses that are mediated by these pathways are glycogen breakdown in the liver in response to vasopressin, smooth muscle contraction in response to acetylcholine, and thrombin-induced platelet aggregation.

PI 3-kinase (PI3K), which phosphorylates the D3 position of PI and its derivatives, has a central role in growth factor signal cascades involved in cell growth, differentiation, and metabolism. PI3K is a heterodimer consisting of an adapter subunit and a catalytic subunit. The adapter subunit acts as a scaffolding protein, interacting with specific tyrosine-phosphorylated proteins, lipid moieties, and other cytosolic factors. When the adapter subunit binds tyrosine phosphorylated targets, such as the insulin responsive substrate (IRS)-1, the catalytic subunit is activated and converts PI (4,5) bisphosphate (PIP_2) to PI (3,4,5) P_3 (PIP_3). PIP_3 then activates a number of other proteins, including PKA, protein kinase B (PKB), protein kinase C (PKC), glycogen synthase kinase (GSK)-3, and p70 ribosomal s6 kinase. PI3K also interacts directly with the cytoskeletal organizing proteins, Rac, rho, and cdc42 (Shepherd, P.R. et al. (1998) Biochem. J. 333:471-490). Animal models for diabetes, such as *obese* and *fat* mice, have altered PI3K adapter subunit levels. Specific mutations in the adapter subunit have also been found in an insulin-resistant Danish population, suggesting a role for PI3K in type-2 diabetes (Shepard, supra).

An example of lipid kinase phosphorylation activity is the phosphorylation of

D-erythro-sphingosine to the sphingolipid metabolite, sphingosine-1-phosphate (SPP). SPP has emerged as a novel lipid second-messenger with both extracellular and intracellular actions (Kohama, T. et al. (1998) J. Biol. Chem. 273:23722-23728). Extracellularly, SPP is a ligand for the G-protein coupled receptor EDG-1 (endothelial-derived, G-protein coupled receptor). Intracellularly, SPP regulates cell growth, survival, motility, and cytoskeletal changes. SPP levels are regulated by sphingosine kinases that specifically phosphorylate D-erythro-sphingosine to SPP. The importance of sphingosine kinase in cell signaling is indicated by the fact that various stimuli, including platelet-derived growth factor (PDGF), nerve growth factor, and activation of protein kinase C, increase cellular levels of SPP by activation of sphingosine kinase, and the fact that competitive inhibitors of the enzyme selectively inhibit cell proliferation induced by PDGF (Kohama et al., supra).

Purine Nucleotide Kinases

The purine nucleotide kinases, adenylate kinase (ATP:AMP phosphotransferase, or AdK) and guanylate kinase (ATP:GMP phosphotransferase, or GuK) play a key role in nucleotide metabolism and are crucial to the synthesis and regulation of cellular levels of ATP and GTP, respectively. These two molecules are precursors in DNA and RNA synthesis in growing cells and provide the primary source of biochemical energy in cells (ATP), and signal transduction pathways (GTP). Inhibition of various steps in the synthesis of these two molecules has been the basis of many antiproliferative drugs for cancer and antiviral therapy (Pillwein, K. et al. (1990) Cancer Res. 50:1576-1579).

AdK is found in almost all cell types and is especially abundant in cells having high rates of ATP synthesis and utilization such as skeletal muscle. In these cells AdK is physically associated with mitochondria and myofibrils, the subcellular structures that are involved in energy production and utilization, respectively. Recent studies have demonstrated a major function for AdK in transferring high energy phosphoryls from metabolic processes generating ATP to cellular components consuming ATP (Zeleznikar, R.J. et al. (1995) J. Biol. Chem. 270:7311-7319). Thus AdK may have a pivotal role in maintaining energy production in cells, particularly those having a high rate of growth or metabolism such as cancer cells, and may provide a target for suppression of its activity to treat certain cancers. Alternatively, reduced AdK activity may be a source of various metabolic, muscle-energy disorders that can result in cardiac or respiratory failure and may be treatable by increasing AdK activity.

GuK, in addition to providing a key step in the synthesis of GTP for RNA and DNA synthesis, also fulfills an essential function in signal transduction pathways of cells through the regulation of GDP and GTP. Specifically, GTP binding to membrane associated G proteins mediates the activation of cell receptors, subsequent intracellular activation of adenyl cyclase, and production of the second

messenger, cyclic AMP. GDP binding to G proteins inhibits these processes. GDP and GTP levels also control the activity of certain oncogenic proteins such as $p21^{ras}$ known to be involved in control of cell proliferation and oncogenesis (Bos, J.L. (1989) Cancer Res. 49:4682-4689). High ratios of GTP:GDP caused by suppression of GuK cause activation of $p21^{ras}$ and promote oncogenesis. Increasing GuK activity to increase levels of GDP and reduce the GTP:GDP ratio may provide a therapeutic strategy to reverse oncogenesis.

GuK is an important enzyme in the phosphorylation and activation of certain antiviral drugs useful in the treatment of herpes virus infections. These drugs include the guanine homologs acyclovir and buciclovir (Miller, W.H. and R.L. Miller (1980) J. Biol. Chem. 255:7204-7207; Stenberg, K. et al. (1986) J. Biol. Chem. 261:2134-2139). Increasing GuK activity in infected cells may provide a therapeutic strategy for augmenting the effectiveness of these drugs and possibly for reducing the necessary dosages of the drugs.

Pyrimidine Kinases

The pyrimidine kinases are deoxycytidine kinase and thymidine kinase 1 and 2. Deoxycytidine kinase is located in the nucleus, and thymidine kinase 1 and 2 are found in the cytosol (Johansson, M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11941-11945). Phosphorylation of deoxyribonucleosides by pyrimidine kinases provides an alternative pathway for de novo synthesis of DNA precursors. The role of pyrimidine kinases, like purine kinases, in phosphorylation is critical to the activation of several chemotherapeutically important nucleoside analogues (Arner E.S. and S. Eriksson (1995) Pharmacol. Ther. 67:155-186).

The discovery of new human kinases, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of human kinases.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, human kinases, referred to collectively as "PKIN" and individually as "PKIN-1," "PKIN-2," "PKIN-3," "PKIN-4," "PKIN-5," "PKIN-6," "PKIN-7," "PKIN-8," "PKIN-9," "PKIN-10," "PKIN-11," "PKIN-12" "PKIN-13," "PKIN-14," "PKIN-15," "PKIN-16," "PKIN-17," "PKIN-18," "PKIN-19," and "PKIN-20." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a

polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-20.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-20. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:21-40.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is

transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID

NO:21-40, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an

amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test

compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each

polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"PKIN" refers to the amino acid sequences of substantially purified PKIN obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of PKIN. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

An "allelic variant" is an alternative form of the gene encoding PKIN. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PKIN include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as PKIN or a polypeptide with at least one functional characteristic of PKIN. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PKIN, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PKIN. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PKIN. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PKIN is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic

molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of PKIN. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of PKIN either by directly interacting with PKIN or by acting on components of the biological pathway in which PKIN participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, $F(ab')_2$, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind PKIN polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring

nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic PKIN, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PKIN or fragments of PKIN may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

Original Residue	Conservative Substitution
Ala	Gly, Ser
Arg	His, Lys

Asn	Asp, Gln, His
Asp	Asn, Glu
Cys	Ala, Ser
Gln	Asn, Glu, His
Glu	Asp, Gln, His
Gly	Ala
His	Asn, Arg, Gln, Glu
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu
Met	Leu, Ile
Phe	His, Met, Leu, Trp, Tyr
Ser	Cys, Thr
Thr	Ser, Val
Trp	Phe, Tyr
Tyr	His, Phe, Trp
Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

"Differential expression" refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

"Exon shuffling" refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the

evolution of new protein functions.

A "fragment" is a unique portion of PKIN or the polynucleotide encoding PKIN which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:21-40 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:21-40, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:21-40 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:21-40 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:21-40 and the region of SEQ ID NO:21-40 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-20 is encoded by a fragment of SEQ ID NO:21-40. A fragment of SEQ ID NO:1-20 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-20. For example, a fragment of SEQ ID NO:1-20 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-20. The precise length of a fragment of SEQ ID NO:1-20 and the region of SEQ ID NO:1-20 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to

the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

Penalty for mismatch: -2

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

Filter: on

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989)

Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of PKIN which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of PKIN which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of PKIN. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PKIN.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an PKIN may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of PKIN.

"Probe" refers to nucleic acid sequences encoding PKIN, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers

may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence

that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing PKIN, nucleic acids encoding PKIN, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

The invention is based on the discovery of new human human kinases (PKIN), the polynucleotides encoding PKIN, and the use of these compositions for the diagnosis, treatment, or prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a

single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are human kinases. For example, SEQ ID NO:2 is 97% identical to mouse tousled-like kinase (GenBank ID g2853031) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:2 also contains an eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:2 is a tousled-like kinase. In an alternative example, SEQ ID NO:10 is 63% identical to human serine/threonine protein kinase (GenBank ID g36615) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The

BLAST probability score is 7.7e-122, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:10 also contains an eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:10 is a serine/threonine kinase. Note that "serine/theronine kinase" is a specific class of kinases. In an alternative example, SEQ ID NO:16 is 53% identical to human receptor protein-tyrosine kinase (GenBank ID g551608) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 4.1e-290, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:16 also contains an eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:16 is a receptor tyrosine kinase. In an alternative example, SEQ ID NO:19 is 93% identical to rat Calcium/calmodulin-dependent protein kinase isoform IV (GenBank ID g1836161) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.0e-257, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:19 also contains an eukaryotic protein kinase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:19 is a protein kinase. SEQ ID NO:1, SEQ ID NO:3-9, SEQ ID NO:11-15, SEQ ID NO:17-18, and SEQ ID NO:20 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-20 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:21-40 or that distinguish between SEQ ID NO:21-40 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA

sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 2564295H1 is the identification number of an Incyte cDNA sequence, and ADRETUT01 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71191190V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g1164223) which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL_*XXXXXX*_N_1_N_2_*YYYYY*_N_3_N_4 represents a "stitched" sequence in which *XXXXXX* is the identification number of the cluster of sequences to which the algorithm was applied, and *YYYYY* is the number of the prediction generated by the algorithm, and $N_{1,2,3...}$, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FL*XXXXXX*_g*AAAAA*_g*BBBBB*_1_*N* is the identification number of a "stretched" sequence, with *XXXXXX* being the Incyte project identification number, g*AAAAA* being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, g*BBBBB* being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and *N* referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, g*BBBBB*).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from

genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

Prefix	Type of analysis and/or examples of programs
GNN, GFG, ENST	Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).
GBI	Hand-edited analysis of genomic sequences.
FL	Stitched or stretched genomic sequences (see Example V).
INCY	Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses PKIN variants. A preferred PKIN variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the PKIN amino acid sequence, and which contains at least one functional or structural characteristic of PKIN.

The invention also encompasses polynucleotides which encode PKIN. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:21-40, which encodes PKIN. The polynucleotide sequences of SEQ ID NO:21-40, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding PKIN. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least

about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PKIN. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:21-40 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:21-40. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of PKIN.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PKIN, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PKIN, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PKIN and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring PKIN under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PKIN or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PKIN and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PKIN and PKIN derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PKIN or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:21-40 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol. 152:507-

511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PKIN may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National

Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PKIN may be cloned in recombinant DNA molecules that direct expression of PKIN, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PKIN.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PKIN-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve

the biological properties of PKIN, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding PKIN may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, PKIN itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of PKIN, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active PKIN, the nucleotide sequences encoding PKIN or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PKIN. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PKIN. Such signals

include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PKIN and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PKIN and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PKIN. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PKIN. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PKIN can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PKIN into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PKIN are needed, e.g. for the production of antibodies, vectors which direct high level expression of PKIN may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PKIN. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PKIN. Transcription of sequences encoding PKIN may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PKIN may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PKIN in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.

Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PKIN in cell lines is preferred. For example, sequences encoding PKIN can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk*⁻ and *apr*⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), ß glucuronidase and its substrate ß-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest

is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PKIN is inserted within a marker gene sequence, transformed cells containing sequences encoding PKIN can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PKIN under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PKIN and that express PKIN may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PKIN using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PKIN is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PKIN include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PKIN, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PKIN may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PKIN may be designed to contain signal sequences which direct secretion of PKIN through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PKIN may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PKIN protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PKIN activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PKIN encoding sequence and the heterologous protein sequence, so that PKIN may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PKIN may be achieved in

vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ^{35}S-methionine.

PKIN of the present invention or fragments thereof may be used to screen for compounds that specifically bind to PKIN. At least one and up to a plurality of test compounds may be screened for specific binding to PKIN. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of PKIN, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which PKIN binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express PKIN, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing PKIN or cell membrane fractions which contain PKIN are then contacted with a test compound and binding, stimulation, or inhibition of activity of either PKIN or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with PKIN, either in solution or affixed to a solid support, and detecting the binding of PKIN to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

PKIN of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of PKIN. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for PKIN activity, wherein PKIN is combined with at least one test compound, and the activity of PKIN in the presence of a test compound is compared with the activity of PKIN in the absence of the test compound. A change in the activity of PKIN in the presence of the test compound is indicative of a compound that modulates the activity of PKIN. Alternatively, a test compound is combined with an in

vitro or cell-free system comprising PKIN under conditions suitable for PKIN activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of PKIN may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding PKIN or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding PKIN may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding PKIN can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding PKIN is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress PKIN, e.g., by secreting PKIN in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PKIN and human kinases. In addition, the expression of PKIN is closely associated with bladder cancer, prostatic, ovarian, brain, colon, ileum, penis, skin, adrenal tumor, digestive, and cancerous tissues. Therefore, PKIN appears to play a role in cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders. In the treatment of disorders associated with increased PKIN expression or activity, it is desirable to decrease the expression or activity of PKIN. In the treatment of disorders associated with decreased PKIN expression or activity, it is desirable to increase the expression or activity of PKIN.

Therefore, in one embodiment, PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in

particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy,

adrenoleukodystrophy, GM_2 gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity.

In another embodiment, a vector capable of expressing PKIN or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified PKIN in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PKIN may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PKIN including, but not limited to, those listed above.

In a further embodiment, an antagonist of PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN. Examples of such disorders include, but are not limited to, those cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders described above. In one aspect, an antibody which specifically binds PKIN may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express PKIN.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PKIN may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PKIN including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic

efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PKIN may be produced using methods which are generally known in the art. In particular, purified PKIN may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PKIN. Antibodies to PKIN may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PKIN or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PKIN have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of PKIN amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PKIN may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PKIN-specific single

chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PKIN may also be generated. For example, such fragments include, but are not limited to, $F(ab')_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PKIN and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PKIN epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for PKIN. Affinity is expressed as an association constant, K_a, which is defined as the molar concentration of PKIN-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PKIN epitopes, represents the average affinity, or avidity, of the antibodies for PKIN. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PKIN epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the PKIN-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of PKIN, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell,

J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of PKIN-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PKIN, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding PKIN. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PKIN. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding PKIN may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency

(Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in PKIN expression or regulation causes disease, the expression of PKIN from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in PKIN are treated by constructing mammalian expression vectors encoding PKIN and introducing these vectors by mechanical means into PKIN-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of PKIN include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). PKIN may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V.

and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding PKIN from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to PKIN expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding PKIN under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., $CD4^+$ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding PKIN to cells which have one or more genetic abnormalities with respect to the expression of PKIN. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to

be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding PKIN to target cells which have one or more genetic abnormalities with respect to the expression of PKIN. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing PKIN to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding PKIN to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for PKIN into the alphavirus

genome in place of the capsid-coding region results in the production of a large number of PKIN-coding RNAs and the synthesis of high levels of PKIN in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of PKIN into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PKIN.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques

for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PKIN. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding PKIN. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased PKIN expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding PKIN may be therapeutically useful, and in the treatment of disorders associated with decreased PKIN expression or activity, a compound which specifically promotes expression of the polynucleotide encoding PKIN may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding PKIN is exposed to at least one test compound thus obtained. The sample

may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding PKIN are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding PKIN. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of PKIN, antibodies to PKIN, and mimetics, agonists, antagonists, or inhibitors of PKIN.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal,

intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising PKIN or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, PKIN or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PKIN or fragments thereof, antibodies of PKIN, and agonists, antagonists or inhibitors of PKIN, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are

used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind PKIN may be used for the diagnosis of disorders characterized by expression of PKIN, or in assays to monitor patients being treated with PKIN or agonists, antagonists, or inhibitors of PKIN. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PKIN include methods which utilize the antibody and a label to detect PKIN in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PKIN, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PKIN expression. Normal or standard values for PKIN expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to PKIN under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of PKIN expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation

between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PKIN may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of PKIN may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PKIN, and to monitor regulation of PKIN levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PKIN or closely related molecules may be used to identify nucleic acid sequences which encode PKIN. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding PKIN, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the PKIN encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:21-40 or from genomic sequences including promoters, enhancers, and introns of the PKIN gene.

Means for producing specific hybridization probes for DNAs encoding PKIN include the cloning of polynucleotide sequences encoding PKIN or PKIN derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PKIN may be used for the diagnosis of disorders associated with expression of PKIN. Examples of such disorders include, but are not limited to, a cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, leukemias such as multiple myeloma and lymphomas such as Hodgkin's disease; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress

syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a growth and developmental disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus, renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a cardiovascular disease, such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy,

myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and complications of lung transplantation; and a lipid disorder such as fatty liver, cholestasis, primary biliary cirrhosis, carnitine deficiency, carnitine palmitoyltransferase deficiency, myoadenylate deaminase deficiency, hypertriglyceridemia, lipid storage disorders such Fabry's disease, Gaucher's disease, Niemann-Pick's disease, metachromatic leukodystrophy, adrenoleukodystrophy, GM_2 gangliosidosis, and ceroid lipofuscinosis, abetalipoproteinemia, Tangier disease, hyperlipoproteinemia, diabetes mellitus, lipodystrophy, lipomatoses, acute panniculitis, disseminated fat necrosis, adiposis dolorosa, lipoid adrenal hyperplasia, minimal change disease, lipomas, atherosclerosis, hypercholesterolemia, hypercholesterolemia with hypertriglyceridemia, primary hypoalphalipoproteinemia, hypothyroidism, renal disease, liver disease, lecithin:cholesterol acyltransferase deficiency, cerebrotendinous xanthomatosis, sitosterolemia, hypocholesterolemia, Tay-Sachs disease, Sandhoff's disease, hyperlipidemia, hyperlipemia, lipid myopathies, and obesity. The polynucleotide sequences encoding PKIN may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PKIN expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PKIN may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PKIN may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PKIN in the sample

indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PKIN, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PKIN, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PKIN may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PKIN, or a fragment of a polynucleotide complementary to the polynucleotide encoding PKIN, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease

in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding PKIN are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of PKIN include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic

profile.

In another embodiment, PKIN, fragments of PKIN, or antibodies specific for PKIN may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not

necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for PKIN to quantify the levels of PKIN expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA

94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding PKIN may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding PKIN on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation,

inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PKIN, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PKIN and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PKIN, or fragments thereof, and washed. Bound PKIN is then detected by methods well known in the art. Purified PKIN can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PKIN specifically compete with a test compound for binding PKIN. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PKIN.

In additional embodiments, the nucleotide sequences which encode PKIN may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/220,038, U.S. Ser. No. 60/222,112, U.S. Ser. No. 60/222,831, and U.S. Ser. No. 60/224,729 are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD

database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP

96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.

Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:21-40. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative human kinases were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an

assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode human kinases, the encoded polypeptides were analyzed by querying against PFAM models for human kinases. Potential human kinases were also identified by homology to Incyte cDNA sequences that had been annotated as human kinases. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data

"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent

type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of PKIN Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:21-40 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:21-40 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid

markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum}\{\text{length(Seq. 1)}, \text{length(Seq. 2)}\}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding PKIN are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are

assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding PKIN. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of PKIN Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+}, $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4

repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 µl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 µl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:21-40 are employed to screen cDNAs,

genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-^{32}P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection.

After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)$^+$ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)$^+$ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/µl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/µl RNase inhibitor, 500 µM dATP, 500 µM dGTP, 500 µM dTTP, 40 µM dCTP, 40 µM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)$^+$ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)$^+$ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 µl 5X SSC/0.2% SDS.

Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 µg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C

oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 µl of the array element DNA, at an average concentration of 100 ng/µl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60° C followed by washes in 0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 µl of sample mixture consisting of 0.2 µg each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm^2 coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 µl of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45° C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source,

although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the PKIN-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PKIN. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PKIN. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PKIN-encoding transcript.

XII. Expression of PKIN

Expression and purification of PKIN is achieved using bacterial or virus-based expression systems. For expression of PKIN in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA

transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PKIN upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PKIN in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PKIN by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PKIN is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PKIN at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified PKIN obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, XVIII, and XIX where applicable.

XIII. Functional Assays

PKIN function is assessed by expressing the sequences encoding PKIN at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a

marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PKIN on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PKIN and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PKIN and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of PKIN Specific Antibodies

PKIN substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PKIN amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-

Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-PKIN activity by, for example, binding the peptide or PKIN to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring PKIN Using Specific Antibodies

Naturally occurring or recombinant PKIN is substantially purified by immunoaffinity chromatography using antibodies specific for PKIN. An immunoaffinity column is constructed by covalently coupling anti-PKIN antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing PKIN are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PKIN (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PKIN binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PKIN is collected.

XVI. Identification of Molecules Which Interact with PKIN

PKIN, or biologically active fragments thereof, are labeled with ^{125}I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PKIN, washed, and any wells with labeled PKIN complex are assayed. Data obtained using different concentrations of PKIN are used to calculate values for the number, affinity, and association of PKIN with the candidate molecules.

Alternatively, molecules interacting with PKIN are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

PKIN may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

XVII. Demonstration of PKIN Activity

Generally, protein kinase activity is measured by quantifying the phosphorylation of a protein

substrate by PKIN in the presence of [γ-^{32}P]ATP. PKIN is incubated with the protein substrate, ^{32}P-ATP, and an appropriate kinase buffer. The ^{32}P incorporated into the substrate is separated from free ^{32}P-ATP by electrophoresis and the incorporated ^{32}P is counted using a radioisotope counter. The amount of incorporated ^{32}P is proportional to the activity of PKIN. A determination of the specific amino acid residue phosphorylated is made by phosphoamino acid analysis of the hydrolyzed protein.

In one alternative, protein kinase activity is measured by quantifying the transfer of gamma phosphate from adenosine triphosphate (ATP) to a serine, threonine or tyrosine residue in a protein substrate. The reaction occurs between a protein kinase sample with a biotinylated peptide substrate and gamma ^{32}P-ATP. Following the reaction, free avidin in solution is added for binding to the biotinylated ^{32}P-peptide product. The binding sample then undergoes a centrifugal ultrafiltration process with a membrane which will retain the product-avidin complex and allow passage of free gamma ^{32}P-ATP. The reservoir of the centrifuged unit containing the ^{32}P-peptide product as retentate is then counted in a scintillation counter. This procedure allows assay of any type of protein kinase sample, depending on the peptide substrate and kinase reaction buffer selected. This assay is provided in kit form (ASUA, Affinity Ultrafiltration Separation Assay, Transbio Corporation, Baltimore MD, U.S. Patent No. 5,869,275). Suggested substrates and their respective enzymes include but are not limited to: Histone H1 (Sigma) and p34^{cdc2}kinase, Annexin I, Angiotensin (Sigma) and EGF receptor kinase, Annexin II and *src* kinase, ERK1 & ERK2 substrates and MEK, and myelin basic protein and ERK (Pearson, J.D. et al. (1991) Methods Enzymol. 200:62-81).

In another alternative, protein kinase activity of PKIN is demonstrated in an assay containing PKIN, 50µl of kinase buffer, 1µg substrate, such as myelin basic protein (MBP) or synthetic peptide substrates, 1 mM DTT, 10 µg ATP, and 0.5 µCi [γ-^{32}P]ATP. The reaction is incubated at 30°C for 30 minutes and stopped by pipetting onto P81 paper. The unincorporated [γ-^{32}P]ATP is removed by washing and the incorporated radioactivity is measured using a scintillation counter. Alternatively, the reaction is stopped by heating to 100°C in the presence of SDS loading buffer and resolved on a 12% SDS polyacrylamide gel followed by autoradiography. The amount of incorporated ^{32}P is proportional to the activity of PKIN.

In yet another alternative, adenylate kinase or guanylate kinase activity may be measured by the incorporation of ^{32}P from [γ-^{32}P]ATP into ADP or GDP using a gamma radioisotope counter. The enzyme, in a kinase buffer, is incubated together with the appropriate nucleotide mono-phosphate substrate (AMP or GMP) and ^{32}P-labeled ATP as the phosphate donor. The reaction is incubated at 37°C and terminated by addition of trichloroacetic acid. The acid extract is neutralized and subjected

to gel electrophoresis to separate the mono-, di-, and triphosphonucleotide fractions. The diphosphonucleotide fraction is excised and counted. The radioactivity recovered is proportional to the enzyme activity.

In yet another alternative, other assays for PKIN include scintillation proximity assays (SPA), scintillation plate technology and filter binding assays. Useful substrates include recombinant proteins tagged with glutathione transferase, or synthetic peptide substrates tagged with biotin. Inhibitors of PKIN activity, such as small organic molecules, proteins or peptides, may be identified by such assays.

XVIII. Enhancement/Inhibition of Protein Kinase Activity

Agonists or antagonists of PKIN activation or inhibition may be tested using assays described in section XVII. Agonists cause an increase in PKIN activity and antagonists cause a decrease in PKIN activity.

XIX. Kinase Binding Assay

Binding of PKIN to a FLAG-CD44 cyt fusion protein can be determined by incubating PKIN to anti-PKIN-conjugated immunoaffinity beads followed by incubating portions of the beads (having 10-20 ng of protein) with 0.5 ml of a binding buffer (20 mM Tris-HCL (pH 7.4), 150 mM NaCl, 0.1% bovine serum albumin, and 0.05% Triton X-100) in the presence of ^{125}I-labeled FLAG-CD44cyt fusion protein (5,000 cpm/ng protein) at 4 °C for 5 hours. Following binding, beads were washed thoroughly in the binding buffer and the bead-bound radioactivity measured in a scintillation counter (Bourguignon, L.Y.W. et al. (2001) J. Biol. Chem. 276:7327-7336). The amount of incorporated ^{32}P is proportional to the amount of bound PKIN.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
2564295	1	2564295CD1	21	2564295CB1
2837050	2	2837050CD1	22	2837050CB1
7474590	3	7474590CD1	23	7474590CB1
7474594	4	7474594CD1	24	7474594CB1
7477585	5	7477585CD1	25	7477585CB1
7477587	6	7477587CD1	26	7477587CB1
7594537	7	7594537CD1	27	7594537CB1
70467491	8	70467491CD1	28	70467491CB1
7478559	9	7478559CD1	29	7478559CB1
1698381	10	1698381CD1	30	1698381CB1
7474637	11	7474637CD1	31	7474637CB1
7170260	12	7170260CD1	32	7170260CB1
1797506	13	1797506CD1	33	1797506CB1
1851973	14	1851973CD1	34	1851973CB1
7474604	15	7474604CD1	35	7474604CB1
7474721	16	7474721CD1	36	7474721CB1
7478815	17	7478815CD1	37	7478815CB1
7477141	18	7477141CD1	38	7477141CB1
2190612	19	2190612CD1	39	2190612CB1
7477549	20	7477549CD1	40	7477549CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	2564295CD1	g186555	0.0	Insulin receptor-related receptor [Homo sapiens]
2	2837050CD1	g2853031	0.0	Tousled-like kinase [Mus musculus]
3	7474590CD1	g6453611	5.1e-86	Protein kinase (mutant form) [Mus musculus]
4	7474594CD1	g3879221	5.6e-99	Predicted using Genefinder similar to casein kinase I [Caenorhabditis elegans]
5	7477585CD1	g348245	3.5e-62	Protein serine/threonine kinase [Homo sapiens]
6	7477587CD1	g312998	7.4e-73	Protein kinase [Homo sapiens]
7	7594537CD1	g485398	0.0	90kDa-diacylglycerol kinase [Rattus norvegicus]
8	70467491CD1	g3089349	0.0	Cdc25C associated protein kinase C-TAK1 [Homo sapiens]
9	7478559CD1	g7960111	4.2e-114	Ethanolamine kinase [Homo sapiens]
		g9998952	1.00E-123	[Homo sapiens] ethanolamine kinase Lykidis,A. et al. Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway J. Biol. Chem. 276, 2174-2179 (2001)
10	1698381CD1	g36615	7.7e-122	[Homo sapiens] serine/threonine protein kinase Meyerson,M. et al. (1992) EMBO J. 11:2909-2917
11	7474637CD1	g1181079	0.0	[Homo sapiens] diacylglycerol kinase delta Sakane,F. et al. (1996) J. Biol. Chem. 271:8394-8401
		g1401232	0	[Cricetinae gen. sp.] diacylglycerol kinase eta Klauck,T.M. et al. Cloning and characterization of a glucocorticoid-induced diacylglycerol kinase J. Biol. Chem. 271, 19781-19788 (1996)

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
12	7170260CD1	g8101585	3.5e-126	[Mus musculus] testis specific serine kinase-3 Zuercher,G. et al (2000) Mech. Dev. 93:175-177
13	1797506CD1	g3300094	4.5e-227	[Homo sapiens] protein kinase/endoribonuclease Tirasophon,W. et al. (1998) Genes Dev. 12:1812-1824
		g12407081	0	[Homo sapiens] protein kinase/ribonuclease IRE1 beta Iwawaki,T. et al. Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress Nat. Cell Biol. 3, 158-164 (2001)
14	1851973CD1	g1853976	1.3e-37	[Schizosaccharomyces pombe] protein kinase Samejima,I., and Yanagida,M. (1994) Mol Cell Biol 14:6361-71
		g9294489	5.00E-47	[Arabidopsis thaliana] IRE homolog; protein kinase-like protein Sato,S., Nakamura,Y., Kaneko,T., Katoh,T. et al. Structural analysis of Arabidopsis thaliana chromosome 3. I. Sequence features of the regions of 4,504,864 bp covered by sixty P1 and TAC clones DNA Res. 7, 131-135 (2000)
15	7474604CD1	g1171250	2.0e-218	[Mus musculus] protein kinase related to Raf protein kinases Therrien,M. et al. (1995) Cell 83:879-888
16	7474721CD1	g551608	4.1e-290	[Homo sapiens] receptor protein-tyrosine kinase Fox,G.M. et al. (1995) Oncogene 10:897-905
17	7478815CD1	g2873349	0.0	[Homo sapiens] Hexokinase I Ruzzo,A. et al. (1998) Biochem. J. 331(Pt 2):607-613

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
18	7477141CD1	g7239696	1.6e-87	[Homo sapiens] myosin light chain kinase Garcia,J.G. et al. (1997) Am. J. Respir. Cell Mol. Biol. 16:489-494 Garcia,J.G.N. et al. (1996) Biochem. Biophys. Res. Commun. 1:1-1
		g11385416	0	[Mus musculus] striated muscle-specific serine/threonine protein kinase Hsieh,C.M. et al. Striated Muscle Preferentially Expressed Genes alpha and beta Are Two Serine/Threonine Protein Kinases Derived from the Same Gene as the Aortic Preferentially Expressed Gene-1 J. Biol. Chem. 275 (47), 36966-36973 (2000)
19	2190612CD1	g1836161	6.0e-257	[Rattus sp.] Ca2+/calmodulin-dependent protein kinase IV kinase Okuno,S., Kitani,T. and Fujisawa,H. (1996) J. Biochem. 119:1176-1181
20	7477549CD1	g5006445	3.6e-179	[Homo sapiens] CDC42-binding protein kinase beta Moncrieff,C.L. et al. (1999) Genomics 57:297-300
		g2736151	0	[Rattus norvegicus] mytonic dystrophy kinase-related Cdc42-binding kinase Leung,T. et al. Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization Mol. Cell. Biol. 18, 130-140 (1998)

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
20		g2217968	1.40E-161	[Homo sapiens] myotonic dystrophy protein kinase Kedra,D. et al. The germinal center kinase gene and a novel CDC25-like gene are located in the vicinity of the PYGM gene on 11q13 Hum. Genet. 100, 611-619 (1997)

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	2564295CD1	1297	S151 S238 S271 S49 S564 S666 S741 S758 S827 S887 S900 S93 S962 T223 T348 T475 T486 T494 T581 T582 T629 T64 Y454 Y652 T1014 T1020 T1063 S1163 T1171 T1187 S1245 T1275 T1284 S1073 T1128 S1253 T1145	N311 N411 N47 N492 N528 N616 N634 N756 N885 N898 N949	PROTEIN KINASE DOMAIN DM00004|P14617|980-1238: S980-F1239	BLAST-DOMO
					RECEPTOR PRECURSOR SIGNAL TRANSFERASE TYROSINEPROTEIN KINASE TRANSMEMBRANE GLYCOPROTEIN ATPBINDING PHOSPHORYLATION PD006834: A603-R745, F760-I818	BLAST-PRODOM
					RECEPTOR PRECURSOR SIGNAL TRANSFERASE TYROSINEPROTEIN KINASE TRANSMEMBRANE GLYCOPROTEIN ATPBINDING PHOSPHORYLATION PD005347: Q466-P602	BLAST-PRODOM
					PUTATIVE INSULINLIKE PEPTIDE RECEPTOR PRECURSOR EC 2.7.1.112 TRANSFERASE TYROSINEPROTEIN KINASE TRANSMEMBRANE GLYCOPROTEIN ATPBINDING PHOSPHORYLATION SIGNAL PD146134: L344-E495, V773-G899, D513-C799, E825-R855	BLAST-PRODOM
					PRECURSOR SIGNAL INSULINLIKE RECEPTOR TRANSFERASE TYROSINEPROTEIN KINASE TRANSMEMBRANE GLYCOPROTEIN ATPBINDING PD004354: V330-G410	BLAST-PRODOM
					Receptor tyrosine kinase BL00239: G464-P473, E1030-E1077, M1092-R1114, A1117-E1142, D1144-Y1193, N1198-I1242	BLIMPS-BLOCKS
					Receptor tyrosine kinase BL00240F: T1143-E1190	BLIMPS-BLOCKS
					Receptor tyrosine kinase BL00790H: S831-L856	BLIMPS-BLOCKS
					Tyrosine kinase catalytic domain PR00109: M1059-R1072, Y1105-V1123, L1154-L1164, S1173-G1195, C1217-F1239	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: E1091-T1143	PROFILESCAN
					Receptor tyrosine kinase class II signature receptor_tyr_kin_ii.prf: R1119-G1167	PROFILESCAN
					Signal peptide: M1-D25	HMMER
					Transmembrane domain: V922-Y944,	HMMER
					Furin-like cysteine rich region: G173-K329	HMMER-PFAM
					Receptor L domain: N47-N170, G346-N472	HMMER-PFAM
					Eukaryotic protein kinase domain pkinase: I979-E1248	HMMER-PFAM
					Protein_Kinase_Atp L985-K1013	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
2	2837050CD1	718	S165 S186 S194 S238 S246 S257 S275 S298 S44 S46 S509 S605 S632 T176 T269 T344 T403 T488 T558 T78 Y571 Y97	N340 N36 N548 N630 N713 N714	PROTEIN KINASE DOMAIN DM00004|P34314|736-1002: L409-D677	BLAST-DOMO
					TOUSLEDLIKE KINASE PD102959: M2-E183	BLAST-PRODOM
					KINASE PROTEIN TOUSLEDLIKE PD013350: M237-D400, Q287-L409	BLAST-PRODOM
					TOUSLEDLIKE KINASE KIAA0137 PROTEIN PD035377: K184-T236	BLAST-PRODOM
					TOUSLEDLIKE KINASE MULTIPLE TESTIS TRANSCRIPT PD026280: A682-N718	BLAST-PRODOM
					Tyrosine kinase catalytic domain PR00109: L490-K503; V608-N630	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: E512-S570	PROFILESCAN
					Eukaryotic protein kinase domain pkinase: Y408-L687	HMMER-PFAM
					Protein_Kinase_Atp: L414-K437	MOTIFS
					Protein_Kinase_St: I534-L546	MOTIFS
3	7474590CD1	497	S17 S286 S291 S3 S314 S356 S372 S375 S381 S382 S409 S440 S447 S5 S70 T225 T265 T427 T445 T461	N243	PROTEIN KINASE DOMAIN DM00004|P27448|58-297: V30-T265	BLAST-DOMO
					Tyrosine kinase catalytic domain PR00109: Y136-V154, V202-S224, L244-A266	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: Q94-G174	PROFILESCAN
					Eukaryotic protein kinase domain pkinase: Y28-L275	HMMER-PFAM
					Protein_Kinase_St: V142-V154	MOTIFS
4	7474594CD1	741	S397 S402 S471 S592 S641 S652 S656 S737 T237 T274 T292 T308 T388 T587	N119 N291	PROTEIN KINASE DOMAIN DM00004|P48730|11-265: K144-Y392	BLAST-DOMO
					SIMILAR TO CASEIN KINASES PD115501: F332-D422, L130-T233	BLAST-PRODOM
					Eukaryotic protein kinase domain pkinase: W140-F374	HMMER-PFAM
					Protein_Kinase_Atp: I146-K169	MOTIFS
					Signal cleavage: M1-L19	SPSCAN

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5	7477585CD1	645	S251 S273 S277 S372 S414 S454 S47 S490 S522 S600 S64 S84 S97 T211 T302 T329 T340 T538 T547 Y368	N598 N71	PROTEIN KINASE DOMAIN DM00004|P51957|8-251: L35-S277	BLAST-DOMO
					Tyrosine kinase catalytic domain PR00109: T108-Q121, Y148-L166, Y256-A278	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: Q134-S185	PROFILESCAN
					Eukaryotic protein kinase domain pkinase: Y29-L287	HMMER-PFAM
					Protein_Kinase_St: I154-L166	MOTIFS
6	7477587CD1	623	S32 S393 S439 S54 S61 S67 S80 S93 T195 T367 T454 T463 T584		PROTEIN KINASE DOMAIN DM00004|P53350|55-295: R99-A267, S253-L310	BLAST-DOMO
					Tyrosine kinase catalytic domain PR00109: Y212-L230	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: E198-G250	PROFILESCAN
					Transmembrane domain transmem_domain: L555-S575	HMMER
					Eukaryotic protein kinase domain pkinase: Y97-A267, S268-F319	HMMER-PFAM
					Protein_Kinase_Atp: I103-K126	MOTIFS
					Protein_Kinase_St: I218-L230	MOTIFS
7	7594537CD1	797	S11 S136 S165 S208 S25 S294 S380 S670 S675 S684 S81 T2 T26 T274 T298 T312 T320 T388 T518 T62 T625 T689 T743 T762 T766 Y449	N546 N646 N793	PHORBOL-ESTER AND DAG BINDING DOMAIN DM01331 |P49621|326-792: V321-K789	BLAST-DOMO
					KINASE DIACYLGLYCEROL PHORBOLESTER BINDING TRANSFERASE DIGLYCERIDE DAG MULTIGENE FAMILY DGK PD002939: I575-P755	BLAST-PRODOM
					PROBABLE DIACYLGLYCEROL KINASE EC 2.7.1.107 DIGLYCERIDE DGK DAG HYPOTHETICAL PROTEIN TRANSFERASE CALCIUMBINDING PHORBOLESTER BINDING PD078865: A118-G236, L10-D85, T50-S81	BLAST-PRODOM
					KINASE DIACYLGLYCEROL PHORBOLESTER BINDING PROTEIN TRANSFERASE DIGLYCERIDE DAG MULTIGENE FAMILY PD002780: P431-W555	BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					DIACYLGLYCEROL KINASE, BETA EC 2.7.1.107 DIGLYCERIDE KINASE DGK DAG 90 KD TRANSFERASE CALCIUMBINDING PHORBOLESTER BINDING MULTIGENE FAMILY PD119174: D352-H430	BLAST-PRODOM
					Diacylglycerol kinase catalytic domain PF00781: H331-Q336 P431-Y462 R483-L497 P509-Y532 K539-V559 N577-Y613 L655-G668 L747-Q758	BLIMPS-PFAM
					Diacylglycerol kinase catalytic domain DAGKc: P431-W555	HMMER-PFAM
					Diacylglycerol kinase accessory domain DAGKa: I575-P755	HMMER-PFAM
					Phorbol esters/diacylglycerol binding domain d DAG_PE-gind: H238-C287, H303-C351	HMMER-PFAM
					EF hand efhand: K146-M174, I191-T219	HMMER-PFAM
					Phorbol esters/diacylglcerol binding domain BL00479: Q264-C279, L514-L526, H238-G260	BLIMPS-BLOCKS
					Phorbol esters/diacylglycerol binding domain dag_pe_binding_domain.prf: Y250-G378	PROFILESCAN
					Dag_Pe_Binding_Domain: H238-C287	MOTIFS
					Ef_Hand: D155-L167, D200-W212	MOTIFS
8	70467491CD1	749	S141 S2 S24 S346 S374 S417 S424 S444 S456 S457 S461 S49 S494 S495 S516 S634 S653 S659 S664 S730 T118 T283 T302 T33 T36 T508 T512 T519 T535 T614 T618 T623 T82 T9 Y113	N386 N399 N400 N479 N533 N637	PROTEIN KINASE DOMAIN DM00004|P27448|58-297: L62-L303	BLAST-DOMO
					KINASE SERINE/THREONINEPROTEIN PROTEIN TRANSFERASE ATPBINDING SERINE/THREONINE PUTATIVE KIN1 EMK PAR1 PD004300: G633-L749	BLAST-PRODOM
					KINASE SERINE/THREONINEPROTEIN SERINE/THREONINE PUTATIVE TRANSFERASE ATPBINDING PROTEIN EMK P78 CDC25C PD008571: S413-E632	BLAST-PRODOM
					KINASE SERINE/THREONINEPROTEIN PUTATIVE SERINE/THREONINE TRANSFERASE ATPBINDING PROTEIN PAR1 KP78 EMK PD005838: I312-R412	BLAST-PRODOM
					SERINE/THREONINE KINASE PD119193: S551-P622	BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Tyrosine kinase catalytic domain PR00109: Y173-L191, V239-Q261	BLIMPS-PRINTS
					Protein kinases signatures and profile protein_kinase_tyr.prf: K122-G212	PROFILESCAN
					Eukaryotic protein kinase domain pkinase: Y60-E85	HMMER-PFAM
					Eukaryotic protein kinase domain pkinase: F137-I312	HMMER-PFAM
					Protein_Kinase_St: I179-L191	MOTIFS
9	7478559CD1	386	S237 S259 S355 S38 S380 T20 T322 T85 T93 Y271	N188	do CHOLINE; KINASE; YDR147W; B0285.10; DM01931|P35790|128-455: D258-K376, F131-P300	BLAST-DOMO
					do CHOLINE; KINASE; YDR147W; B0285.10; DM01931|P46560|1-305: E125-A289	BLAST-DOMO
					KINASE CHOLINE TRANSFERASE PROTEIN MULTIGENE FAMILY PUTATIVE LIKE CHROMOSOME III PD003547: V222-L382, V109-E240	BLAST-PRODOM
					KINASE TRANSFERASE CHOLINE PD02952: V243-I256, H263-N292	BLIMPS-PRODOM
					Choline/ethanolamine kinase Choline_kinase: T85-T356	HMMER-PFAM
10	1698381CD1	342	S180 S205 S238 S284 S288 S38 T247 Y15 Y211	N23	Eukaryotic protein kinase domain pkinase:Y4-F286,	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: E90-G154	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|Q00532|7-278: K6-C277	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|Q00526|6-286: K6-F286	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P23437|6-286: K6-G218	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P51958|6-277: K6-G218	BLAST_DOMO
					KINASE TRANSFERASE PROTEIN SERINE/THREONINE PROTEIN ATP-BINDING II PHOSPHORYLATION CASEIN ALPHA CHAIN PD002608: V161-F286	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					Tyrosine kinase catalytic domain signature PR00109: F116-I134	BLIMPS_PRINTS
					Serine/Threonine protein kinases active-site signature C122-I134	MOTIFS
11	7474637CD1	1164	S114 S119 S152 S258 S39 S399 S41 S432 S450 S511 S56 S586 S587 S591 S608 S623 S654 S66 S664 S695 S766 S820 S873 S958 S967 S1075 T316 T419 T486 T514 T518 T659 T678 T863 T908 T955 T1046 T1118	N124 N314 N651 N1059 N1122	Phorbol esters/ diacylglycerol binding domain: F188-A259	PROFILESCAN
					signal_cleavage:M1-A32	SPSCAN
					Phorbol esters/diacylglycerol binding domain (C1 domain): H176-C225, H248-C298	HMMER_PFAM
					PH domain: S66-T158	HMMER_PFAM
					DAG kinase catalytic domain: P332-W457	HMMER_PFAM
					DAG kinase accessory domain: V770-A927	HMMER_PFAM
					PHORBOL-ESTER AND DAG BINDING DOMAIN DM01331|P49621|326-792: P332-H505, V770-E865, F869-L946, C279-L313, G198-C225	BLAST_DOMO
					PHORBOL-ESTER AND DAG BINDING DOMAIN DM01331|Q09103|683-1148: V330-I459, T752-R948, C279-P310, A2-I61	BLAST_DOMO
					PHORBOL-ESTER AND DAG BINDING DOMAIN DM01331|P23743|308-734: P332-L500, V770-F869, P872-L946	BLAST_DOMO
					PHORBOL-ESTER AND DAG BINDING DOMAIN DM01331|I59282|352-782: C279-H505, V770-L946	BLAST_DOMO
					KINASE DIACYLGLYCEROL ETA DIGLYCERIDE DAG TRANSFERASE PHORBOLESTER BINDING REPEAT MULTIGENE PD040467: S458-C769	BLAST_PRODOM
					DIACYLGLYCEROL PHORBOLESTER BINDING KINASE ETA DIGLYCERIDE DAG TRANSFERASE REPEAT MULTIGENE PD038733: A927-V1130	BLAST_PRODOM
					KINASE DIACYLGLYCEROL PHORBOLESTER BINDING TRANSFERASE DIGLYCERIDE DAG MULTIGENE FAMILY DGK PD002939: V770-E926	BLAST_PRODOM
					KINASE DIACYLGLYCEROL PHORBOLESTER BINDING PROTEIN TRANSFERASE DIGLYCERIDE DAG MULTIGENE FAMILY PD002780: V330-W457	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE; THREONINE; ATP; SERINE; DM06305|P32361|972-1114: Q813-L946	BLAST_DOMO
					PROTEIN KINASE/ENDORIBONULCEASE PUTATIVE SERINE/THREONINE PROTEIN KINASE C41C4.4 CHROMOSOME II PRECURSOR TRANSFERASE PD152704: T197-L422, L88-E190	BLAST_PRODOM
					SERINE/THREONINE PROTEIN KINASE PRECURSOR TRANSMEMBRANE SIGNAL TRANSFERASE ATP-BINDING PROTEIN IRE1 GLYCOPROTEIN PD032590: W821-Y949	BLAST_PRODOM
					Tyrosine kinase catalytic domain signature PR00109: H666-I684, G721-L731, V743-D765	BLIMPS_PRINTS
					Serine/Threonine protein kinases active-site signature: I672-I684	MOTIFS
					Phosphorylase kinase family signature PR01049: P812-R823	BLIMPS_PRINTS
14	1851973CD1	329	S264 S270 S293 S31 S311 S320 S7	N73	Eukaryotic protein kinase domain pkinase: F35-V180	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: M132-R184	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|P43565|796-1240: I37-R184	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|A56155|714-1002: V38-L177	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P38679|238-527: V38-S178	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P53894|353-658: V38-S178	BLAST_DOMO
					Tyrosine kinase catalytic domain signature PR00109: M110-H123, Y146-I164	BLIMPS_PRINTS
					Serine/Threonine protein kinases active-site signature: I152-I164	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
15	7474604CD1	945	S110 S157 S193 S246 S289 S290 S31 S329 S356 S359 S405 S411 S611 S623 S636 S645 S67 S934 T170 T2 T217 T322 T42 T47 T496 T712 T839	N140 N155 N382 N631 N756 N888	Eukaryotic protein kinase domain pkinase: L661-M920	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: K757-L801	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|P27966|85-332: I663-F916	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P15056|458-705: I663-F916,	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P10398|312-559: I667-F916	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|B26126|305-552: I667-F916	BLAST_DOMO
					KINASE SUPPRESSOR OF RAS1 KSR1 HB PROTEIN PD103125: V390-P557, K501-L661 L222-P323	BLAST_PRODOM
					KINASE SUPPRESSOR OF RAS KSR PHORBOLESTER BINDING RAS1 KSR1 HB PD017776: L21-E344 S485-T519	BLAST_PRODOM
					Tyrosine kinase catalytic domain signature PR00109: Y771-Y789, W867-I877, M894-F916	BLIMPS_PRINTS
					Serine/Threonine protein kinases active-site signature: I777-Y789	MOTIFS
16	7474721CD1	1009	S184 S203 S244 S293 S325 S44 S473 S62 S625 S682 S686 S805 S825 S851 S980 T108 T121 T133 T162 T214 T224 T232 T32 T423 T488 T551 T616 T619 Y504 Y766 Y801	N311 N486	Eukaryotic protein kinase domain pkinase: V645-H897	HMMER_PFAM
					Ephrin receptor ligand binding domain EPH_lbd: E35-C211	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: Q746-A799	PROFILESCAN
					RECEPTOR TYROSINE KINASE CLASS V DM00501|S51741|33-382: V36-G394	BLAST_DOMO
					RECEPTOR TYROSINE KINASE CLASS V DM00501|P54759|33-382: V36-G394	BLAST_DOMO
					RECEPTOR TYROSINE KINASE CLASS V DM00501|I48611|34-382: I37-G394	BLAST_DOMO
					RECEPTOR TYROSINE KINASE CLASS V DM00501|I48612|34-382: I37-G394	BLAST_DOMO
					KINASE RECEPTOR PRECURSOR TYROSINE PROTEIN EPHRIN TRANSFERASE ATP-BINDING PHOSPHORYLATION TRANSMEMBRANE GLYCOPROTEIN PD001495: E35-C211	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE RECEPTOR PRECURSOR TYROSINE PROTEIN EPHRIN TRANSFERASE ATP-BINDING PHOSPHORYLATION TRANSMEMBRANE GLYCOPROTEIN PD149648: A213-A284	BLAST_PRODOM
					EPH FAMILY PROTEIN PD002683: P339-T451	BLAST_PRODOM
					KINASE RECEPTOR PRECURSOR TYROSINE PROTEIN EPHRIN TRANSFERASE ATP-BINDING PHOSPHORYLATION TRANSMEMBRANE SIGNAL PD001551: C285-R336	BLAST_PRODOM
					Receptor tyrosine kinase BL00239: E694-Q741, L747-R769, A772-S797, E798-Y847, G852-I896	BLIMPS_BLOCKS
16	74777421CD1	1009			Receptor tyrosine kinase BL00790: L751-A772, S805-W837, E838-G862, F863-K911, A955-R998, E35-N56, D65-P116, K172-A225, P252-Q276, C282-P329, R351-L377, C390-S433	BLIMPS_BLOCKS
					signal peptide: M1-A33	HMMER
					transmembrane domain: V568-W589	HMMER
					signal_cleavage: M1-A33	SPSCAN
17	7478815CD1	917	S243 S364 S379 S449 S503 S547 S551 S772 S787 S791 S810 S826 S896 T114 T161 T172 T275 T35 T508 T523 T569 T625 T722 T726 T811 T877 Y27 Y497	N122 N208 N655	Hexokinase hexokinase:E16-V463 Q464-L910	HMMER_PFAM
					Hexokinases signature hexokinases: I577-R642, V130-R195	PROFILESCAN
					HEXOKINASES DM00597|P27881|465-915: Q466-A913, D17-Q464	BLAST_DOMO
					HEXOKINASES DM00597|P52789|465-915: Q466-A913, D17-Q464	BLAST_DOMO
					HEXOKINASES DM00597|S48809|465-915: Q466-A913, D17-Q464	BLAST_DOMO
					HEXOKINASES DM00597|P27595|465-915: Q466-Q911, D17-Q466	BLAST_DOMO
					HEXOKINASE TRANSFERASE KINASE GLYCOLYSIS ATP-BINDING TYPE ALLOSTERIC ENZYME HK DUPLICATION PD001109: Q466-D886, E699-A907, E16-D439, D251-R462	BLAST_PRODOM
					Hexokinases proteins. BL00378: V22-K49, V509-I545, V207-G250, M255-D266, Y724-G769, S892-V906	BLIMPS_BLOCKS
					Hexokinase family signature PR00475: L529-I545, L597-F622, I650-Y666, V226-E240, Q291-M313, V818-I840, M890-V906	BLIMPS_PRINTS
					Hexokinases L597-F622	MOTIFS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18	7477141CD1	2380	S143 S166 S241 S277 S278 S285 S299 S343 S480 S537 S553 S568 S602 S711 S736 S996 S1033 S1035 S1037 S1062 S1127 S1523 S1571 S1245 S1435 S1468 S1506 S1586 S1609 S1679 S1691 S1747 S1117 S1527 S1557 S1578 S1594 S1613 S1736 S1747 S1876 S1947 S2137 S2171 S2253 S2321 S2058 S2062 S2165 S2269 S680 S754 S986 T108 T153 T158 T170 T350 T408 T476 T498 T578 T614 T692 T803 T862 T957 T1068 T1082 T1311 T1493 T1802 T1981 T2080 T1301 T1856 T1901 T2069 T2101 T2144 T2348 T1608 T2343 Y632 Y772 Y822	N37 N1675, N1847 N1874 N2099 N2299	Eukaryotic protein kinase domain pkinase: Y714-F967, Y2079-L2331	HMMER_PFAM
					PROTEIN KINASE DOMAIN DM00004|S07571|5152-5396: D715-D952, E2083-L2322	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P53355|15-257: Q718-D952, E2083-L2322	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|JN0583|727-969: I716-D952, L2082-L2312	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P07313|298-541: Q718-R953, G2088-S2321	BLAST_DOMO
					Tyrosine kinase catalytic domain signature PR00109: Y822-V840	BLIMPS_PRINTS
					signal peptide: M52-A70	HMMER
					Eukaryotic protein kinase domain pkinase: Y2079-L2331	HMMER_PFAM
					Protein kinases ATP-binding region signature: I720-K743	MOTIFS
					Serine/Threonine protein kinases active-site signature: V828-V840, V2194-L2206	MOTIFS
19	2190612CD1	505	S100 S117 S160 S330 S419 S425 S437 S458 S69 S74 S82 T108 T26 T430 T58	N147	Eukaryotic protein kinase domain: Y128-V409	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: Q251-N303	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|A57156|130-399: L130-V400	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P50526|136-399: E133-I398	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P38990|135-438: E133-E320, N303-V400	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P43637|52-334: I134-I378	BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE PROTEIN BETA CA2+/CALMODULIN DEPENDENT CA+/CALMODULIN DEPENDENT CAM KINASE IV ISOFORM PHOSPHORYLASE B PD031900: M1-Q127	BLAST_PRODOM
					KINASE PROTEIN BETA CA2+/CALMODULIN DEPENDENT CA+/CALMODULIN DEPENDENT CAM KINASE IV ISOFORM PHOSPHORYLASE B PD019141: V409-F463	BLAST_PRODOM
					KINASE PROTEIN CA2+/CALMODULIN DEPENDENT IV ISOFORM PHOSPHORYLASE B GLYCOGEN SYNTHASE A PD027014: E464-S505	BLAST_PRODOM
					Tyrosine kinase catalytic domain signature PR00109: Y265-L283, G312-I322	BLIMPS_PRINTS
					ATP/GTP-binding site motif A (P-loop) G485-S492	MOTIFS
					Protein kinases ATP-binding region signature: I134-K157	MOTIFS
					Serine/Threonine protein kinases active-site signature: I271-L283	MOTIFS
20	7477549CD1	1572	S161 S280 S307 S363 S407 S430 S471 S545 S625 S629 S646 S675 S711 S730 S737 S807 S811 S815 S841 S1058 S1294 S1162 S1500 S1405 S1414 S1556 T455 T590 T673 T888 T956 T1088 T1378		Phorbol esters diacylglycerol binding domain: C900-S963	PROFILESCAN
					Eukaryotic protein kinase domain pkinase: F71-F337	HMMER_PFAM
					PROTEIN KINASE DOMAIN DM00004|Q09013|83-336: I73-R325	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|S42867|75-498: I73-H252, V232-Y398	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|I38133|90-369: E72-L220, V232-G324	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P53894|353-658: L74-G215, V232-R325	BLAST_DOMO
					PHORBOL ESTER BINDING KINASE DYSTROPHY KINASE RELATED CDC42 BINDING SIMILAR SERINE/THREONINE PROTEIN GENGHIS KHAN PD150840: W1355-G1462	BLAST_PRODOM
					PHORBOL ESTER BINDING KINASE DYSTROPHY KINASE RELATED CDC42 BINDING SIMILAR SERINE /THREONINE PROTEIN GENGHIS KHAN PD151400: T1039-R1140	BLAST_PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
					KINASE RHO ASSOCIATED COILED COIL PROTEIN FORMING PHORBOL ESTER BINDING DYSTROPHY KINASE RELATED CDC42 BINDING PD006715: T944-V1038, H433-L456	BLAST_PRODOM
					PHORBOL ESTER BINDING DYSTROPHY KINASE RELATED CDC42 BINDING KINASE GENGHIS KHAN MYTONIC MYOTONIC PD011252:S694-S815	BLAST_PRODOM
					Tyrosine kinase catalytic domain signature PR00109: C257-E279, M148-S161, S185-L203	BLIMPS_PRINTS
					Phorbol esters/diacylglycerol binding dom DAG_PE-bind: H887-C935	HMMER_PFAM
					Phorbol esters/diacylglycerol binding domain: H887-C935,	MOTIFS
					Protein kinases ATP-binding region signature I77-K100	MOTIFS
					Serine/Threonine protein kinases active-site signature: Y191-L203	MOTIFS
					CNH domain: L1100-K1380	HMMER_PFAM
					Protein kinase C terminal domain: P351-D366	HMMER_PFAM
					PH domain PH: T956-R1074	HMMER_PFAM
					signal_cleavage: M1-S37	SPSCAN

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
21	2564295CB1	4298	701-1736, 3536-3629, 1-356, 2349-2589, 3956-4298, 2841-3428	FL2564295_g7160581_000014_g387060_1_15-16	3200	3482
				FL2564295_g7160581_000014_g387060_1_16-17	3253	3593
				FL2564295_g7160581_000014_g387060_1_7-8	1938	2334
				55078393J1	37	717
				FL2564295_g7160581_000014_g387060_1_8-9	2167	2530
				55078386J1	1	709
				FL2564295_g7160581_000014_g387060_1_18-19	3594	3883
				2564295H1 (ADRETUT01)	4048	4298
				g186554_CD	442	4250
				FL2564295_g7160581_000014_g387060_1_9-10	2335	2572
				3599581H1 (DRGTNOT01)	3453	3756
				FL2564295_g7160581_000014_g387060_1_1-2	441	1297
				FL2564295_g7160581_000014_g387060_1_10-11	2531	2793
				FL2564295_g7160581_000014_g387060_1_20-21	3884	4250
				FL2564295_g7160581_000014_g387060_1_11-12	2573	2930
				FL2564295_g7160581_000014_g387060_1_2-3	994	1440
				FL2564295_g7160581_000014_g387060_1_12-13	2794	3093
				FL2564295_g7160581_000014_g387060_1_3-4	1298	1585
				FL2564295_g7160581_000014_g387060_1_4-5	1441	1800

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
21				FL2564295_g7160581_000014_g387060_1_14-15	3094	3252
				FL2564295_g7160581_000014_g387060_1_19-20	3754	4018
22	2837050CB1	2863	1-430, 2346-2863	6854541H1 (BRAIFEN08)	782	1467
				g1164223	1	496
				71191190V1	1439	2085
				7728560H1 (UTRCDIE01)	79	681
				71972220V1	2227	2863
				71972389V1	2180	2857
				6881340H1 (BRAHTDR03)	1555	2209
				7401101H1 (SINIDME01)	598	1293
23	7474590CB1	1494	1-1494	GBI.g8103343_000001.edit	1	1494
				FL7474590_g7630344_000002_g6779549_1_1	1	1116
24	7474594CB1	2341	682-792, 1-262, 1522-2341, 1254-1373, 339-361	55053685J1	1512	2341
				6949237H1 (BRAITDR02)	858	1544
				8016740J1 (BMARTXE01)	340	959
				GNN.g8247875_000031_002	1	426
				7278940H1 (BMARTXE01)	1281	1779
				GNN.g6689704_000006_002	1180	1590
25	7477585CB1	2552	1-465, 1075-1150	71975408V1	1988	2534
				55030002H1	612	1305
				55030074J1	1241	1900
				1406660F6 (LATRTUT02)	1	686
				6329987H1 (BRANDIN01)	1384	1930
				71987367V1	2019	2552
				6704049H1 (DRGCNOT02)	1849	2517
				55030089H1	679	1390
26	7477587CB1	2176	1276-1873, 1-286	g8671962_edit	1	1980
				5823464F7 (PROSTUS23)	1662	2164

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
27	7594537CB1	4277	2383-2614, 611-1170, 1-518, 2763-2834, 1714-1859, 3119-4277	7594537H1 (LIVRNOC07)	130	766
				7328693H1 (UTRCDIE01)	1	351
28	70467491CB1	2616	1717-2616, 1-425	2395018F6 (THP1AZT01)	2015	2520
				FL70467491_g7708222_g7595800	1	2250
29	7478559CB1	1253	1215-1253, 1-53	g3770955	1	321
				7661715J1 (OVARNOE02)	655	1253
				g5769093	314	804
30	1698381CB1	1790	1-146, 892-1313, 1659-1790, 186-237	1698381F6 (BLADTUT05)	523	1019
				55068293J1	1	786
				71870273V1	1186	1790
				1698381T6 (BLADTUT05)	774	1363
31	7474637CB1	4132	3420-3535, 1-377, 4035-4132, 1301-2486	4129796F6 (CARGDIT01)	3639	4132
				55076747H1	2871	3468
				55075847H1	1379	1783
				55075848H1	1623	1987
				55077477H1	1045	1472
				GBI.g8247425_000008_000011.edit	504	1126
				55076756J1	3148	3745
				GNN.g6648263_002.edit5p	2805	3026
				6286993H2 (EPIPUNA01)	1041	1168
				7721743H2 (THYRDIE01)	35	503
				6766106H1 (BRAUNOR01)	1893	2356
				55061367H1	2149	2841
				6766106J1 (BRAUNOR01)	368	909
				1752420H1 (LIVRTUT01)	1	157
32	7170260CB1	1137	877-1137	55046242J2	694	1137
				3152909F6 (TLYMTXT02)	1	145

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
32				7659273J1 (OVARNOE02)	416	971
				55046250H1	692	1108
				3343082F7 (SPLNNOT09)	144	555
33	1797506CB1	3365	1-1032, 3340-3365, 1532-1735	1513994T6 (PANCTUT01)	2793	3365
				FL1797506_g7458755_000012_g3766209	1	2898
34	1851973CB1	2049	1-125, 1836-2049, 806-915	7667239H1 (URETTUC01)	1289	1800
				55075655J1	547	1222
				55077257J1	378	1221
				55067487H1	1	532
				1454205F1 (PENITUT01)	1179	1617
				1454205T6 (PENITUT01)	1436	2049
35	7474604CB1	2962	1-1526, 1757-2114, 2481-2962	55075789J1	1760	2440
				8104459J1 (MIXDDIE02)	1	746
				55056946J2	1734	2433
				6884701F6 (BRAHTDR03)	2255	2962
				55067076J1	1214	1763
				55075383J1	651	1335
36	7474721CB1	3112	2395-3112, 1353-1459, 2014-2280	6802884F6 (COLENOR03)	2055	2826
				71976507V1	1564	2315
				55057353J1	314	980
				GBI:g6996165_000001.raw	1910	3112
				GBI:g6996165.raw	140	1735
				55062828H1	1	712
				71980671V1	1418	2051
37	7478815CB1	3650	862-1366, 1826-1999, 1-787, 3623-3650	55076655H1	1	658
				6934749H1 (SINTTMR02)	1710	2388
				238539R6 (SINTNOT02)	3159	3647
				614864T6 (COLNTUT02)	3004	3614
				70845065V1	1862	2441
				70842842V1	2420	3073

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
37				72026676V1	966	1742
				55075416J1)	358	926
				g657793	919	1011
				70863076V1	2471	3154
				2605255F6 (LUNGTUT07)	3378	3650
38	7477141CB1	7789	1-699, 6785-6880, 7767-7789, 7184-7214, 1237-6218	7355120H1 (HEARNON03)	7201	7767
				GBI:g8014664	1	260
				g7242948_CD	63	6763
				3012344H1 (MUSCNOT07)	7488	7772
				71179707V1	6783	7436
				7642405J1 (SEMVTDE01)	6728	7294
39	2190612CB1	1937	727-1188, 1-643, 1731-1761	70775995V1	1	498
				55024095J1 (PKINDNV04)	914	1558
				6854667H1 (BRAIFEN08)	1441	1937
				7188730H2 (BRATDIC01)	1353	1820
				70780513V1	500	981
				70780809V1	384	919
40	7477549CB1	5373	4983-5373, 1-1612, 2046-2470, 4414-4442, 2596-2647, 2814-3056	55121415H1	4574	5373
				55121423J1	4413	5274
				7992167H1 (UTRSDIC01)	3402	4043
				71999521V1	1448	1590
				6822270H1 (SINTNOR01)	857	1407
				GNN.g4755212_010.edit	1	4567
				6594083H1 (LUNGFER02)	2835	3147
				7164493R8 (PLACNOR01)	3204	3711
				71583419V1	713	1385
				7402224H1 (SINIDME01)	289	795
				7694930H1 (LNODTUE01)	1082	1448
				7978995H1 (LSUBDMC01)	1478	2186

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
21	2564295CB1	ADRETUT01
22	2837050CB1	THYRNOT03
24	7474594CB1	BMARTXE01
25	7477585CB1	BRALNON02
26	7477587CB1	PROSTUS23
27	7594537CB1	LIVRNOC07
28	70467491CB1	PROSNOT18
29	7478559CB1	OVARNOE02
30	1698381CB1	BLADTUT05
31	7474637CB1	EPIPUNA01
32	7170260CB1	OVARNOE02
33	1797506CB1	COLENOR03
34	1851973CB1	PENITUT01
35	7474604CB1	BRAHTDR03
36	7474721CB1	COLENOR03
37	7478815CB1	SINITUT03
38	7477141CB1	SKIRNOR01
39	2190612CB1	ADRETUT07
40	7477549CB1	SINTNOR01

Table 6

Library	Vector	Library Description
ADRETUT01	PSPORT	Library was constructed using RNA isolated from right adrenal tumor tissue removed from a 50-year-old Turkish male during aunilateral adrenalectomy. Pathology indicated a metastatic renal cell carcinoma that formed a circumscribed, spongy, hemorrhagic nodule situated in the region of the medulla. The patient presented with corticoadrenal insufficiency, incisional hernia, and non-alcoholic steato hepatitis. Patient history included renal cell carcinoma. Family history included liver cancer.
ADRETUT07	pINCY	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 43-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated pheochromocytoma.
BLADTUT05	pINCY	Library was constructed using RNA isolated from bladder tumor tissue removed from a 66-year-old Caucasian male during a radical prostatectomy, radical cystectomy, and urinary diversion. Pathology indicated grade 3 transitional cell carcinoma on the anterior wall of the bladder. Patient history included lung neoplasm and tobacco abuse in remission. Family history included malignant breast neoplasm, tuberculosis, cerebrovascular disease, atherosclerotic coronary artery disease, and lung cancer.
BMARTXE01	pINCY	This 5' biased random primed library was constructed using RNA isolated from treated SH-SY5Y cells derived from a metastatic bone marrow neuroblastoma, removed from a 4-year-old Caucasian female (Schering AG). The medium was MEM/HAM'S F12 with 10% fetal calf serum. After reaching about 80% confluency cells were treated with 6-Hydroxydopamine (6-OHDA) at 100 microM for 8 hours.
BRAHTDR03	PCDNA2.1	This random primed library was constructed using RNA isolated from archaecortex, anterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydorthorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver.
BRALNON02	pINCY	This thalamus tissue library was constructed from 4.24 million independent clones from a thalamus tissue library. Starting RNA was made from thalamus tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. Scattered throughout the cerebral cortex, there were multiple small microscopic areas of cavitation with surrounding

Table 6 (cont.)

Library	Vector	Library Description
		gliosis. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.
COLENOR03	PCDNA2.1	Library was constructed using RNA isolated from colon epithelium tissue removed from a 13-year-old Caucasian female who died from a motor vehicle accident.
EPIPUNA01	PSPORT	Library was constructed using RNA isolated from untreated prostatic epithelial cell tissue removed from a 17-year-old Hispanic male. Serologies were negative.
LIVRNOC07	pINCY	Library was constructed using pooled cDNA from two different donors. cDNA was generated using RNA isolated from liver tissue removed from a 20-week-old Caucasian male fetus who died from Patau's Syndrome (donor A) and a 16-week-old Caucasian female fetus who died from anencephaly (donor B). Family history included mitral valve prolapse in the mother of donor B.
OVARNOE02	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from right ovary tissue removed from a 47-year-old Caucasian female during total abdominal hysterectomy, bilateral salpingo-oophorectomy, incisional hernia repair, and panniculectomy. The patient presented with premenopausal menorrhagia. Patient history included osteoarthritis, tubal pregnancy, and polio osteopathy of the left leg. Previous surgeries included gastroenterostomy, plastic repair of the palate, adenotonsillectomy, dilation and curettage, cholecystectomy, and bladder reconstruction. Patient medications included vitamins, iron, and zinc. Family history included benign hypertension and type II diabetes in the father; and type II diabetes in the sibling(s).
PENITUT01	pINCY	Library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.

Table 6 (cont.)

Library	Vector	Library Description
PROSNOT18	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated adenofibromatous hyperplasia; this tissue was associated with a grade 3 transitional cell carcinoma. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
PROSTUS23	pINCY	This subtracted prostate tumor library was constructed using 10 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 10 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C), and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate stroma from 3 different donors. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991):1954 and Bonaldo, et al. Genome Research 6 (1996):791.
SKIRNOR01	PCDNA2.1	Random-primed library was constructed using RNA isolated from skin tissue removed from the breast of a 17-year-old Caucasian female during bilateral reduction mammoplasty. Patient history included breast hypertrophy. Family history included benign hypertension.
SINITUT03	pINCY	Library was constructed using RNA isolated from ileal tumor tissue obtained from a 49-year-old Caucasian female during destruction of peritoneal tissue, peritoneal adhesiolysis, ileum resection, and permanent colostomy. Pathology indicated grade 4 adenocarcinoma. Patient history included benign hypertension. Previous surgeries included total abdominal hysterectomy, bilateral salpingo-oophorectomy, regional lymph node excision, an incidental appendectomy, and dilation and curettage. Family history included benign hypertension, cerebrovascular disease, hyperlipidemia, atherosclerotic coronary artery disease, hyperlipidemia, type II diabetes, and stomach cancer.
SINTNOR01	PCDNA2.1	This random primed library was constructed using RNA isolated from small intestine tissue removed from a 31-year-old Caucasian female during Roux-en-Y gastric bypass. Patient history included clinical obesity.

Table 6 (cont.)

Library	Vector	Library Description
THYRNOT03	pINCY	Library was constructed using RNA isolated from thyroid tissue removed from the left thyroid of a 28-year-old Caucasian female during a complete thyroidectomy. Pathology indicated a small nodule of adenomatous hyperplasia present in the left thyroid. Pathology for the associated tumor tissue indicated dominant follicular adenoma, forming a well-encapsulated mass in the left thyroid.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	*ESTs:* Probability value= 1.0E-8 or less *Full Length sequences*: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	*ESTs:* fasta E value=1.06E-6 *Assembled ESTs*: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less *Full Length sequences:* fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	*PFAM hits:* Probability value= 1.0E-3 or less *Signal peptide hits:* Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score≥GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:

a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-20,

b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-20,

c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, and

d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-20.

3. An isolated polynucleotide encoding a polypeptide of claim 1.

4. An isolated polynucleotide encoding a polypeptide of claim 2.

5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:21-40.

6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.

9. A method for producing a polypeptide of claim 1, the method comprising:

a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and

b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40,

b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:21-40,

c) a polynucleotide complementary to a polynucleotide of a),

d) a polynucleotide complementary to a polynucleotide of b), and

e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and

b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable

excipient.

17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

18. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

a) exposing a sample comprising a polypeptide of claim 1 to a compound, and

b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional PKIN, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim

1, said method comprising the steps of:

a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,

b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and

c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,

b) detecting altered expression of the target polynucleotide, and

c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

a) treating a biological sample containing nucleic acids with the test compound;

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;

c) quantifying the amount of hybridization complex; and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

29. A diagnostic test for a condition or disease associated with the expression of PKIN in a biological sample comprising the steps of:

a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

30. The antibody of claim 10, wherein the antibody is:

a) a chimeric antibody,

b) a single chain antibody,

c) a Fab fragment,

d) a $F(ab')_2$ fragment, or

e) a humanized antibody.

31. A composition comprising an antibody of claim 10 and an acceptable excipient.

32. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

33. A composition of claim 31, wherein the antibody is labeled.

34. A method of diagnosing a condition or disease associated with the expression of PKIN in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, or an immunogenic fragment thereof, under conditions to elicit

an antibody response;

b) isolating antibodies from said animal; and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

36. An antibody produced by a method of claim 35.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal;

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

43. A method for detecting a polypeptide having an amino acid sequence selected from the

group consisting of SEQ ID NO:1-20 in a sample, comprising the steps of:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20 in the sample.

44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20 from a sample, the method comprising:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-20.

45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.

65. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:21.

66. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:22.

67. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:23.

68. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:24.

69. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:25.

70. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:26.

71. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:27.

72. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:28.

73. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:29.

74. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:30.

75. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:31.

76. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:32.

77. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:33.

78. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:34.

79. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:35.

80. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:36.

81. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:37.

82. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:38.

83. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:39.

84. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:40.

<110> INCYTE GENOMICS, INC.
YUE, Henry
KHAN, Farrah A.
GURURAJAN, Rajagopal
HAFALIA, April J. A.
WALIA, Narinder K.
PATTERSON, Chandra
RAMKUMAR, Jayalaxmi
GANDHI, Ameena R.
POLICKY, Jennifer L.
BAUGHN, Mariah R.
TRIBOULEY, Catherine M.
THORNTON, Michael
BANDMAN, Olga
NGUYEN, Danniel B.
LU, Yan
BURFORD, Neil
LAL, Preeti
DING, Li
YAO, Monique G.
ELLIOTT, Vicki S.
RECIPON, Shirley A.
KEARNEY, Liam
LU, Dyung Aina M.
GREENWALD, Sara R.
TANG, Y. Tom
XU, Yuming
WALSH, Roderick T.
GIETZEN, Kimberly J.
YANG, Junming
HILLMAN, Jennifer L.

<120> HUMAN KINASES

<130> PI-0162 PCT

<140> To Be Assigned
<141> Herewith

<150> 60/220,038; 60/222,112; 60/222,831; 60/224,729
<151> 2000-07-21; 2000-07-28; 2000-08-04; 2000-08-11

<160> 40
<170> PERL Program

<210> 1
<211> 1297
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2564295CD1

<400> 1
Met Ala Val Pro Ser Leu Trp Pro Trp Gly Ala Cys Leu Pro Val

```
                  20                  25                  30
Pro Ser Leu Asp Ile Arg Ser Glu Val Ala Glu Leu Arg Gln Leu
                  35                  40                  45
Glu Asn Cys Ser Val Val Glu Gly His Leu Gln Ile Leu Leu Met
                  50                  55                  60
Phe Thr Ala Thr Gly Glu Asp Phe Arg Gly Leu Ser Phe Pro Arg
                  65                  70                  75
Leu Thr Gln Val Thr Asp Tyr Leu Leu Leu Phe Arg Val Tyr Gly
                  80                  85                  90
Leu Glu Ser Leu Arg Asp Leu Phe Pro Asn Leu Ala Val Ile Arg
                  95                 100                 105
Gly Thr Arg Leu Phe Leu Gly Tyr Ala Leu Val Ile Phe Glu Met
                 110                 115                 120
Pro His Leu Arg Asp Val Ala Leu Pro Ala Leu Gly Ala Val Leu
                 125                 130                 135
Arg Gly Ala Val Arg Val Glu Lys Asn Gln Glu Leu Cys His Leu
                 140                 145                 150
Ser Thr Ile Asp Trp Gly Leu Leu Gln Pro Ala Pro Gly Ala Asn
                 155                 160                 165
His Ile Val Gly Asn Lys Leu Gly Glu Glu Cys Ala Asp Val Cys
                 170                 175                 180
Pro Gly Val Leu Gly Ala Ala Gly Glu Pro Cys Ala Lys Thr Thr
                 185                 190                 195
Phe Ser Gly His Thr Asp Tyr Arg Cys Trp Thr Ser Ser His Cys
                 200                 205                 210
Gln Arg Val Cys Pro Cys Pro His Gly Met Ala Cys Thr Ala Arg
                 215                 220                 225
Gly Glu Cys Cys His Thr Glu Cys Leu Gly Gly Cys Ser Gln Pro
                 230                 235                 240
Glu Asp Pro Arg Ala Cys Val Ala Cys Arg His Leu Tyr Phe Gln
                 245                 250                 255
Gly Ala Cys Leu Trp Ala Cys Pro Pro Gly Thr Tyr Gln Tyr Glu
                 260                 265                 270
Ser Trp Arg Cys Val Thr Ala Glu Arg Cys Ala Ser Leu His Ser
                 275                 280                 285
Val Pro Gly Arg Ala Ser Thr Phe Gly Ile His Gln Gly Ser Cys
                 290                 295                 300
Leu Ala Gln Cys Pro Ser Gly Phe Thr Arg Asn Ser Ser Ser Ile
                 305                 310                 315
Phe Cys His Lys Cys Glu Gly Leu Cys Pro Lys Glu Cys Lys Val
                 320                 325                 330
Gly Thr Lys Thr Ile Asp Ser Ile Gln Ala Ala Gln Asp Leu Val
                 335                 340                 345
Gly Cys Thr His Val Glu Gly Ser Leu Ile Leu Asn Leu Arg Gln
                 350                 355                 360
Gly Tyr Asn Leu Glu Pro Gln Leu Gln His Ser Leu Gly Leu Val
                 365                 370                 375
Glu Thr Ile Thr Gly Phe Leu Lys Ile Lys His Ser Phe Ala Leu
                 380                 385                 390
Val Ser Leu Gly Phe Phe Lys Asn Leu Lys Leu Ile Arg Gly Asp
                 395                 400                 405
Ala Met Val Asp Gly Asn Tyr Thr Leu Tyr Val Leu Asp Asn Gln
                 410                 415                 420
Asn Leu Gln Gln Leu Gly Ser Trp Val Ala Ala Gly Leu Thr Ile
                 425                 430                 435
Pro Val Gly Lys Ile Tyr Phe Ala Phe Asn Pro Arg Leu Cys Leu
```

```
                440                 445                 450
Glu His Ile Tyr Arg Leu Glu Glu Val Thr Gly Thr Arg Gly Arg
                455                 460                 465
Gln Asn Lys Ala Glu Ile Asn Pro Arg Thr Asn Gly Asp Arg Ala
                470                 475                 480
Ala Cys Gln Thr Arg Thr Leu Arg Phe Val Ser Asn Val Thr Glu
                485                 490                 495
Ala Asp Arg Ile Leu Leu Arg Trp Glu Arg Tyr Glu Pro Leu Glu
                500                 505                 510
Ala Arg Asp Leu Leu Ser Phe Ile Val Tyr Tyr Lys Glu Ser Pro
                515                 520                 525
Phe Gln Asn Ala Thr Glu His Val Gly Pro Asp Ala Cys Gly Thr
                530                 535                 540
Gln Ser Trp Asn Leu Leu Asp Val Glu Leu Pro Leu Ser Arg Thr
                545                 550                 555
Gln Glu Pro Gly Val Thr Leu Ala Ser Leu Lys Pro Trp Thr Gln
                560                 565                 570
Tyr Ala Val Phe Val Arg Ala Ile Thr Leu Thr Thr Glu Glu Asp
                575                 580                 585
Ser Pro His Gln Gly Ala Gln Ser Pro Ile Val Tyr Leu Arg Thr
                590                 595                 600
Leu Pro Ala Ala Pro Thr Val Pro Gln Asp Val Ile Ser Thr Ser
                605                 610                 615
Asn Ser Ser Ser His Leu Leu Val Arg Trp Lys Pro Pro Thr Gln
                620                 625                 630
Arg Asn Gly Asn Leu Thr Tyr Tyr Leu Val Leu Trp Gln Arg Leu
                635                 640                 645
Ala Glu Asp Gly Asp Leu Tyr Leu Asn Asp Tyr Cys His Arg Gly
                650                 655                 660
Leu Arg Leu Pro Thr Ser Asn Asn Asp Pro Arg Phe Asp Gly Glu
                665                 670                 675
Asp Gly Asp Pro Glu Ala Glu Met Glu Ser Asp Cys Cys Pro Cys
                680                 685                 690
Gln His Pro Pro Pro Gly Gln Val Leu Pro Pro Leu Glu Ala Gln
                695                 700                 705
Glu Ala Ser Phe Gln Lys Lys Phe Glu Asn Phe Leu His Asn Ala
                710                 715                 720
Ile Thr Ile Pro Ile Ser Pro Trp Lys Val Thr Ser Ile Asn Lys
                725                 730                 735
Ser Pro Gln Arg Asp Ser Gly Arg His Arg Arg Ala Ala Gly Pro
                740                 745                 750
Leu Arg Leu Gly Gly Asn Ser Ser Asp Phe Glu Ile Gln Glu Asp
                755                 760                 765
Lys Val Pro Arg Glu Arg Ala Val Leu Ser Gly Leu Arg His Phe
                770                 775                 780
Thr Glu Tyr Arg Ile Asp Ile His Ala Cys Asn His Ala Ala His
                785                 790                 795
Thr Val Gly Cys Ser Ala Ala Thr Phe Val Phe Ala Arg Thr Met
                800                 805                 810
Pro His Arg Glu Ala Asp Gly Ile Pro Gly Lys Val Ala Trp Glu
                815                 820                 825
Ala Ser Ser Lys Asn Ser Val Leu Leu Arg Trp Leu Glu Pro Pro
                830                 835                 840
Asp Pro Asn Gly Leu Ile Leu Lys Tyr Glu Ile Lys Tyr Arg Arg
                845                 850                 855
Leu Gly Glu Glu Ala Thr Val Leu Cys Val Ser Arg Leu Arg Tyr
```

```
                860                 865                 870
Ala Lys Phe Gly Gly Val His Leu Ala Leu Leu Pro Pro Gly Asn
                875                 880                 885
Tyr Ser Ala Arg Val Arg Ala Thr Ser Leu Ala Gly Asn Gly Ser
                890                 895                 900
Trp Thr Asp Ser Val Ala Phe Tyr Ile Leu Gly Pro Glu Glu Glu
                905                 910                 915
Asp Ala Gly Gly Leu His Val Leu Leu Thr Ala Thr Pro Val Gly
                920                 925                 930
Leu Thr Leu Leu Ile Val Leu Ala Ala Leu Gly Phe Phe Tyr Gly
                935                 940                 945
Lys Lys Arg Asn Arg Thr Leu Tyr Ala Ser Val Asn Pro Glu Tyr
                950                 955                 960
Phe Ser Ala Ser Asp Met Tyr Val Pro Asp Glu Trp Glu Val Pro
                965                 970                 975
Arg Glu Gln Ile Ser Ile Ile Arg Glu Leu Gly Gln Gly Ser Phe
                980                 985                 990
Gly Met Val Tyr Glu Gly Leu Ala Arg Gly Leu Glu Ala Gly Glu
                995                1000                1005
Glu Ser Thr Pro Val Ala Leu Lys Thr Val Asn Glu Leu Ala Ser
               1010                1015                1020
Pro Arg Glu Cys Ile Glu Phe Leu Lys Glu Ala Ser Val Met Lys
               1025                1030                1035
Ala Phe Lys Cys His His Val Val Arg Leu Leu Gly Val Val Ser
               1040                1045                1050
Gln Gly Gln Pro Thr Leu Val Ile Met Glu Leu Met Thr Arg Gly
               1055                1060                1065
Asp Leu Lys Ser His Leu Arg Ser Leu Arg Pro Glu Ala Glu Asn
               1070                1075                1080
Asn Pro Gly Leu Pro Gln Pro Ala Leu Gly Glu Met Ile Gln Met
               1085                1090                1095
Ala Gly Glu Ile Ala Asp Gly Met Ala Tyr Leu Ala Ala Asn Lys
               1100                1105                1110
Phe Val His Arg Asp Leu Ala Ala Arg Asn Cys Met Val Ser Gln
               1115                1120                1125
Asp Phe Thr Val Lys Ile Gly Asp Phe Gly Met Thr Arg Asp Val
               1130                1135                1140
Tyr Glu Thr Asp Tyr Tyr Arg Lys Gly Gly Lys Gly Leu Leu Pro
               1145                1150                1155
Val Arg Trp Met Ala Pro Glu Ser Leu Lys Asp Gly Ile Phe Thr
               1160                1165                1170
Thr His Ser Asp Val Trp Ser Phe Gly Val Val Leu Trp Glu Ile
               1175                1180                1185
Val Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu Ser Asn Glu Gln
               1190                1195                1200
Val Leu Lys Phe Val Met Asp Gly Gly Val Leu Glu Glu Leu Glu
               1205                1210                1215
Gly Cys Pro Leu Gln Leu Gln Glu Leu Met Ser Arg Cys Trp Gln
               1220                1225                1230
Pro Asn Pro Arg Leu Arg Pro Ser Phe Thr His Ile Leu Asp Ser
               1235                1240                1245
Ile Gln Glu Glu Leu Arg Pro Ser Phe Arg Leu Leu Ser Phe Tyr
               1250                1255                1260
Tyr Ser Pro Glu Cys Arg Gly Ala Arg Gly Ser Leu Pro Thr Thr
               1265                1270                1275
Asp Ala Glu Pro Asp Ser Ser Pro Thr Pro Arg Asp Cys Ser Pro
```

```
                1280                1285                1290
Gln Asn Gly Gly Pro Gly His
                1295

<210> 2
<211> 718
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2837050CD1

<400> 2
Met Met Glu Glu Leu His Ser Leu Asp Pro Arg Arg Gln Glu Leu
  1               5                  10                  15
Leu Glu Ala Arg Phe Thr Arg Val Gly Val Ser Lys Gly Pro Leu
                 20                  25                  30
Asn Ser Glu Ser Ser Asn Gln Ser Leu Cys Ser Val Gly Ser Leu
                 35                  40                  45
Ser Asp Lys Glu Val Glu Thr Pro Glu Lys Lys Gln Asn Asp Gln
                 50                  55                  60
Arg Asn Arg Lys Arg Lys Ala Glu Pro Tyr Glu Thr Ser Gln Gly
                 65                  70                  75
Lys Gly Thr Pro Arg Gly His Lys Ile Ser Asp Tyr Phe Glu Arg
                 80                  85                  90
Arg Val Glu Gln Pro Leu Tyr Gly Leu Asp Gly Ser Ala Ala Lys
                 95                 100                 105
Glu Ala Thr Glu Glu Gln Ser Ala Leu Pro Thr Leu Met Ser Val
                110                 115                 120
Met Leu Ala Lys Pro Arg Leu Asp Thr Glu His Val Ala Gln Arg
                125                 130                 135
Gly Ala Gly Leu Cys Phe Thr Phe Val Ser Ala Gln Gln Asn Ser
                140                 145                 150
Pro Ser Ser Thr Gly Ser Gly Asn Thr Glu His Ser Cys Ser Ser
                155                 160                 165
Gln Lys Gln Ile Ser Ile Gln His Arg Gln Thr Gln Ser Asp Leu
                170                 175                 180
Thr Ile Glu Lys Ile Ser Ala Leu Glu Asn Ser Lys Asn Ser Asp
                185                 190                 195
Leu Glu Lys Lys Glu Gly Arg Ile Asp Asp Leu Leu Arg Ala Asn
                200                 205                 210
Cys Asp Leu Arg Arg Gln Ile Asp Glu Gln Gln Lys Met Leu Glu
                215                 220                 225
Lys Tyr Lys Glu Arg Leu Asn Arg Cys Val Thr Met Ser Lys Lys
                230                 235                 240
Leu Leu Ile Glu Lys Ser Lys Gln Glu Lys Met Ala Cys Arg Asp
                245                 250                 255
Lys Ser Met Gln Asp Arg Leu Arg Leu Gly His Phe Thr Thr Val
                260                 265                 270
Arg His Gly Ala Ser Phe Thr Glu Gln Trp Thr Asp Gly Tyr Ala
                275                 280                 285
Phe Gln Asn Leu Ile Lys Gln Gln Glu Arg Ile Asn Ser Gln Arg
                290                 295                 300
Glu Glu Ile Glu Arg Gln Arg Lys Met Leu Ala Lys Arg Lys Pro
                305                 310                 315
```

```
Pro Ala Met Gly Gln Ala Pro Pro Ala Thr Asn Glu Gln Lys Gln
                320                 325                 330
Arg Lys Ser Lys Thr Asn Gly Ala Glu Asn Glu Thr Leu Thr Leu
                335                 340                 345
Ala Glu Tyr His Glu Gln Glu Glu Ile Phe Lys Leu Arg Leu Gly
                350                 355                 360
His Leu Lys Lys Glu Glu Ala Glu Ile Gln Ala Glu Leu Glu Arg
                365                 370                 375
Leu Glu Arg Val Arg Asn Leu His Ile Arg Glu Leu Lys Arg Ile
                380                 385                 390
His Asn Glu Asp Asn Ser Gln Phe Lys Asp His Pro Thr Leu Asn
                395                 400                 405
Asp Arg Tyr Leu Leu Leu His Leu Leu Gly Arg Gly Gly Phe Ser
                410                 415                 420
Glu Val Tyr Lys Ala Phe Asp Leu Thr Glu Gln Arg Tyr Val Ala
                425                 430                 435
Val Lys Ile His Gln Leu Asn Lys Asn Trp Arg Asp Glu Lys Lys
                440                 445                 450
Glu Asn Tyr His Lys His Ala Cys Arg Glu Tyr Arg Ile His Lys
                455                 460                 465
Glu Leu Asp His Pro Arg Ile Val Lys Leu Tyr Asp Tyr Phe Ser
                470                 475                 480
Leu Asp Thr Asp Ser Phe Cys Thr Val Leu Glu Tyr Cys Glu Gly
                485                 490                 495
Asn Asp Leu Asp Phe Tyr Leu Lys Gln His Lys Leu Met Ser Glu
                500                 505                 510
Lys Glu Ala Trp Ser Ile Ile Met Gln Ile Val Asn Ala Leu Lys
                515                 520                 525
Tyr Leu Asn Glu Ile Lys Pro Pro Ile Ile His Tyr Asp Leu Lys
                530                 535                 540
Pro Gly Asn Ile Leu Leu Val Asn Gly Thr Val Cys Gly Glu Arg
                545                 550                 555
Lys Ile Thr Asp Phe Gly Leu Ser Lys Ile Met Asp Asp Asp Ser
                560                 565                 570
Tyr Asn Ser Val Gly Gly Met Glu Leu Thr Ser Gln Gly Ala Gly
                575                 580                 585
Thr Tyr Trp Tyr Leu Pro Pro Glu Cys Phe Val Val Glu Lys Glu
                590                 595                 600
Pro Pro Lys Ile Ser Asn Lys Val Asp Val Trp Ser Val Gly Val
                605                 610                 615
Ile Phe Tyr Gln Cys Leu Ser Gly Gly Lys Pro Phe Gly His Asn
                620                 625                 630
Gln Ser Gln Gln Asp Ile Leu Gln Glu Asn Thr Ile Leu Lys Ala
                635                 640                 645
Ala Glu Val Gln Phe Pro Pro Lys Pro Val Val Thr Pro Glu Ala
                650                 655                 660
Lys Ala Phe Ile Arg Arg Cys Leu Ala Tyr Arg Lys Glu Asp Cys
                665                 670                 675
Ile Asp Ala Gln Gln Leu Ala Cys Asp Pro Tyr Leu Leu Pro His
                680                 685                 690
Ile Arg Lys Ser Val Ser Thr Ser Ser Pro Ala Gly Ala Ala Ile
                695                 700                 705
Ala Ser Thr Ser Gly Ala Ser Asn Asn Ser Ser Ser Asn
                710                 715
```

<210> 3

<211> 497
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474590CD1

<400> 3
Met Tyr Ser Asp Ser Glu Asp Glu Ser Ser Glu Leu Ser Thr Val
1 5 10 15
Leu Ser Met Phe Glu Glu Lys Glu Phe Thr Arg Gln Tyr Thr Val
20 25 30
Leu Lys Thr Leu Ser Gln His Gly Thr Thr Glu Val Arg Leu Cys
35 40 45
Ser His His Leu Thr Gly Val Thr Val Ala Val Lys Ala Leu Lys
50 55 60
Tyr Gln Arg Trp Trp Glu Pro Lys Val Ser Glu Val Glu Ile Met
65 70 75
Lys Met Leu Ser His Pro Asn Ile Val Ser Leu Leu Gln Val Ile
80 85 90
Glu Thr Glu Gln Asn Ile Tyr Leu Ile Met Glu Val Ala Gln Gly
95 100 105
Thr Gln Leu His Asn Arg Val Gln Glu Ala Arg Cys Leu Lys Glu
110 115 120
Asp Glu Ala Arg Ser Ile Phe Val Gln Leu Leu Ser Ala Ile Gly
125 130 135
Tyr Cys His Gly Glu Gly Val Val His Arg Asp Leu Lys Pro Asp
140 145 150
Asn Val Ile Val Asp Glu His Gly Asn Val Lys Ile Val Asp Phe
155 160 165
Gly Leu Gly Ala Arg Phe Met Pro Gly Gln Lys Leu Glu Arg Leu
170 175 180
Cys Gly Ala Phe Gln Phe Ile Pro Pro Glu Ile Phe Leu Gly Leu
185 190 195
Pro Tyr Asp Gly Pro Lys Val Asp Ile Trp Ala Leu Gly Val Leu
200 205 210
Leu Tyr Tyr Met Val Thr Gly Ile Phe Pro Phe Val Gly Ser Thr
215 220 225
Leu Ser Glu Ile Ser Lys Glu Val Leu Gln Gly Arg Tyr Glu Ile
230 235 240
Pro Tyr Asn Leu Ser Lys Asp Leu Arg Ser Met Ile Gly Leu Leu
245 250 255
Leu Ala Thr Asn Ala Arg Gln Arg Pro Thr Ala Gln Asp Leu Leu
260 265 270
Ser His Pro Trp Leu Gln Glu Gly Glu Lys Thr Ile Thr Phe His
275 280 285
Ser Asn Gly Asp Thr Ser Phe Pro Asp Pro Asp Ile Met Ala Ala
290 295 300
Met Lys Asn Ile Gly Phe His Val Gln Asp Ile Arg Glu Ser Leu
305 310 315
Lys His Arg Lys Phe Asp Glu Thr Met Ala Thr Tyr Asn Leu Leu
320 325 330
Arg Ala Glu Ala Cys Gln Asp Asp Gly Asn Tyr Val Gln Thr Lys
335 340 345
Leu Met Asn Pro Gly Met Pro Pro Phe Pro Ser Val Thr Asp Ser

```
                350                 355                 360
Gly Ala Phe Ser Leu Pro Pro Arg Arg Arg Ala Ser Glu Pro Ser
                365                 370                 375
Phe Lys Val Leu Val Ser Ser Thr Glu Glu His Gln Leu Arg Gln
                380                 385                 390
Thr Gly Gly Thr Asn Ala Pro Phe Pro Pro Lys Lys Thr Pro Thr
                395                 400                 405
Met Gly Arg Ser Gln Lys Gln Lys Arg Ala Met Thr Ala Pro Cys
                410                 415                 420
Ile Cys Leu Leu Arg Asn Thr Tyr Ile Asp Thr Glu Asp Ser Ser
                425                 430                 435
Phe Cys Thr Ser Ser Gln Ala Glu Lys Thr Ser Ser Asp Pro Glu
                440                 445                 450
Lys Ser Glu Thr Ser Thr Ser Cys Pro Leu Thr Pro Arg Gly Trp
                455                 460                 465
Arg Lys Trp Lys Lys Arg Ile Val Ala Cys Ile Gln Thr Leu Cys
                470                 475                 480
Cys Cys Thr Leu Pro Gln Lys Lys Cys Pro Arg Ser Val His Pro
                485                 490                 495
Gln Lys
```

<210> 4
<211> 741
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474594CD1

<400> 4

```
Met Ser Gly Leu Val Leu Met Leu Ala Ala Arg Cys Ile Val Gly
  1                 5                  10                  15
Ser Ser Pro Leu Cys Arg Cys Arg Arg Arg Arg Pro Arg Arg Ile
                 20                  25                  30
Gly Ala Gly Pro Gly Arg Asp Asp Pro Gly Arg Lys Ala Ala Ala
                 35                  40                  45
Ala Gly Gly Ser Gly Ser Pro Asn Ala Ala Leu Ser Arg Pro Arg
                 50                  55                  60
Pro Ala Pro Ala Pro Gly Asp Ala Pro Pro Arg Ala Ala Ala Ser
                 65                  70                  75
Ala Ala Ala Ala Ala Ala Ala Ala Ala Gly Thr Glu Gln Val Asp
                 80                  85                  90
Gly Pro Leu Arg Ala Gly Pro Ala Asp Thr Pro Pro Ser Gly Trp
                 95                 100                 105
Arg Met Gln Cys Leu Ala Ala Ala Leu Lys Asp Glu Thr Asn Met
                110                 115                 120
Ser Gly Gly Gly Glu Gln Ala Asp Ile Leu Pro Ala Asn Tyr Val
                125                 130                 135
Val Lys Asp Arg Trp Lys Val Leu Lys Lys Ile Gly Gly Gly Gly
                140                 145                 150
Phe Gly Glu Ile Tyr Glu Ala Met Asp Leu Leu Thr Arg Glu Asn
                155                 160                 165
Val Ala Leu Lys Val Glu Ser Ala Gln Gln Pro Lys Gln Val Leu
                170                 175                 180
```

```
Lys Met Glu Val Ala Val Leu Lys Lys Leu Gln Gly Lys Asp His
                185                 190                 195
Val Cys Arg Phe Ile Gly Cys Gly Arg Asn Glu Lys Phe Asn Tyr
                200                 205                 210
Val Val Met Gln Leu Gln Gly Arg Asn Leu Ala Asp Leu Arg Arg
                215                 220                 225
Ser Gln Pro Arg Gly Thr Phe Thr Leu Ser Thr Thr Leu Arg Leu
                230                 235                 240
Gly Lys Gln Ile Leu Glu Ser Ile Glu Ala Ile His Ser Val Gly
                245                 250                 255
Phe Leu His Arg Asp Ile Lys Pro Ser Asn Phe Ala Met Gly Arg
                260                 265                 270
Leu Pro Ser Thr Tyr Arg Lys Cys Tyr Met Leu Asp Phe Gly Leu
                275                 280                 285
Ala Arg Gln Tyr Thr Asn Thr Thr Gly Asp Val Arg Pro Pro Arg
                290                 295                 300
Asn Val Ala Gly Phe Arg Gly Thr Val Arg Tyr Ala Ser Val Asn
                305                 310                 315
Ala His Lys Asn Arg Glu Met Gly Arg His Asp Asp Leu Trp Ser
                320                 325                 330
Leu Phe Tyr Met Leu Val Glu Phe Ala Val Gly Gln Leu Pro Trp
                335                 340                 345
Arg Lys Ile Lys Asp Lys Glu Gln Val Gly Met Ile Lys Glu Lys
                350                 355                 360
Tyr Glu His Arg Met Leu Leu Lys His Met Pro Ser Glu Phe His
                365                 370                 375
Leu Phe Leu Asp His Ile Ala Ser Leu Asp Tyr Phe Thr Lys Pro
                380                 385                 390
Asp Tyr Gln Leu Ile Met Ser Val Phe Glu Asn Ser Met Lys Glu
                395                 400                 405
Arg Gly Ile Ala Glu Asn Glu Ala Phe Asp Trp Glu Lys Ala Gly
                410                 415                 420
Thr Asp Ala Leu Leu Ser Thr Ser Thr Ser Thr Pro Pro Gln Gln
                425                 430                 435
Asn Thr Arg Gln Thr Ala Ala Met Phe Gly Val Val Asn Val Thr
                440                 445                 450
Pro Val Pro Gly Asp Leu Leu Arg Glu Asn Thr Glu Asp Val Leu
                455                 460                 465
Gln Gly Glu His Leu Ser Asp Gln Glu Asn Ala Pro Pro Ile Leu
                470                 475                 480
Pro Gly Arg Pro Ser Glu Gly Leu Gly Pro Ser Pro His Leu Val
                485                 490                 495
Pro His Pro Gly Gly Pro Glu Ala Glu Val Trp Glu Glu Thr Asp
                500                 505                 510
Val Asn Arg Asn Lys Leu Arg Ile Asn Ile Gly Lys Val Thr Ala
                515                 520                 525
Ala Arg Ala Lys Gly Val Gly Gly Leu Phe Ser His Pro Arg Phe
                530                 535                 540
Pro Ala Leu Cys Pro Cys Pro Val Pro Pro Lys His Pro Val Pro
                545                 550                 555
Gly His Leu Pro Ala Cys Pro Ala Ser Val Ser Arg Ser Leu Pro
                560                 565                 570
Ala Leu Ala Ser Leu Cys Leu Pro Ser Ser Ser Ser Ser Val Ser
                575                 580                 585
Phe Thr Leu Arg Arg Pro Ser Ala His Ser Arg Leu Ile Ser Pro
                590                 595                 600
```

```
Ser Ser Trp His Ser Pro Leu Leu Gln Ser Pro Cys Val Glu Glu
                605                 610                 615
Glu Gln Ser Arg Gly Met Gly Val Pro Ser Ser Pro Val Arg Ala
                620                 625                 630
Pro Pro Asp Ser Pro Thr Thr Pro Val Arg Ser Leu Arg Tyr Arg
                635                 640                 645
Arg Val Asn Ser Pro Glu Ser Glu Arg Leu Ser Thr Ala Asp Gly
                650                 655                 660
Arg Val Glu Leu Pro Glu Arg Arg Trp Val Trp Gly Gln Gly His
                665                 670                 675
Gly Trp Gly Pro Arg Pro Ser Pro Pro Ser Arg Gly Trp Ser Gly
                680                 685                 690
Gly Lys Val Arg Cys Val Ala Glu Val Gly Arg Pro Trp Glu Val
                695                 700                 705
Leu Arg Gly Leu Tyr Leu Gly Leu Gly Ser Asp Ser Val Gly Ala
                710                 715                 720
Arg Asp Arg Ala Trp Glu Asn Gln Trp Gly Ile Gln Arg Gly Pro
                725                 730                 735
Gly Ser Cys Gln Glu Thr
                740

<210> 5
<211> 645
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477585CD1

<400> 5
Met Leu Lys Phe Gln Glu Ala Ala Lys Cys Val Ser Gly Ser Thr
  1                 5                  10                  15
Ala Ile Ser Thr Tyr Pro Lys Thr Leu Ile Ala Arg Arg Tyr Val
                 20                  25                  30
Leu Gln Gln Lys Leu Gly Ser Gly Ser Phe Gly Thr Val Tyr Leu
                 35                  40                  45
Val Ser Asp Lys Lys Ala Lys Arg Gly Glu Glu Leu Lys Val Leu
                 50                  55                  60
Lys Glu Ile Ser Val Gly Glu Leu Asn Pro Asn Glu Thr Val Gln
                 65                  70                  75
Ala Asn Leu Glu Ala Gln Leu Leu Ser Lys Leu Asp His Pro Ala
                 80                  85                  90
Ile Val Lys Phe His Ala Ser Phe Val Glu Gln Asp Asn Phe Cys
                 95                 100                 105
Ile Ile Thr Glu Tyr Cys Glu Gly Arg Asp Leu Asp Asp Lys Ile
                110                 115                 120
Gln Glu Tyr Lys Gln Ala Gly Lys Ile Phe Pro Glu Asn Gln Ile
                125                 130                 135
Ile Glu Trp Phe Ile Gln Leu Leu Leu Gly Val Asp Tyr Met His
                140                 145                 150
Glu Arg Arg Ile Leu His Arg Asp Leu Lys Ser Lys Asn Val Phe
                155                 160                 165
Leu Lys Asn Asn Leu Leu Lys Ile Gly Asp Phe Gly Val Ser Arg
                170                 175                 180
Leu Leu Met Gly Ser Cys Asp Leu Ala Thr Thr Leu Thr Gly Thr
```

```
                185                 190                 195
Pro His Tyr Met Ser Pro Glu Ala Leu Lys His Gln Gly Tyr Asp
                200                 205                 210
Thr Lys Ser Asp Ile Trp Ser Leu Ala Cys Ile Leu Tyr Glu Met
                215                 220                 225
Cys Cys Met Asn His Ala Phe Ala Gly Ser Asn Phe Leu Ser Ile
                230                 235                 240
Val Leu Lys Ile Val Glu Gly Asp Thr Pro Ser Leu Pro Glu Arg
                245                 250                 255
Tyr Pro Lys Glu Leu Asn Ala Ile Met Glu Ser Met Leu Asn Lys
                260                 265                 270
Asn Pro Ser Leu Arg Pro Ser Ala Ile Glu Ile Leu Lys Ile Pro
                275                 280                 285
Tyr Leu Asp Glu Gln Leu Gln Asn Leu Met Cys Arg Tyr Ser Glu
                290                 295                 300
Met Thr Leu Glu Asp Lys Asn Leu Asp Cys Gln Lys Glu Ala Ala
                305                 310                 315
His Ile Ile Asn Ala Met Gln Lys Arg Ile His Leu Gln Thr Leu
                320                 325                 330
Arg Ala Leu Ser Glu Val Gln Lys Met Thr Pro Arg Glu Arg Met
                335                 340                 345
Arg Leu Arg Lys Leu Gln Ala Ala Asp Glu Lys Ala Arg Lys Leu
                350                 355                 360
Lys Lys Ile Val Glu Glu Lys Tyr Glu Glu Asn Ser Lys Arg Met
                365                 370                 375
Gln Glu Leu Arg Ser Arg Asn Phe Gln Gln Leu Ser Val Asp Val
                380                 385                 390
Leu His Glu Lys Thr His Leu Lys Gly Met Glu Glu Lys Glu Glu
                395                 400                 405
Gln Pro Glu Gly Arg Leu Ser Cys Ser Pro Gln Asp Glu Asp Glu
                410                 415                 420
Glu Arg Trp Gln Gly Arg Glu Glu Glu Ser Asp Glu Pro Thr Leu
                425                 430                 435
Glu Asn Leu Pro Glu Ser Gln Pro Ile Pro Ser Met Asp Leu His
                440                 445                 450
Glu Leu Glu Ser Ile Val Glu Asp Ala Thr Ser Asp Leu Gly Tyr
                455                 460                 465
His Glu Ile Pro Glu Asp Pro Leu Val Ala Glu Glu Tyr Tyr Ala
                470                 475                 480
Asp Ala Phe Asp Ser Tyr Cys Val Glu Ser Asp Glu Glu Glu Glu
                485                 490                 495
Glu Ile Ala Leu Glu Arg Pro Glu Lys Glu Ile Arg Asn Glu Gly
                500                 505                 510
Ser Gln Pro Ala Tyr Arg Thr Asn Gln Gln Asp Ser Asp Ile Glu
                515                 520                 525
Ala Leu Ala Arg Cys Leu Glu Asn Val Leu Gly Cys Thr Ser Leu
                530                 535                 540
Asp Thr Lys Thr Ile Thr Thr Met Ala Glu Asp Met Ser Pro Gly
                545                 550                 555
Pro Pro Ile Phe Asn Ser Val Met Ala Arg Thr Lys Met Lys Arg
                560                 565                 570
Met Arg Glu Ser Ala Met Gln Lys Leu Gly Thr Glu Val Phe Glu
                575                 580                 585
Glu Val Tyr Asn Tyr Leu Lys Arg Ala Arg His Gln Asn Ala Ser
                590                 595                 600
Glu Ala Glu Ile Arg Glu Cys Leu Glu Lys Val Val Pro Gln Ala
```

```
                605                 610                 615
Ser Asp Cys Phe Glu Val Asp Gln Leu Leu Tyr Phe Glu Glu Gln
                620                 625                 630
Leu Leu Ile Thr Met Gly Lys Glu Pro Thr Leu Gln Asn His Leu
                635                 640                 645


<210> 6
<211> 623
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477587CD1

<400> 6
Met Trp Ala Pro Gly Thr Arg Gln Gln Gly Gly Pro Glu Met Ala
  1               5                  10                  15
His Ile Gln Asn Val Glu Ala His Thr Ser Ser Ala Leu Trp Gly
                20                  25                  30
Arg Ser Pro Arg Lys Pro Pro Thr Pro His Ala Arg Glu Ser Leu
                35                  40                  45
Ser Phe Pro Leu Glu Arg Pro Arg Ser Gly Arg Ser Ala Val Val
                50                  55                  60
Ser Ala Arg Leu Arg Gln Ser Pro Arg Met Glu Pro Arg Pro Arg
                65                  70                  75
Arg Arg Arg Arg Ser Arg Pro Leu Val Ala Ala Phe Leu Arg Asp
                80                  85                  90
Pro Gly Ser Gly Arg Val Tyr Arg Arg Gly Lys Leu Ile Gly Lys
                95                 100                 105
Gly Ala Phe Ser Arg Cys Tyr Lys Leu Thr Asp Met Ser Thr Ser
               110                 115                 120
Ala Val Phe Ala Leu Lys Val Val Pro Cys Gly Gly Ala Gly Ala
               125                 130                 135
Gly Trp Leu Arg Pro Gln Gly Lys Val Glu Arg Glu Ile Ala Leu
               140                 145                 150
His Ser Arg Leu Arg Pro Arg Asn Ile Val Ala Phe His Gly His
               155                 160                 165
Phe Ala Asp Arg Asp His Val Tyr Met Val Leu Glu Tyr Cys Ser
               170                 175                 180
Arg Gln Ser Leu Ala His Val Leu Arg Ala Arg Gln Ile Leu Thr
               185                 190                 195
Glu Pro Glu Val Arg Asp Tyr Leu Arg Gly Leu Val Ser Gly Leu
               200                 205                 210
Arg Tyr Leu His Gln Arg Cys Ile Leu His Arg Asp Leu Lys Leu
               215                 220                 225
Ser Asn Phe Phe Leu Asn Lys Asn Met Glu Val Lys Ile Gly Asp
               230                 235                 240
Leu Gly Leu Ala Ala Lys Val Gly Pro Gly Gly Arg Cys His Arg
               245                 250                 255
Tyr Thr Val Leu Thr Gly Thr Pro Pro Phe Met Ala Ser Pro Leu
               260                 265                 270
Ser Glu Met Tyr Gln Asn Ile Arg Glu Gly His Tyr Pro Glu Pro
               275                 280                 285
Ala His Leu Ser Ala Asn Ala Arg Arg Leu Ile Val His Leu Leu
```

```
                290                 295                 300
Ala Pro Asn Pro Ala Glu Arg Pro Ser Leu Asp His Leu Leu Gln
                305                 310                 315
Asp Asp Phe Phe Thr Gln Gly Phe Thr Pro Asp Arg Leu Pro Ala
                320                 325                 330
His Ser Cys His Ser Pro Pro Ile Phe Ala Ile Pro Pro Pro Leu
                335                 340                 345
Gly Arg Ile Phe Arg Lys Val Gly Gln Arg Leu Leu Thr Gln Cys
                350                 355                 360
Arg Pro Pro Cys Pro Phe Thr Pro Lys Glu Ala Ser Gly Pro Gly
                365                 370                 375
Glu Gly Gly Pro Asp Pro Asp Ser Met Glu Trp Asp Gly Glu Ser
                380                 385                 390
Ser Leu Ser Ala Lys Glu Val Pro Cys Leu Glu Gly Pro Ile His
                395                 400                 405
Leu Val Ala Gln Gly Thr Leu Gln Ser Asp Leu Ala Ala Thr Gln
                410                 415                 420
Asp Pro Leu Gly Glu Gln Gln Pro Ile Leu Trp Ala Pro Lys Trp
                425                 430                 435
Val Asp Tyr Ser Ser Lys Tyr Gly Phe Gly Tyr Gln Leu Leu Asp
                440                 445                 450
Gly Gly Arg Thr Gly Arg His Pro His Gly Pro Ala Thr Pro Arg
                455                 460                 465
Arg Tyr Leu Leu Ser Thr Tyr Cys Ala His Leu Gln Val Leu Pro
                470                 475                 480
Ala Cys Gln Val Cys Tyr Met Pro Asn Cys Gly Arg Leu Glu Ala
                485                 490                 495
Phe Ala Leu Arg Asp Val Pro Gly Leu Leu Gly Ala Lys Leu Ala
                500                 505                 510
Val Leu Gln Leu Phe Ala Gly Cys Leu Arg Arg Arg Leu Arg Glu
                515                 520                 525
Glu Gly Thr Leu Pro Thr Pro Val Pro Pro Ala Gly Pro Gly Leu
                530                 535                 540
Cys Leu Leu Arg Phe Leu Ala Ser Glu His Ala Leu Leu Leu Leu
                545                 550                 555
Phe Ser Asn Gly Met Val Gln Val Ser Phe Ser Gly Val Pro Ala
                560                 565                 570
Gln Leu Val Leu Ser Gly Glu Gly Glu Gly Leu Gln Leu Thr Leu
                575                 580                 585
Trp Glu Gln Gly Ser Pro Gly Thr Ser Tyr Ser Leu Asp Val Pro
                590                 595                 600
Arg Ser His Gly Cys Ala Pro Thr Thr Gly Gln His Leu His His
                605                 610                 615
Ala Leu Arg Met Leu Gln Ser Ile
                620
```

<210> 7
<211> 797
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7594537CD1

<400> 7

```
Met Thr Asn Gln Glu Lys Trp Ala His Leu Ser Pro Ser Glu Phe
 1               5                  10                  15
Ser Gln Leu Gln Lys Tyr Ala Glu Tyr Ser Thr Lys Lys Leu Lys
            20                  25                  30
Asp Val Leu Glu Glu Phe His Gly Asn Gly Val Leu Ala Lys Tyr
        35                  40                  45
Asn Pro Glu Gly Thr Ile Asp Phe Glu Gly Phe Lys Leu Phe Met
    50                  55                  60
Lys Thr Phe Leu Glu Ala Glu Leu Pro Asp Asp Phe Thr Ala His
65                  70                  75
Leu Phe Met Ser Phe Ser Asn Lys Phe Pro His Ser Ser Pro Met
                80                  85                  90
Val Lys Ser Lys Pro Ala Leu Leu Ser Gly Gly Leu Arg Met Asn
            95                  100                 105
Lys Gly Ala Ile Thr Pro Pro Arg Thr Thr Ser Pro Ala Asn Thr
        110                 115                 120
Cys Ser Pro Glu Val Ile His Leu Lys Asp Ile Val Cys Tyr Leu
    125                 130                 135
Ser Leu Leu Glu Arg Gly Arg Pro Glu Asp Lys Leu Glu Phe Met
140                 145                 150
Phe Arg Leu Tyr Asp Thr Asp Gly Asn Gly Phe Leu Asp Ser Ser
                155                 160                 165
Glu Leu Glu Asn Ile Ile Ser Gln Met Met His Val Ala Glu Tyr
            170                 175                 180
Leu Glu Trp Asp Val Thr Glu Leu Asn Pro Ile Leu His Glu Met
        185                 190                 195
Met Glu Glu Ile Asp Tyr Asp His Asp Gly Thr Val Ser Leu Glu
    200                 205                 210
Glu Trp Ile Gln Gly Gly Met Thr Thr Ile Pro Leu Leu Val Leu
215                 220                 225
Leu Gly Leu Glu Asn Asn Val Lys Asp Asp Gly Gln His Val Trp
                230                 235                 240
Arg Leu Lys His Phe Asn Lys Pro Ala Tyr Cys Asn Leu Cys Leu
            245                 250                 255
Asn Met Leu Ile Gly Val Gly Lys Gln Gly Leu Cys Cys Ser Phe
        260                 265                 270
Cys Lys Tyr Thr Val His Glu Arg Cys Val Ala Arg Ala Pro Pro
    275                 280                 285
Ser Cys Ile Lys Thr Tyr Val Lys Ser Lys Arg Asn Thr Asp Val
290                 295                 300
Met His His Tyr Trp Val Glu Gly Asn Cys Pro Thr Lys Cys Asp
                305                 310                 315
Lys Cys His Lys Thr Val Lys Cys Tyr Gln Gly Leu Thr Gly Leu
            320                 325                 330
His Cys Val Trp Cys Gln Ile Thr Leu His Asn Lys Cys Ala Ser
        335                 340                 345
His Leu Lys Pro Glu Cys Asp Cys Gly Pro Leu Lys Asp His Ile
    350                 355                 360
Leu Pro Pro Thr Thr Ile Cys Pro Val Val Leu Gln Thr Leu Pro
365                 370                 375
Thr Ser Gly Val Ser Val Pro Glu Glu Arg Gln Ser Thr Val Lys
                380                 385                 390
Lys Glu Lys Ser Gly Ser Gln Gln Pro Asn Lys Val Ile Asp Lys
            395                 400                 405
Asn Lys Met Gln Arg Ala Asn Ser Val Thr Val Asp Gly Gln Gly
        410                 415                 420
```

```
Leu Gln Val Thr Pro Val Pro Gly Thr His Pro Leu Leu Val Phe
                425                 430                 435
Val Asn Pro Lys Ser Gly Gly Lys Gln Gly Glu Arg Ile Tyr Arg
                440                 445                 450
Lys Phe Gln Tyr Leu Leu Asn Pro Arg Gln Val Tyr Ser Leu Ser
                455                 460                 465
Gly Asn Gly Pro Met Pro Gly Leu Asn Phe Phe Arg Asp Val Pro
                470                 475                 480
Asp Phe Arg Val Leu Ala Cys Gly Gly Asp Gly Thr Val Gly Trp
                485                 490                 495
Val Leu Asp Cys Ile Glu Lys Ala Asn Val Gly Lys His Pro Pro
                500                 505                 510
Val Ala Ile Leu Pro Leu Gly Thr Gly Asn Asp Leu Ala Arg Cys
                515                 520                 525
Leu Arg Trp Gly Gly Gly Tyr Glu Gly Glu Asn Leu Met Lys Ile
                530                 535                 540
Leu Lys Asp Ile Glu Asn Ser Thr Glu Ile Met Leu Asp Arg Trp
                545                 550                 555
Lys Phe Glu Val Ile Pro Asn Asp Lys Asp Glu Lys Gly Asp Pro
                560                 565                 570
Val Pro Tyr Ser Ile Ile Asn Asn Tyr Phe Ser Ile Gly Val Asp
                575                 580                 585
Ala Ser Ile Ala His Arg Phe His Ile Met Arg Glu Lys His Pro
                590                 595                 600
Glu Lys Phe Asn Ser Arg Met Lys Asn Lys Phe Trp Tyr Phe Glu
                605                 610                 615
Phe Gly Thr Ser Glu Thr Phe Ser Ala Thr Cys Lys Lys Leu His
                620                 625                 630
Glu Ser Val Glu Ile Glu Cys Asp Gly Val Gln Ile Asp Leu Ile
                635                 640                 645
Asn Ile Ser Leu Glu Gly Ile Ala Ile Leu Asn Ile Pro Ser Met
                650                 655                 660
His Gly Gly Ser Asn Leu Trp Gly Glu Ser Lys Lys Arg Arg Ser
                665                 670                 675
His Arg Arg Ile Glu Lys Lys Gly Ser Asp Lys Arg Thr Thr Val
                680                 685                 690
Thr Asp Ala Lys Glu Leu Lys Phe Ala Ser Gln Asp Leu Ser Asp
                695                 700                 705
Gln Leu Leu Glu Val Val Gly Leu Glu Gly Ala Met Glu Met Gly
                710                 715                 720
Gln Ile Tyr Thr Gly Leu Lys Ser Ala Gly Arg Arg Leu Ala Gln
                725                 730                 735
Cys Ser Cys Val Val Ile Arg Thr Ser Lys Ser Leu Pro Met Gln
                740                 745                 750
Ile Asp Gly Glu Pro Trp Met Gln Thr Pro Cys Thr Ile Lys Ile
                755                 760                 765
Thr His Lys Asn Gln Ala Pro Met Leu Met Gly Pro Pro Pro Lys
                770                 775                 780
Thr Gly Leu Phe Cys Ser Leu Val Lys Arg Thr Arg Asn Arg Ser
                785                 790                 795
Lys Glu
```

<210> 8
<211> 749
<212> PRT

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 70467491CD1

<400> 8

```
Met Ser Thr Arg Thr Pro Leu Pro Thr Val Asn Glu Arg Asp Thr
  1               5                  10                  15
Glu Asn Ala Val Leu Pro His Thr Ser His Gly Asp Gly Arg Gln
                 20                  25                  30
Glu Val Thr Ser Arg Thr Ser Arg Ser Gly Ala Arg Cys Arg Asn
                 35                  40                  45
Ser Ile Ala Ser Cys Ala Asp Glu Gln Pro His Ile Gly Asn Tyr
                 50                  55                  60
Arg Leu Leu Lys Thr Ile Gly Lys Gly Asn Phe Ala Lys Val Lys
                 65                  70                  75
Leu Ala Arg His Ile Leu Thr Gly Arg Glu Lys Asn Val Arg Ile
                 80                  85                  90
Ser Lys Glu Ile Asp Asn Phe Leu Gly Lys His Asp Leu Pro Lys
                 95                 100                 105
Leu Thr Leu Glu Lys Asn Arg Tyr Thr Ser Val Thr Thr Glu Val
                110                 115                 120
Glu Lys Val Val Asn Ile Leu Pro Asn Leu Glu Phe Met Ile Glu
                125                 130                 135
Phe Phe Glu Ile Tyr Ser Ile Gly Glu Val Phe Asp Tyr Leu Val
                140                 145                 150
Ala His Gly Arg Met Lys Glu Lys Glu Ala Arg Ser Lys Phe Arg
                155                 160                 165
Gln Ile Val Ser Ala Val Gln Tyr Cys His Gln Lys Arg Ile Val
                170                 175                 180
His Arg Asp Leu Lys Ala Glu Asn Leu Leu Leu Asp Ala Asp Met
                185                 190                 195
Asn Ile Lys Ile Ala Asp Phe Gly Phe Ser Asn Glu Phe Thr Val
                200                 205                 210
Gly Gly Lys Leu Asp Thr Phe Cys Gly Ser Pro Pro Tyr Ala Ala
                215                 220                 225
Pro Glu Leu Phe Gln Gly Lys Lys Tyr Asp Gly Pro Glu Val Asp
                230                 235                 240
Val Trp Ser Leu Gly Val Ile Leu Tyr Thr Leu Val Ser Gly Ser
                245                 250                 255
Leu Pro Phe Asp Gly Gln Asn Leu Lys Glu Leu Arg Glu Arg Val
                260                 265                 270
Leu Arg Gly Lys Tyr Arg Ile Pro Phe Tyr Met Ser Thr Asp Cys
                275                 280                 285
Glu Asn Leu Leu Lys Arg Phe Leu Val Leu Asn Pro Ile Lys Arg
                290                 295                 300
Gly Thr Leu Glu Gln Ile Met Lys Asp Arg Trp Ile Asn Ala Gly
                305                 310                 315
His Glu Glu Asp Glu Leu Lys Pro Phe Val Glu Pro Glu Leu Asp
                320                 325                 330
Ile Ser Asp Gln Lys Arg Ile Asp Ile Met Val Gly Met Gly Tyr
                335                 340                 345
Ser Gln Glu Glu Ile Gln Glu Ser Leu Ser Lys Met Lys Tyr Asp
                350                 355                 360
Glu Ile Thr Ala Thr Tyr Leu Leu Leu Gly Arg Lys Ser Ser Glu
```

```
                365                 370                 375
Leu Asp Ala Ser Asp Ser Ser Ser Ser Ser Asn Leu Ser Leu Ala
                380                 385                 390
Lys Val Arg Pro Ser Ser Asp Leu Asn Asn Ser Thr Gly Gln Ser
                395                 400                 405
Pro His His Lys Val Gln Arg Ser Val Ser Ser Ser Gln Lys Gln
                410                 415                 420
Arg Arg Tyr Ser Asp His Ala Gly Pro Ala Ile Pro Ser Val Val
                425                 430                 435
Ala Tyr Pro Lys Arg Ser Gln Thr Ser Thr Ala Asp Ser Asp Leu
                440                 445                 450
Lys Glu Asp Gly Ile Ser Ser Arg Lys Ser Ser Gly Ser Ala Val
                455                 460                 465
Gly Gly Lys Gly Ile Ala Pro Ala Ser Pro Met Leu Gly Asn Ala
                470                 475                 480
Ser Asn Pro Asn Lys Ala Asp Ile Pro Glu Arg Lys Lys Ser Ser
                485                 490                 495
Thr Val Pro Ser Ser Asn Thr Ala Ser Gly Gly Met Thr Arg Arg
                500                 505                 510
Asn Thr Tyr Val Cys Ser Glu Arg Thr Thr Ala Asp Arg His Ser
                515                 520                 525
Val Ile Gln Asn Gly Lys Glu Asn Ser Thr Ile Pro Asp Gln Arg
                530                 535                 540
Thr Pro Val Ala Ser Thr His Ser Ile Ser Ser Ala Ala Thr Pro
                545                 550                 555
Asp Arg Ile Arg Phe Pro Arg Gly Thr Ala Ser Arg Ser Thr Phe
                560                 565                 570
His Gly Gln Pro Arg Glu Arg Arg Thr Ala Thr Tyr Asn Gly Pro
                575                 580                 585
Pro Ala Ser Pro Ser Leu Ser His Glu Ala Thr Pro Leu Ser Gln
                590                 595                 600
Thr Arg Ser Arg Gly Ser Thr Asn Leu Phe Ser Lys Leu Thr Ser
                605                 610                 615
Lys Leu Thr Arg Arg Leu Pro Thr Glu Tyr Glu Arg Asn Gly Arg
                620                 625                 630
Tyr Glu Gly Ser Ser Arg Asn Val Ser Ala Glu Gln Lys Asp Glu
                635                 640                 645
Asn Lys Glu Ala Lys Pro Arg Ser Leu Arg Phe Thr Trp Ser Met
                650                 655                 660
Lys Thr Thr Ser Ser Met Asp Pro Gly Asp Met Met Arg Glu Ile
                665                 670                 675
Arg Lys Val Leu Asp Ala Asn Asn Cys Asp Tyr Glu Gln Arg Glu
                680                 685                 690
Arg Phe Leu Leu Phe Cys Val His Gly Asp Gly His Ala Glu Asn
                695                 700                 705
Leu Val Gln Trp Glu Met Glu Val Cys Lys Leu Pro Arg Leu Ser
                710                 715                 720
Leu Asn Gly Val Arg Phe Lys Arg Ile Ser Gly Thr Ser Ile Ala
                725                 730                 735
Phe Lys Asn Ile Ala Ser Lys Ile Ala Asn Glu Leu Lys Leu
                740                 745
```

<210> 9
<211> 386
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7478559CD1

<400> 9

```
Met Ala Val Pro Pro Ser Ala Pro Gln Pro Arg Ala Ser Phe His
  1               5                  10                  15
Leu Arg Arg His Thr Pro Cys Pro Gln Cys Ser Trp Gly Met Glu
             20                  25                  30
Glu Lys Ala Ala Ala Ser Ala Ser Cys Arg Glu Pro Pro Gly Pro
             35                  40                  45
Pro Arg Ala Ala Ala Val Ala Tyr Phe Gly Ile Ser Val Asp Pro
             50                  55                  60
Asp Asp Ile Leu Pro Gly Ala Leu Arg Leu Ile Gln Glu Leu Arg
             65                  70                  75
Pro His Trp Lys Pro Glu Gln Val Arg Thr Lys Arg Phe Met Asp
             80                  85                  90
Gly Ile Thr Asn Lys Leu Val Ala Cys Tyr Val Glu Glu Asp Met
             95                 100                 105
Gln Asp Cys Val Leu Val Arg Val Tyr Gly Glu Arg Thr Glu Leu
            110                 115                 120
Leu Val Asp Arg Glu Asn Glu Val Arg Asn Phe Gln Leu Leu Arg
            125                 130                 135
Ala His Ser Cys Ala Pro Lys Leu Tyr Cys Thr Phe Gln Asn Gly
            140                 145                 150
Leu Cys Tyr Glu Tyr Met Gln Gly Val Ala Leu Glu Pro Glu His
            155                 160                 165
Ile Arg Glu Pro Arg Leu Phe Arg Leu Ile Ala Leu Glu Met Ala
            170                 175                 180
Lys Ile His Thr Ile His Ala Asn Gly Ser Leu Pro Lys Pro Ile
            185                 190                 195
Leu Trp His Lys Met His Asn Tyr Phe Thr Leu Val Lys Asn Glu
            200                 205                 210
Ile Asn Pro Ser Leu Ser Ala Asp Val Pro Lys Val Glu Val Leu
            215                 220                 225
Glu Arg Glu Leu Ala Trp Leu Lys Glu His Leu Ser Gln Leu Glu
            230                 235                 240
Ser Pro Val Val Phe Cys His Asn Asp Leu Leu Cys Lys Asn Ile
            245                 250                 255
Ile Tyr Asp Ser Ile Lys Gly His Val Arg Phe Ile Asp Tyr Glu
            260                 265                 270
Tyr Ala Gly Tyr Asn Tyr Gln Ala Phe Asp Ile Gly Asn His Phe
            275                 280                 285
Asn Glu Phe Ala Gly Val Asn Glu Val Asp Tyr Cys Leu Tyr Pro
            290                 295                 300
Ala Arg Glu Thr Gln Leu Gln Trp Leu His Tyr Tyr Leu Gln Ala
            305                 310                 315
Gln Lys Gly Met Ala Val Thr Pro Arg Glu Val Gln Arg Leu Tyr
            320                 325                 330
Val Gln Val Asn Lys Phe Ala Leu Ala Ser His Phe Phe Trp Ala
            335                 340                 345
Leu Trp Ala Leu Ile Gln Asn Gln Tyr Ser Thr Ile Asp Phe Asp
            350                 355                 360
Phe Leu Arg Tyr Ala Val Ile Arg Phe Asn Gln Tyr Phe Lys Val
            365                 370                 375
Lys Pro Gln Ala Ser Ala Leu Glu Met Pro Lys
```

380 385

<210> 10
<211> 342
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1698381CD1

<400> 10
Met Glu Lys Tyr Glu Lys Leu Ala Lys Thr Gly Glu Gly Ser Tyr
1 5 10 15
Gly Val Val Phe Lys Cys Arg Asn Lys Thr Ser Gly Gln Val Val
20 25 30
Ala Val Lys Lys Phe Val Glu Ser Glu Asp Asp Pro Val Val Lys
35 40 45
Lys Ile Ala Leu Arg Glu Ile Arg Met Leu Lys Gln Leu Lys His
50 55 60
Pro Asn Leu Val Asn Leu Ile Glu Val Phe Arg Arg Lys Arg Lys
65 70 75
Met His Leu Val Phe Glu Tyr Cys Asp His Thr Leu Leu Asn Glu
80 85 90
Leu Glu Arg Asn Pro Asn Gly Val Ala Asp Gly Val Ile Lys Ser
95 100 105
Val Leu Trp Gln Thr Leu Gln Ala Leu Asn Phe Cys His Ile His
110 115 120
Asn Cys Ile His Arg Asp Ile Lys Pro Glu Asn Ile Leu Ile Thr
125 130 135
Lys Gln Gly Ile Ile Lys Ile Cys Asp Phe Gly Phe Ala Gln Ile
140 145 150
Leu Ile Pro Gly Asp Ala Tyr Thr Asp Tyr Val Ala Thr Arg Trp
155 160 165
Tyr Arg Ala Pro Glu Leu Leu Val Gly Asp Thr Gln Tyr Gly Ser
170 175 180
Ser Val Asp Ile Trp Ala Ile Gly Cys Val Phe Ala Glu Leu Leu
185 190 195
Thr Gly Gln Pro Leu Trp Pro Gly Lys Ser Asp Val Asp Gln Leu
200 205 210
Tyr Leu Ile Ile Arg Thr Leu Gly Lys Leu Ile Pro Arg His Gln
215 220 225
Ser Ile Phe Lys Ser Asn Gly Phe Phe His Gly Ile Ser Ile Pro
230 235 240
Glu Pro Glu Asp Met Glu Thr Leu Glu Glu Lys Phe Ser Asp Val
245 250 255
His Pro Val Ala Leu Asn Phe Met Lys Gly Cys Leu Lys Met Asn
260 265 270
Pro Asp Asp Arg Leu Thr Cys Ser Gln Leu Leu Glu Ser Ser Tyr
275 280 285
Phe Asp Ser Phe Gln Glu Ala Gln Ile Lys Arg Lys Ala Arg Asn
290 295 300
Glu Gly Arg Asn Arg Arg Arg Gln Gln Asn Gln Leu Leu Pro Leu
305 310 315
Ile Pro Gly Ser His Ile Ser Pro Thr Pro Asp Gly Arg Lys Gln
320 325 330

```
Val Leu Gln Leu Lys Phe Asp His Leu Pro Asn Ile
                335                 340

<210> 11
<211> 1164
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474637CD1

<400> 11
Met Ala Gly Ala Gly Gly Gln His His Pro Pro Gly Ala Ala Gly
  1               5                  10                  15
Gly Ala Ala Ala Gly Ala Gly Ala Ala Val Thr Ser Ala Ala Ala
                20                  25                  30
Ser Ala Gly Pro Gly Glu Asp Ser Ser Asp Ser Glu Ala Glu Gln
                35                  40                  45
Glu Gly Pro Gln Lys Leu Ile Arg Lys Val Ser Thr Ser Gly Gln
                50                  55                  60
Ile Arg Thr Lys Thr Ser Ile Lys Glu Gly Gln Leu Leu Lys Gln
                65                  70                  75
Thr Ser Ser Phe Gln Arg Trp Lys Lys Arg Tyr Phe Lys Leu Arg
                80                  85                  90
Gly Arg Thr Leu Tyr Tyr Ala Lys Asp Ser Lys Ser Leu Ile Phe
                95                 100                 105
Asp Glu Val Asp Leu Ser Asp Ala Ser Val Ala Glu Ala Ser Thr
               110                 115                 120
Lys Asn Ala Asn Asn Ser Phe Thr Ile Ile Thr Pro Phe Arg Arg
               125                 130                 135
Leu Met Leu Cys Ala Glu Asn Arg Lys Glu Met Glu Asp Trp Ile
               140                 145                 150
Ser Ser Leu Lys Ser Val Gln Thr Arg Glu Pro Tyr Glu Val Ala
               155                 160                 165
Gln Phe Asn Val Glu His Phe Ser Gly Met His Asn Trp Tyr Ala
               170                 175                 180
Cys Ser His Ala Arg Pro Thr Phe Cys Asn Val Cys Arg Glu Ser
               185                 190                 195
Leu Ser Gly Val Thr Ser His Gly Leu Ser Cys Glu Val Cys Lys
               200                 205                 210
Phe Lys Ala His Lys Arg Cys Ala Val Arg Ala Thr Asn Asn Cys
               215                 220                 225
Lys Trp Thr Thr Leu Ala Ser Ile Gly Lys Asp Ile Ile Glu Asp
               230                 235                 240
Glu Asp Gly Val Ala Met Pro His Gln Trp Leu Glu Gly Asn Leu
               245                 250                 255
Pro Val Ser Ala Lys Cys Ala Val Cys Asp Lys Thr Cys Gly Ser
               260                 265                 270
Val Leu Arg Leu Gln Asp Trp Lys Cys Leu Trp Cys Lys Thr Met
               275                 280                 285
Val His Thr Ala Cys Lys Asp Leu Tyr His Pro Ile Cys Pro Leu
               290                 295                 300
Gly Gln Cys Lys Val Ser Ile Ile Pro Pro Ile Ala Leu Asn Ser
               305                 310                 315
Thr Asp Ser Asp Gly Phe Cys Arg Ala Thr Phe Ser Phe Cys Val
```

```
                320                 325                 330
Ser Pro Leu Leu Val Phe Val Asn Ser Lys Ser Gly Asp Asn Gln
                335                 340                 345
Gly Val Lys Phe Leu Arg Arg Phe Lys Gln Leu Leu Asn Pro Ala
                350                 355                 360
Gln Val Phe Asp Leu Met Asn Gly Gly Pro His Leu Gly Leu Arg
                365                 370                 375
Leu Phe Gln Lys Phe Asp Asn Phe Arg Ile Leu Val Cys Gly Gly
                380                 385                 390
Asp Gly Ser Val Gly Trp Val Leu Ser Glu Ile Asp Lys Leu Asn
                395                 400                 405
Leu Asn Lys Gln Cys Gln Leu Gly Val Leu Pro Leu Gly Thr Gly
                410                 415                 420
Asn Asp Leu Ala Arg Val Leu Gly Trp Gly Gly Ser Tyr Asp Asp
                425                 430                 435
Asp Thr Gln Leu Pro Gln Ile Leu Glu Lys Leu Glu Arg Ala Ser
                440                 445                 450
Thr Lys Met Leu Asp Arg Trp Ser Ile Met Thr Tyr Glu Leu Lys
                455                 460                 465
Leu Pro Pro Lys Ala Ser Leu Leu Pro Gly Pro Pro Glu Ala Ser
                470                 475                 480
Glu Glu Phe Tyr Met Thr Ile Tyr Glu Asp Ser Val Ala Thr His
                485                 490                 495
Leu Thr Lys Ile Leu Asn Ser Asp Glu His Ala Val Val Ile Ser
                500                 505                 510
Ser Ala Lys Thr Leu Cys Glu Thr Val Lys Asp Phe Val Ala Lys
                515                 520                 525
Val Glu Lys Thr Tyr Asp Lys Thr Leu Glu Asn Ala Val Val Ala
                530                 535                 540
Asp Ala Val Ala Ser Lys Cys Ser Val Leu Asn Glu Lys Leu Glu
                545                 550                 555
Gln Leu Leu Gln Ala Leu His Thr Asp Ser Gln Ala Ala Pro Val
                560                 565                 570
Leu Pro Gly Leu Ser Pro Leu Ile Val Glu Glu Asp Ala Val Glu
                575                 580                 585
Ser Ser Ser Glu Glu Ser Leu Gly Glu Ser Lys Glu Gln Leu Gly
                590                 595                 600
Asp Asp Val Thr Lys Pro Ser Ser Gln Lys Ala Val Lys Pro Arg
                605                 610                 615
Glu Ile Met Leu Arg Ala Asn Ser Leu Lys Lys Ala Val Arg Gln
                620                 625                 630
Val Ile Glu Glu Ala Gly Lys Val Met Asp Asp Pro Thr Val His
                635                 640                 645
Pro Cys Glu Pro Ala Asn Gln Ser Ser Asp Tyr Asp Ser Thr Glu
                650                 655                 660
Thr Asp Glu Ser Lys Glu Glu Ala Lys Asp Asp Gly Ala Lys Glu
                665                 670                 675
Ser Ile Thr Val Lys Thr Ala Pro Arg Ser Pro Asp Ala Arg Ala
                680                 685                 690
Ser Tyr Gly His Ser Gln Thr Asp Ser Val Pro Gly Pro Ala Val
                695                 700                 705
Ala Ala Ser Lys Glu Asn Leu Pro Val Leu Asn Thr Arg Ile Ile
                710                 715                 720
Cys Pro Gly Leu Arg Ala Gly Leu Ala Ala Ser Ile Ala Gly Ser
                725                 730                 735
Ser Ile Ile Asn Lys Met Leu Leu Ala Asn Ile Asp Pro Phe Gly
```

```
                740                 745                 750
Ala Thr Pro Phe Ile Asp Pro Asp Leu Asp Ser Val Asp Gly Tyr
                755                 760                 765
Ser Glu Lys Cys Val Met Asn Asn Tyr Phe Gly Ile Gly Leu Asp
                770                 775                 780
Ala Lys Ile Ser Leu Glu Phe Asn Asn Lys Arg Glu Glu His Pro
                785                 790                 795
Glu Lys Cys Arg Ser Arg Thr Lys Asn Leu Met Trp Tyr Gly Val
                800                 805                 810
Leu Gly Thr Arg Glu Leu Leu Gln Arg Ser Tyr Lys Asn Leu Glu
                815                 820                 825
Gln Arg Val Gln Leu Glu Cys Asp Gly Gln Tyr Ile Pro Leu Pro
                830                 835                 840
Ser Leu Gln Gly Ile Ala Val Leu Asn Ile Pro Ser Tyr Ala Gly
                845                 850                 855
Gly Thr Asn Phe Trp Gly Gly Thr Lys Glu Asp Asp Ile Phe Ala
                860                 865                 870
Ala Pro Ser Phe Asp Asp Lys Ile Leu Glu Val Val Ala Ile Phe
                875                 880                 885
Asp Ser Met Gln Met Ala Val Ser Arg Val Ile Lys Leu Gln His
                890                 895                 900
His Arg Ile Ala Gln Cys Arg Thr Val Lys Ile Thr Ile Phe Gly
                905                 910                 915
Asp Glu Gly Val Pro Val Gln Val Asp Gly Glu Ala Trp Val Gln
                920                 925                 930
Pro Pro Gly Ile Ile Lys Ile Val His Lys Asn Arg Ala Gln Met
                935                 940                 945
Leu Thr Arg Asp Arg Ala Phe Glu Ser Thr Leu Lys Ser Trp Glu
                950                 955                 960
Asp Lys Gln Lys Cys Asp Ser Gly Lys Pro Val Leu Arg Thr His
                965                 970                 975
Leu Tyr Ile His His Ala Ile Asp Leu Ala Thr Glu Glu Val Ser
                980                 985                 990
Gln Met Gln Leu Cys Ser Gln Ala Ala Glu Glu Leu Ile Thr Arg
                995                1000                1005
Ile Cys Asp Ala Ala Thr Ile His Cys Leu Leu Glu Gln Glu Leu
               1010                1015                1020
Ala His Ala Val Asn Ala Cys Ser His Ala Leu Asn Lys Ala Asn
               1025                1030                1035
Pro Arg Cys Pro Glu Ser Leu Thr Arg Asp Thr Ala Thr Glu Ile
               1040                1045                1050
Ala Ile Asn Val Lys Ala Leu Tyr Asn Glu Thr Glu Ser Leu Leu
               1055                1060                1065
Val Gly Arg Val Pro Leu Gln Leu Glu Ser Pro His Glu Glu Arg
               1070                1075                1080
Val Ser Asn Ala Leu His Ser Val Glu Val Glu Leu Gln Lys Leu
               1085                1090                1095
Thr Glu Ile Pro Trp Leu Tyr Tyr Ile Leu His Pro Asn Glu Asp
               1100                1105                1110
Glu Glu Pro Pro Met Asp Cys Thr Lys Arg Asn Asn Arg Ser Thr
               1115                1120                1125
Val Phe Arg Ile Val Pro Lys Phe Lys Lys Glu Lys Val Gln Lys
               1130                1135                1140
Gln Lys Thr Ser Ser Gln Pro Gly Ser Gly Asp Thr Glu Ser Gly
               1145                1150                1155
Ser Cys Glu Ala Asn Ser Pro Gly Asn
```

1160

<210> 12
<211> 268
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7170260CD1

<400> 12
Met Glu Asp Phe Leu Leu Ser Asn Gly Tyr Gln Leu Gly Lys Thr
1 5 10 15
Ile Gly Glu Gly Thr Tyr Ser Lys Val Lys Glu Ala Phe Ser Lys
20 25 30
Lys His Gln Arg Lys Val Ala Ile Lys Val Ile Asp Lys Met Gly
35 40 45
Gly Pro Glu Glu Phe Ile Gln Arg Phe Leu Pro Arg Glu Leu Gln
50 55 60
Ile Val Arg Thr Leu Asp His Lys Asn Ile Ile Gln Val Tyr Glu
65 70 75
Met Leu Glu Ser Ala Asp Gly Lys Ile Cys Leu Val Met Glu Leu
80 85 90
Ala Glu Gly Gly Asp Val Phe Asp Cys Val Leu Asn Gly Gly Pro
95 100 105
Leu Pro Glu Ser Arg Ala Lys Ala Leu Phe Arg Gln Met Val Glu
110 115 120
Ala Ile Arg Tyr Cys His Gly Cys Gly Val Ala His Arg Asp Leu
125 130 135
Lys Cys Glu Asn Ala Leu Leu Gln Gly Phe Asn Leu Lys Leu Thr
140 145 150
Asp Phe Gly Phe Ala Lys Val Leu Pro Lys Ser His Arg Glu Leu
155 160 165
Ser Gln Thr Phe Cys Gly Ser Thr Ala Tyr Ala Ala Pro Glu Val
170 175 180
Leu Gln Gly Ile Pro His Asp Ser Lys Lys Gly Asp Val Trp Ser
185 190 195
Met Gly Val Val Leu Tyr Val Met Leu Cys Ala Ser Leu Pro Phe
200 205 210
Asp Asp Thr Asp Ile Pro Lys Met Leu Trp Gln Gln Gln Lys Gly
215 220 225
Val Ser Phe Pro Thr His Leu Ser Ile Ser Ala Asp Cys Gln Asp
230 235 240
Leu Leu Lys Arg Leu Leu Glu Pro Asp Met Ile Leu Arg Pro Ser
245 250 255
Ile Glu Glu Val Ser Trp His Pro Trp Leu Ala Ser Thr
260 265

<210> 13
<211> 965
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 1797506CD1

<400> 13

```
Met Arg Arg Ala Gly Ile Gly Glu Asp Ser Arg Leu Gly Leu Gln
  1               5                  10                  15
Ala Gln Pro Gly Ala Glu Pro Ser Pro Gly Arg Ala Gly Thr Glu
             20                  25                  30
Arg Ser Leu Gly Gly Thr Gln Gly Pro Gly Gln Pro Cys Ser Cys
             35                  40                  45
Pro Gly Ala Met Ala Ser Ala Val Arg Gly Ser Arg Pro Trp Pro
             50                  55                  60
Arg Leu Gly Leu Gln Leu Gln Phe Ala Ala Leu Leu Leu Gly Thr
             65                  70                  75
Leu Ser Pro Gln Val His Thr Leu Arg Pro Glu Asn Leu Leu Leu
             80                  85                  90
Val Ser Thr Leu Asp Gly Ser Leu His Ala Leu Ser Lys Gln Thr
             95                 100                 105
Gly Asp Leu Lys Trp Thr Leu Arg Asp Asp Pro Val Ile Glu Gly
            110                 115                 120
Pro Met Tyr Val Thr Glu Met Ala Phe Leu Ser Asp Pro Ala Asp
            125                 130                 135
Gly Ser Leu Tyr Ile Leu Gly Thr Gln Lys Gln Gln Gly Leu Met
            140                 145                 150
Lys Leu Pro Phe Thr Ile Pro Glu Leu Val His Ala Ser Pro Cys
            155                 160                 165
Arg Ser Ser Asp Gly Val Phe Tyr Thr Gly Arg Lys Gln Asp Ala
            170                 175                 180
Trp Phe Val Val Asp Pro Glu Ser Gly Glu Thr Gln Met Thr Leu
            185                 190                 195
Thr Thr Glu Gly Pro Ser Thr Pro Arg Leu Tyr Ile Gly Arg Thr
            200                 205                 210
Gln Tyr Thr Val Thr Met His Asp Pro Arg Ala Pro Ala Leu Arg
            215                 220                 225
Trp Asn Thr Thr Tyr Arg Arg Tyr Ser Ala Pro Pro Met Asp Gly
            230                 235                 240
Ser Pro Gly Lys Tyr Met Ser His Leu Ala Ser Cys Gly Met Gly
            245                 250                 255
Leu Leu Leu Thr Val Asp Pro Gly Ser Gly Thr Val Leu Trp Thr
            260                 265                 270
Gln Asp Leu Gly Val Pro Val Met Gly Val Tyr Thr Trp His Gln
            275                 280                 285
Asp Gly Leu Arg Gln Leu Pro His Leu Thr Leu Ala Arg Asp Thr
            290                 295                 300
Leu His Phe Leu Ala Leu Arg Trp Gly His Ile Arg Leu Pro Ala
            305                 310                 315
Ser Gly Pro Arg Asp Thr Ala Thr Leu Phe Ser Thr Leu Asp Thr
            320                 325                 330
Gln Leu Leu Met Thr Leu Tyr Val Gly Lys Asp Glu Thr Gly Phe
            335                 340                 345
Tyr Val Ser Lys Ala Leu Val His Thr Gly Val Ala Leu Val Pro
            350                 355                 360
Arg Gly Leu Thr Leu Ala Pro Ala Asp Gly Pro Thr Thr Asp Glu
            365                 370                 375
Val Thr Leu Gln Val Ser Gly Glu Arg Glu Gly Ser Pro Ser Thr
            380                 385                 390
Ala Val Arg Tyr Pro Ser Gly Ser Val Ala Leu Pro Ser Gln Trp
```

```
                395                 400                 405
Leu Leu Ile Gly His His Glu Leu Pro Pro Val Leu His Thr Thr
            410                 415                 420
Met Leu Arg Val His Pro Thr Leu Gly Ser Gly Thr Ala Glu Thr
        425                 430                 435
Arg Pro Pro Glu Asn Thr Gln Ala Pro Ala Phe Phe Leu Glu Leu
    440                 445                 450
Leu Ser Leu Ser Arg Glu Lys Leu Trp Asp Ser Glu Leu His Pro
455                 460                 465
Glu Glu Lys Thr Pro Asp Ser Tyr Leu Gly Leu Gly Pro Gln Asp
            470                 475                 480
Leu Leu Ala Ala Ser Leu Thr Ala Val Leu Leu Gly Gly Trp Ile
        485                 490                 495
Leu Phe Val Met Arg Gln Gln Gln Glu Thr Pro Leu Ala Pro Ala
    500                 505                 510
Asp Phe Ala His Ile Ser Gln Asp Ala Gln Ser Leu His Ser Gly
515                 520                 525
Ala Ser Arg Arg Ser Gln Lys Arg Leu Gln Ser Pro Ser Pro Glu
            530                 535                 540
Ser Pro Pro Ser Ser Pro Pro Ala Glu Gln Leu Thr Val Val Gly
        545                 550                 555
Lys Ile Ser Phe Asn Pro Lys Asp Val Leu Gly Arg Gly Ala Gly
    560                 565                 570
Gly Thr Phe Val Phe Arg Gly Gln Phe Glu Gly Arg Ala Val Ala
575                 580                 585
Val Lys Arg Leu Leu Arg Glu Cys Phe Gly Leu Val Arg Arg Glu
            590                 595                 600
Val Gln Leu Leu Gln Glu Ser Asp Arg His Pro Asn Val Leu Arg
        605                 610                 615
Tyr Phe Cys Thr Glu Arg Gly Pro Gln Phe His Tyr Ile Ala Leu
    620                 625                 630
Glu Leu Cys Arg Ala Ser Leu Gln Glu Tyr Val Glu Asn Pro Asp
635                 640                 645
Leu Asp Arg Gly Gly Leu Glu Pro Glu Val Val Leu Gln Gln Leu
            650                 655                 660
Met Ser Gly Leu Ala His Leu His Ser Leu His Ile Val His Arg
        665                 670                 675
Asp Leu Lys Pro Gly Asn Ile Leu Ile Thr Gly Pro Asp Ser Gln
    680                 685                 690
Gly Leu Gly Arg Val Val Leu Ser Asp Phe Gly Leu Cys Lys Lys
695                 700                 705
Leu Pro Ala Gly Arg Cys Ser Phe Ser Leu His Ser Gly Ile Pro
            710                 715                 720
Gly Thr Glu Gly Trp Met Ala Pro Glu Leu Leu Gln Leu Leu Pro
        725                 730                 735
Pro Asp Ser Pro Thr Ser Ala Val Asp Ile Phe Ser Ala Gly Cys
    740                 745                 750
Val Phe Tyr Tyr Val Leu Ser Gly Gly Ser His Pro Phe Gly Asp
755                 760                 765
Ser Leu Tyr Arg Gln Ala Asn Ile Leu Thr Gly Ala Pro Cys Leu
            770                 775                 780
Ala His Leu Glu Glu Glu Val His Asp Lys Val Val Ala Arg Asp
        785                 790                 795
Leu Val Gly Ala Met Leu Ser Pro Leu Pro Gln Pro Arg Pro Ser
    800                 805                 810
Ala Pro Gln Val Leu Ala His Pro Phe Phe Trp Ser Arg Ala Lys
```

```
                815                 820                 825
Gln Leu Gln Phe Phe Gln Asp Val Ser Asp Trp Leu Glu Lys Glu
                830                 835                 840
Ser Glu Gln Glu Pro Leu Val Arg Ala Leu Glu Ala Gly Gly Cys
                845                 850                 855
Ala Val Val Arg Asp Asn Trp His Glu His Ile Ser Met Pro Leu
                860                 865                 870
Gln Thr Asp Leu Arg Lys Phe Arg Ser Tyr Lys Gly Thr Ser Val
                875                 880                 885
Arg Asp Leu Leu Arg Ala Val Arg Asn Lys Lys His His Tyr Arg
                890                 895                 900
Glu Leu Pro Val Glu Val Arg Gln Ala Leu Gly Gln Val Pro Asp
                905                 910                 915
Gly Phe Val Gln Tyr Phe Thr Asn Arg Phe Pro Arg Leu Leu Leu
                920                 925                 930
His Thr His Arg Ala Met Arg Ser Cys Ala Ser Glu Ser Leu Phe
                935                 940                 945
Leu Pro Tyr Tyr Pro Pro Asp Ser Glu Ala Arg Arg Pro Cys Pro
                950                 955                 960
Gly Ala Thr Gly Arg
                965
```

<210> 14
<211> 329
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1851973CD1

<400> 14

```
Met Asp Pro Thr Ala Gly Ser Lys Lys Glu Pro Gly Gly Gly Ala
  1                 5                  10                  15
Ala Thr Glu Glu Gly Val Asn Arg Ile Ala Val Pro Lys Pro Pro
                 20                  25                  30
Ser Ile Glu Glu Phe Ser Ile Val Lys Pro Ile Ser Arg Gly Ala
                 35                  40                  45
Phe Gly Lys Val Tyr Leu Gly Gln Lys Gly Gly Lys Leu Tyr Ala
                 50                  55                  60
Val Lys Val Val Lys Lys Ala Asp Met Ile Asn Lys Asn Met Thr
                 65                  70                  75
His Gln Val Gln Ala Glu Arg Asp Ala Leu Ala Leu Ser Lys Ser
                 80                  85                  90
Pro Phe Ile Val His Leu Tyr Tyr Ser Leu Gln Ser Ala Asn Asn
                 95                 100                 105
Val Tyr Leu Val Met Glu Tyr Leu Ile Gly Gly Asp Val Lys Ser
                110                 115                 120
Leu Leu His Ile Tyr Gly Tyr Phe Asp Glu Glu Met Ala Val Lys
                125                 130                 135
Tyr Ile Ser Glu Val Ala Leu Ala Leu Asp Tyr Leu His Arg His
                140                 145                 150
Gly Ile Ile His Arg Asp Leu Lys Pro Asp Asn Met Leu Ile Ser
                155                 160                 165
Asn Glu Gly His Ile Lys Leu Thr Asp Phe Gly Leu Ser Lys Val
                170                 175                 180
```

```
Thr Leu Asn Arg Asp Ile Asn Met Met Asp Ile Leu Thr Thr Pro
                185                 190                 195
Ser Met Ala Lys Pro Arg Gln Asp Tyr Ser Arg Thr Pro Gly Gln
                200                 205                 210
Val Leu Ser Leu Ile Ser Ser Leu Gly Phe Asn Thr Pro Ile Ala
                215                 220                 225
Glu Lys Asn Gln Asp Pro Ala Asn Ile Leu Ser Ala Cys Leu Ser
                230                 235                 240
Glu Thr Ser Gln Leu Ser Gln Gly Leu Val Cys Pro Met Ser Val
                245                 250                 255
Asp Gln Lys Asp Thr Thr Pro Tyr Ser Ser Lys Leu Leu Lys Ser
                260                 265                 270
Cys Leu Glu Thr Val Ala Ser Asn Pro Gly Met Pro Val Lys Cys
                275                 280                 285
Leu Thr Ser Asn Leu Leu Gln Ser Arg Lys Arg Leu Ala Thr Ser
                290                 295                 300
Ser Ala Ser Ser Gln Ser His Thr Phe Ile Ser Ser Val Glu Ser
                305                 310                 315
Glu Cys His Ser Ser Pro Lys Trp Glu Lys Asp Cys Gln Val
                320                 325

<210> 15
<211> 945
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474604CD1

<400> 15
Met Thr Lys Ser Glu Glu Gln Gln Pro Leu Ser Leu Gln Lys Ala
  1                 5                  10                  15
Leu Gln Gln Cys Glu Leu Val Gln Asn Met Ile Asp Leu Ser Ile
                20                  25                  30
Ser Asn Leu Glu Gly Leu Arg Thr Lys Cys Ala Thr Ser Asn Asp
                35                  40                  45
Leu Thr Gln Lys Glu Ile Arg Thr Leu Glu Ser Lys Leu Val Lys
                50                  55                  60
Tyr Phe Ser Arg Gln Leu Ser Cys Lys Lys Lys Val Ala Leu Gln
                65                  70                  75
Glu Arg Asn Ala Glu Leu Asp Gly Phe Pro Gln Leu Arg His Trp
                80                  85                  90
Phe Arg Ile Val Asp Val Arg Lys Glu Val Leu Glu Glu Ile Ser
                95                 100                 105
Pro Gly Gln Leu Ser Leu Glu Asp Leu Leu Glu Met Thr Asp Glu
                110                 115                 120
Gln Val Cys Glu Thr Val Glu Lys Tyr Gly Ala Asn Arg Glu Glu
                125                 130                 135
Cys Ala Arg Leu Asn Ala Ser Leu Ser Cys Leu Arg Asn Val His
                140                 145                 150
Met Ser Gly Gly Asn Leu Ser Lys Gln Asp Trp Thr Ile Gln Trp
                155                 160                 165
Pro Thr Thr Glu Thr Gly Lys Glu Asn Asn Pro Val Cys Pro Pro
                170                 175                 180
Glu Pro Thr Pro Trp Ile Arg Thr His Leu Ser Gln Ser Pro Arg
```

```
                185                 190                 195
Val Pro Ser Lys Cys Val Gln His Tyr Cys His Thr Ser Pro Thr
                200                 205                 210
Pro Gly Ala Pro Val Tyr Thr His Val Asp Arg Leu Thr Val Asp
                215                 220                 225
Ala Tyr Pro Gly Leu Cys Pro Pro Pro Pro Leu Glu Ser Gly His
                230                 235                 240
Arg Ser Leu Pro Pro Ser Pro Arg Gln Arg His Ala Val Arg Thr
                245                 250                 255
Pro Pro Arg Thr Pro Asn Ile Val Thr Thr Val Thr Pro Pro Gly
                260                 265                 270
Thr Pro Pro Met Arg Lys Lys Asn Lys Leu Lys Pro Pro Gly Thr
                275                 280                 285
Pro Pro Pro Ser Ser Arg Lys Leu Ile His Leu Ile Pro Gly Phe
                290                 295                 300
Thr Ala Leu His Arg Ser Lys Ser His Glu Phe Gln Leu Gly His
                305                 310                 315
Arg Val Asp Glu Ala His Thr Pro Lys Ala Lys Lys Lys Ser Lys
                320                 325                 330
Pro Leu Asn Leu Lys Ile His Ser Ser Val Gly Ser Cys Glu Asn
                335                 340                 345
Ile Pro Ser Gln Gln Arg Ser Pro Leu Leu Ser Glu Arg Ser Leu
                350                 355                 360
Arg Ser Phe Phe Val Gly His Ala Pro Phe Leu Pro Ser Thr Pro
                365                 370                 375
Pro Val His Thr Glu Ala Asn Phe Ser Ala Asn Thr Leu Ser Val
                380                 385                 390
Pro Arg Trp Ser Pro Gln Ile Pro Arg Arg Asp Leu Gly Asn Ser
                395                 400                 405
Ile Lys His Arg Phe Ser Thr Lys Tyr Trp Met Ser Gln Thr Cys
                410                 415                 420
Thr Val Cys Gly Lys Gly Met Leu Phe Gly Leu Lys Cys Lys Asn
                425                 430                 435
Cys Lys Leu Lys Cys His Asn Lys Cys Thr Lys Glu Ala Pro Pro
                440                 445                 450
Cys His Leu Leu Ile Ile His Arg Gly Asp Pro Ala Arg Leu Val
                455                 460                 465
Arg Thr Glu Ser Val Pro Cys Asp Ile Asn Asn Pro Leu Arg Lys
                470                 475                 480
Pro Pro Arg Tyr Ser Asp Leu His Ile Ser Gln Thr Leu Pro Lys
                485                 490                 495
Thr Asn Lys Ile Asn Lys Asp His Ile Pro Val Pro Tyr Gln Pro
                500                 505                 510
Asp Ser Ser Ser Asn Pro Ser Ser Thr Thr Ser Ser Thr Pro Ser
                515                 520                 525
Ser Pro Ala Pro Pro Leu Pro Pro Ser Ala Thr Pro Pro Ser Pro
                530                 535                 540
Leu His Pro Ser Pro Gln Cys Thr Arg Gln Gln Lys Asn Phe Asn
                545                 550                 555
Leu Pro Ala Ser His Tyr Tyr Lys Tyr Lys Gln Gln Phe Ile Phe
                560                 565                 570
Pro Asp Val Val Pro Val Pro Glu Thr Pro Thr Arg Ala Pro Gln
                575                 580                 585
Val Ile Leu His Pro Val Thr Ser Asn Pro Ile Leu Glu Gly Asn
                590                 595                 600
Pro Leu Leu Gln Ile Glu Val Glu Pro Thr Ser Glu Asn Glu Glu
```

```
                605                 610                 615
Val His Asp Glu Ala Glu Glu Ser Glu Asp Asp Phe Glu Glu Met
                620                 625                 630
Asn Leu Ser Leu Leu Ser Ala Arg Ser Phe Pro Arg Lys Ala Ser
                635                 640                 645
Gln Thr Ser Ile Phe Leu Gln Glu Trp Asp Ile Pro Phe Glu Gln
                650                 655                 660
Leu Glu Ile Gly Glu Leu Ile Gly Lys Gly Arg Phe Gly Gln Val
                665                 670                 675
Tyr His Gly Arg Trp His Gly Glu Val Ala Ile Arg Leu Ile Asp
                680                 685                 690
Ile Glu Arg Asp Asn Glu Asp Gln Leu Lys Ala Phe Lys Arg Glu
                695                 700                 705
Val Met Ala Tyr Arg Gln Thr Arg His Glu Asn Val Val Leu Phe
                710                 715                 720
Met Gly Ala Cys Met Ser Pro Pro His Leu Ala Ile Ile Thr Ser
                725                 730                 735
Leu Cys Lys Gly Arg Thr Leu Tyr Ser Val Val Arg Asp Ala Lys
                740                 745                 750
Ile Val Leu Asp Val Asn Lys Thr Arg Gln Ile Ala Gln Glu Ile
                755                 760                 765
Val Lys Gly Met Gly Tyr Leu His Ala Lys Gly Ile Leu His Lys
                770                 775                 780
Asp Leu Lys Ser Lys Asn Val Phe Tyr Asp Asn Gly Lys Val Val
                785                 790                 795
Ile Thr Asp Phe Gly Leu Phe Ser Ile Ser Gly Val Leu Gln Ala
                800                 805                 810
Gly Arg Arg Glu Asp Lys Leu Arg Ile Gln Asn Gly Trp Leu Cys
                815                 820                 825
His Leu Ala Pro Glu Ile Ile Arg Gln Leu Ser Pro Asp Thr Glu
                830                 835                 840
Glu Asp Lys Leu Pro Phe Ser Lys His Ser Asp Val Phe Ala Leu
                845                 850                 855
Gly Thr Ile Trp Tyr Glu Leu His Ala Arg Glu Trp Pro Phe Lys
                860                 865                 870
Thr Gln Pro Ala Glu Ala Ile Ile Trp Gln Met Gly Thr Gly Met
                875                 880                 885
Lys Pro Asn Leu Ser Gln Ile Gly Met Gly Lys Glu Ile Ser Asp
                890                 895                 900
Ile Leu Leu Phe Cys Trp Ala Phe Glu Gln Glu Glu Arg Pro Thr
                905                 910                 915
Phe Thr Lys Leu Met Asp Met Leu Glu Lys Leu Pro Lys Arg Asn
                920                 925                 930
Arg Arg Leu Ser His Pro Gly His Phe Trp Lys Ser Ala Glu Leu
                935                 940                 945
```

<210> 16
<211> 1009
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474721CD1

<400> 16

```
Met Glu Thr Cys Ala Gly Pro His Pro Leu Arg Leu Phe Leu Cys
  1               5                  10                  15
Arg Met Gln Leu Cys Leu Ala Leu Leu Leu Gly Pro Trp Arg Pro
                20                  25                  30
Gly Thr Ala Glu Glu Val Ile Leu Leu Asp Ser Lys Ala Ser Gln
                35                  40                  45
Ala Glu Leu Gly Trp Thr Ala Leu Pro Ser Asn Gly Trp Glu Glu
                50                  55                  60
Ile Ser Gly Val Asp Glu His Asp Arg Pro Ile Arg Thr Tyr Gln
                65                  70                  75
Val Cys Asn Val Leu Glu Pro Asn Gln Asp Asn Trp Leu Gln Thr
                80                  85                  90
Gly Trp Ile Ser Arg Gly Arg Gly Gln Arg Ile Phe Val Glu Leu
                95                 100                 105
Gln Phe Thr Leu Arg Asp Cys Ser Ser Ile Pro Gly Ala Ala Gly
               110                 115                 120
Thr Cys Lys Glu Thr Phe Asn Val Tyr Tyr Leu Glu Thr Glu Ala
               125                 130                 135
Asp Leu Gly Arg Gly Arg Pro Arg Leu Gly Gly Ser Arg Pro Arg
               140                 145                 150
Lys Ile Asp Thr Ile Ala Ala Asp Glu Ser Phe Thr Gln Gly Asp
               155                 160                 165
Leu Gly Glu Arg Lys Met Lys Leu Asn Thr Glu Val Arg Glu Ile
               170                 175                 180
Gly Pro Leu Ser Arg Arg Gly Phe His Leu Ala Phe Gln Asp Val
               185                 190                 195
Gly Ala Cys Val Ala Leu Val Ser Val Arg Val Tyr Tyr Lys Gln
               200                 205                 210
Cys Arg Ala Thr Val Arg Gly Leu Ala Thr Phe Pro Ala Thr Ala
               215                 220                 225
Ala Glu Ser Ala Phe Ser Thr Leu Val Glu Val Ala Gly Thr Cys
               230                 235                 240
Val Ala His Ser Glu Gly Glu Pro Gly Ser Pro Pro Arg Met His
               245                 250                 255
Cys Gly Ala Asp Gly Glu Trp Leu Val Pro Val Gly Arg Cys Ser
               260                 265                 270
Cys Ser Ala Gly Phe Gln Glu Arg Gly Asp Ile Cys Glu Ala Cys
               275                 280                 285
Pro Pro Gly Phe Tyr Lys Val Ser Pro Arg Arg Arg Val Cys Ser
               290                 295                 300
Pro Cys Pro Glu His Ser Arg Ala Leu Glu Asn Ala Ser Thr Phe
               305                 310                 315
Cys Val Cys Gln Asp Ser Tyr Ala Arg Ser Pro Thr Asp Pro Pro
               320                 325                 330
Ser Ala Ser Cys Thr Arg Gly Pro Pro Ser Ala Pro Arg Asp Leu
               335                 340                 345
Gln Tyr Ser Leu Ser Arg Ser Pro Leu Val Leu Arg Leu Arg Trp
               350                 355                 360
Leu Pro Pro Ala Asp Ser Gly Gly Arg Ser Asp Val Thr Tyr Ser
               365                 370                 375
Leu Leu Cys Leu Arg Cys Gly Arg Glu Gly Pro Ala Gly Ala Cys
               380                 385                 390
Glu Pro Cys Gly Pro Arg Val Ala Phe Leu Pro Arg Gln Ala Gly
               395                 400                 405
Leu Arg Glu Arg Ala Ala Thr Leu Leu His Leu Arg Pro Gly Ala
```

```
                410                 415                 420
Arg Tyr Thr Val Arg Val Ala Val Leu Asn Gly Val Ser Gly Pro
                425                 430                 435
Ala Ala Ala Leu Val Pro Val Gly Ala Val Ser Ile Asn Pro Gly
                440                 445                 450
Thr Val Gly Pro Val Pro Val Ala Gly Val Ile Arg Asp Arg Val
                455                 460                 465
Glu Pro Gln Ser Val Ser Leu Ser Trp Arg Glu Pro Ile Pro Ala
                470                 475                 480
Gly Ala Pro Gly Ala Asn Asp Thr Glu Tyr Glu Ile Arg Tyr Tyr
                485                 490                 495
Glu Lys Val Gln Ser Glu Gln Thr Tyr Ser Met Val Lys Thr Gly
                500                 505                 510
Ala Pro Thr Val Thr Val Thr Asn Leu Lys Pro Ala Thr Arg Tyr
                515                 520                 525
Val Phe Gln Ile Arg Ala Ala Ser Pro Gly Pro Ser Trp Glu Ala
                530                 535                 540
Gln Ser Phe Asn Pro Ser Ile Glu Val Gln Thr Leu Gly Glu Ala
                545                 550                 555
Ala Ser Gly Ser Arg Asp Gln Ser Pro Ala Ile Val Val Thr Val
                560                 565                 570
Val Thr Ile Ser Ala Leu Leu Val Leu Gly Ser Val Met Ser Val
                575                 580                 585
Leu Ala Ile Trp Arg Arg Pro Cys Ser Tyr Gly Lys Gly Gly Gly
                590                 595                 600
Asp Ala His Asp Glu Glu Glu Leu Tyr Phe His Phe Lys Val Pro
                605                 610                 615
Thr Arg Arg Thr Phe Leu Asp Pro Gln Ser Cys Gly Asp Leu Leu
                620                 625                 630
Gln Ala Val His Leu Phe Ala Lys Glu Leu Asp Ala Lys Ser Val
                635                 640                 645
Thr Leu Glu Arg Ser Leu Gly Gly Gly Arg Phe Gly Glu Leu Cys
                650                 655                 660
Cys Gly Cys Leu Gln Leu Pro Gly Arg Gln Glu Leu Leu Val Ala
                665                 670                 675
Val His Met Leu Arg Asp Ser Ala Ser Asp Ser Gln Arg Leu Gly
                680                 685                 690
Phe Leu Ala Glu Ala Leu Thr Leu Gly Gln Phe Asp His Ser His
                695                 700                 705
Ile Val Arg Leu Glu Gly Val Val Thr Arg Gly Ser Thr Leu Met
                710                 715                 720
Ile Val Thr Glu Tyr Met Ser His Gly Ala Leu Asp Gly Phe Leu
                725                 730                 735
Arg Arg His Glu Gly Gln Leu Val Ala Gly Gln Leu Met Gly Leu
                740                 745                 750
Leu Pro Gly Leu Ala Ser Ala Met Lys Tyr Leu Ser Glu Met Gly
                755                 760                 765
Tyr Val His Arg Gly Leu Ala Ala Arg His Val Leu Val Ser Ser
                770                 775                 780
Asp Leu Val Cys Lys Ile Ser Gly Phe Gly Arg Gly Pro Arg Asp
                785                 790                 795
Arg Ser Glu Ala Val Tyr Thr Thr Met Ser Gly Arg Ser Pro Ala
                800                 805                 810
Leu Trp Ala Ala Pro Glu Thr Leu Gln Phe Gly His Phe Ser Ser
                815                 820                 825
Ala Ser Asp Val Trp Ser Phe Gly Ile Ile Met Trp Glu Val Met
```

```
                830                 835                 840
Ala Phe Gly Glu Arg Pro Tyr Trp Asp Met Ser Gly Gln Asp Val
                845                 850                 855
Ile Lys Ala Val Glu Asp Gly Phe Arg Leu Pro Pro Pro Arg Asn
                860                 865                 870
Cys Pro Asn Leu Leu His Arg Leu Met Leu Asp Cys Trp Gln Lys
                875                 880                 885
Asp Pro Gly Glu Arg Pro Arg Phe Ser Gln Ile His Ser Ile Leu
                890                 895                 900
Ser Lys Met Val Gln Asp Pro Glu Pro Pro Lys Cys Ala Leu Thr
                905                 910                 915
Thr Cys Pro Arg Pro Pro Thr Pro Leu Ala Asp Arg Ala Phe Ser
                920                 925                 930
Thr Phe Pro Ser Phe Gly Ser Val Gly Ala Trp Leu Glu Ala Leu
                935                 940                 945
Asp Leu Cys Arg Tyr Lys Asp Ser Phe Ala Ala Ala Gly Tyr Gly
                950                 955                 960
Ser Leu Glu Ala Val Ala Glu Met Thr Ala Gln Arg Asp Leu Val
                965                 970                 975
Ser Leu Gly Ile Ser Leu Ala Glu His Arg Glu Ala Leu Leu Ser
                980                 985                 990
Gly Ile Ser Ala Leu Gln Ala Arg Val Leu Gln Leu Gln Gly Gln
                995                1000                1005
Gly Val Gln Val
```

<210> 17
<211> 917
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7478815CD1

<400> 17

```
Met Phe Ala Val His Leu Met Ala Phe Tyr Phe Ser Lys Leu Lys
  1                 5                  10                  15
Glu Asp Gln Ile Lys Lys Val Asp Arg Phe Leu Tyr His Met Arg
                 20                  25                  30
Leu Ser Asp Asp Thr Leu Leu Asp Ile Met Arg Arg Phe Arg Ala
                 35                  40                  45
Glu Met Glu Lys Gly Leu Ala Lys Asp Thr Asn Pro Thr Ala Ala
                 50                  55                  60
Val Lys Met Leu Pro Thr Phe Val Arg Ala Ile Pro Asp Gly Ser
                 65                  70                  75
Glu Asn Gly Glu Phe Leu Ser Leu Asp Leu Gly Gly Ser Lys Phe
                 80                  85                  90
Arg Val Leu Lys Val Gln Val Ala Glu Glu Gly Lys Arg His Val
                 95                 100                 105
Gln Met Glu Ser Gln Phe Tyr Pro Thr Pro Asn Glu Ile Ile Arg
                110                 115                 120
Gly Asn Gly Thr Glu Leu Phe Glu Tyr Val Ala Asp Cys Leu Ala
                125                 130                 135
Asp Phe Met Lys Thr Lys Asp Leu Lys His Lys Lys Leu Pro Leu
                140                 145                 150
```

```
Gly Leu Thr Phe Ser Phe Pro Cys Arg Gln Thr Lys Leu Glu Glu
                155                 160                 165
Gly Val Leu Leu Ser Trp Thr Lys Lys Phe Lys Ala Arg Gly Val
                170                 175                 180
Gln Asp Thr Asp Val Val Ser Arg Leu Thr Lys Ala Met Arg Arg
                185                 190                 195
His Lys Asp Met Asp Val Asp Ile Leu Ala Leu Val Asn Asp Thr
                200                 205                 210
Val Gly Thr Met Met Thr Cys Ala Tyr Asp Asp Pro Tyr Cys Glu
                215                 220                 225
Val Gly Val Ile Ile Gly Thr Gly Thr Asn Ala Cys Tyr Met Glu
                230                 235                 240
Asp Met Ser Asn Ile Asp Leu Val Glu Gly Asp Glu Gly Arg Met
                245                 250                 255
Cys Ile Asn Thr Glu Trp Gly Ala Phe Gly Asp Asp Gly Ala Leu
                260                 265                 270
Glu Asp Ile Arg Thr Glu Phe Asp Arg Glu Leu Asp Leu Gly Ser
                275                 280                 285
Leu Asn Pro Gly Lys Gln Leu Phe Glu Lys Met Ile Ser Gly Leu
                290                 295                 300
Tyr Leu Gly Glu Leu Val Arg Leu Ile Leu Leu Lys Met Ala Lys
                305                 310                 315
Ala Gly Leu Leu Phe Gly Gly Glu Lys Ser Ser Ala Leu His Thr
                320                 325                 330
Lys Gly Lys Ile Glu Thr Arg His Val Ala Ala Met Glu Lys Tyr
                335                 340                 345
Lys Glu Gly Leu Ala Asn Thr Arg Glu Ile Leu Val Asp Leu Gly
                350                 355                 360
Leu Glu Pro Ser Glu Ala Asp Cys Ile Ala Val Gln His Val Cys
                365                 370                 375
Thr Ile Val Ser Phe Arg Ser Ala Asn Leu Cys Ala Ala Ala Leu
                380                 385                 390
Ala Ala Ile Leu Thr Arg Leu Arg Glu Asn Lys Lys Val Glu Arg
                395                 400                 405
Leu Arg Thr Thr Val Gly Met Asp Gly Thr Leu Tyr Lys Ile His
                410                 415                 420
Pro Gln Tyr Pro Lys Arg Leu His Lys Val Val Arg Lys Leu Val
                425                 430                 435
Pro Ser Cys Asp Val Arg Phe Leu Leu Ser Glu Ser Gly Ser Thr
                440                 445                 450
Lys Gly Ala Ala Met Val Thr Ala Val Ala Ser Arg Val Gln Ala
                455                 460                 465
Gln Arg Lys Gln Ile Asp Arg Val Leu Ala Leu Phe Gln Leu Thr
                470                 475                 480
Arg Glu Gln Leu Val Asp Val Gln Ala Lys Met Arg Ala Glu Leu
                485                 490                 495
Glu Tyr Gly Leu Lys Lys Lys Ser His Gly Leu Ala Thr Val Arg
                500                 505                 510
Met Leu Pro Thr Tyr Val Cys Gly Leu Pro Asp Gly Thr Glu Lys
                515                 520                 525
Gly Lys Phe Leu Ala Leu Asp Leu Gly Gly Thr Asn Phe Arg Val
                530                 535                 540
Leu Leu Val Lys Ile Arg Ser Gly Arg Arg Ser Val Arg Met Tyr
                545                 550                 555
Asn Lys Ile Phe Ala Ile Pro Leu Glu Ile Met Gln Gly Thr Gly
                560                 565                 570
```

```
Glu Glu Leu Phe Asp His Ile Val Gln Cys Ile Ala Asp Phe Leu
            575                 580                 585
Asp Tyr Met Gly Leu Lys Gly Ala Ser Leu Pro Leu Gly Phe Thr
        590                 595                 600
Phe Ser Phe Pro Cys Arg Gln Met Ser Ile Asp Lys Gly Thr Leu
    605                 610                 615
Ile Gly Trp Thr Lys Gly Phe Lys Ala Thr Asp Cys Glu Gly Glu
620                 625                 630
Asp Val Val Asp Met Leu Arg Glu Ala Ile Lys Arg Arg Asn Glu
635                 640                 645
Phe Asp Leu Asp Ile Val Ala Val Val Asn Asp Thr Val Gly Thr
650                 655                 660
Met Met Thr Cys Gly Tyr Glu Asp Pro Asn Cys Glu Ile Gly Leu
665                 670                 675
Ile Ala Gly Thr Gly Ser Asn Met Cys Tyr Met Glu Asp Met Arg
680                 685                 690
Asn Ile Glu Met Val Glu Gly Gly Glu Gly Lys Met Cys Ile Asn
695                 700                 705
Thr Glu Trp Gly Gly Phe Gly Asp Asn Gly Cys Ile Asp Asp Ile
710                 715                 720
Arg Thr Arg Tyr Asp Thr Glu Val Asp Glu Gly Ser Leu Asn Pro
725                 730                 735
Gly Lys Gln Arg Tyr Glu Lys Met Thr Ser Gly Met Tyr Leu Gly
740                 745                 750
Glu Ile Val Arg Gln Ile Leu Ile Asp Leu Thr Lys Gln Gly Leu
755                 760                 765
Leu Phe Arg Gly Gln Ile Ser Glu Arg Leu Arg Thr Arg Gly Ile
770                 775                 780
Phe Glu Thr Lys Phe Leu Ser Gln Ile Glu Ser Asp Arg Leu Ala
785                 790                 795
Leu Leu Gln Val Arg Arg Ile Leu Gln Gln Leu Gly Leu Asp Ser
800                 805                 810
Thr Cys Glu Asp Ser Ile Val Val Lys Glu Val Cys Gly Ala Val
815                 820                 825
Ser Arg Arg Ala Ala Gln Leu Cys Gly Ala Gly Leu Ala Ala Ile
830                 835                 840
Val Glu Lys Arg Arg Glu Asp Gln Gly Leu Glu His Leu Arg Ile
845                 850                 855
Thr Val Gly Val Asp Gly Thr Leu Tyr Lys Leu His Pro His Phe
860                 865                 870
Ser Arg Ile Leu Gln Glu Thr Val Lys Glu Leu Ala Pro Arg Cys
875                 880                 885
Asp Val Thr Phe Met Leu Ser Glu Asp Gly Ser Gly Lys Gly Ala
890                 895                 900
Ala Leu Ile Thr Ala Val Ala Lys Arg Leu Gln Gln Ala Gln Lys
905                 910                 915
Glu Asn
```

<210> 18
<211> 2380
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature

<223> Incyte ID No: 7477141CD1

<400> 18

```
Met Asn His Pro Pro Trp Pro Ser Leu Asp Cys His Leu Lys Ala
  1               5                  10                  15
Arg Ser Gly His Ala Leu Leu Ser Trp Pro Gly Gly Trp Ala Phe
                 20                  25                  30
Pro Ile Ser Arg Glu Gln Asn Ala Ser Leu Ser Leu Cys Leu Ser
                 35                  40                  45
Val Ser Leu Cys Val Arg Met Cys Val Ser Leu Thr Leu Cys Val
                 50                  55                  60
Ser Ala Leu Cys Val Ala Pro Val Ala Ala Phe Pro Ser Ala His
                 65                  70                  75
Pro Glu Ser Arg Ser Leu Ala Val Leu Ala Pro Leu Gln Asp Val
                 80                  85                  90
Asp Val Gly Ala Gly Glu Met Ala Leu Phe Glu Cys Leu Val Ala
                 95                 100                 105
Gly Pro Thr Asp Val Glu Val Asp Trp Leu Cys Arg Gly Arg Leu
                110                 115                 120
Leu Gln Pro Ala Leu Leu Lys Cys Lys Met His Phe Asp Gly Arg
                125                 130                 135
Lys Cys Lys Leu Leu Leu Thr Ser Val His Glu Asp Asp Ser Gly
                140                 145                 150
Val Tyr Thr Cys Lys Leu Ser Thr Ala Lys Asp Glu Leu Thr Cys
                155                 160                 165
Ser Ala Arg Leu Thr Val Arg Pro Ser Leu Ala Pro Leu Phe Thr
                170                 175                 180
Arg Leu Leu Glu Asp Val Glu Val Leu Glu Gly Arg Ala Ala Arg
                185                 190                 195
Phe Asp Cys Lys Ile Ser Gly Thr Pro Pro Pro Val Val Thr Trp
                200                 205                 210
Thr His Phe Gly Cys Pro Met Glu Glu Ser Glu Asn Leu Arg Leu
                215                 220                 225
Arg Gln Asp Gly Gly Leu His Ser Leu His Ile Ala His Val Gly
                230                 235                 240
Ser Glu Asp Glu Gly Leu Tyr Ala Val Ser Ala Val Asn Thr His
                245                 250                 255
Gly Gln Ala His Cys Ser Ala Gln Leu Tyr Val Glu Glu Pro Arg
                260                 265                 270
Thr Ala Ala Ser Gly Pro Ser Ser Lys Leu Glu Lys Met Pro Ser
                275                 280                 285
Ile Pro Glu Glu Pro Glu Gln Gly Glu Leu Glu Arg Leu Ser Ile
                290                 295                 300
Pro Asp Phe Leu Arg Pro Leu Gln Asp Leu Glu Val Gly Leu Ala
                305                 310                 315
Lys Glu Ala Met Leu Glu Cys Gln Val Thr Gly Leu Pro Tyr Pro
                320                 325                 330
Thr Ile Ser Trp Phe His Asn Gly His Arg Ile Gln Ser Ser Asp
                335                 340                 345
Asp Arg Arg Met Thr Gln Tyr Arg Asp Val His Arg Leu Val Phe
                350                 355                 360
Pro Ala Val Gly Pro Gln His Ala Gly Val Tyr Lys Ser Val Ile
                365                 370                 375
Ala Asn Lys Leu Gly Lys Ala Ala Cys Tyr Ala His Leu Tyr Val
                380                 385                 390
Thr Asp Val Val Pro Gly Pro Pro Asp Gly Ala Pro Gln Val Val
```

```
                395                 400                 405
Ala Val Thr Gly Arg Met Val Thr Leu Thr Trp Asn Pro Pro Arg
                410                 415                 420
Ser Leu Asp Met Ala Ile Asp Pro Asp Ser Leu Thr Tyr Thr Val
                425                 430                 435
Gln His Gln Val Leu Gly Ser Asp Gln Trp Thr Ala Leu Val Thr
                440                 445                 450
Gly Leu Arg Glu Pro Gly Trp Ala Ala Thr Gly Leu Arg Lys Gly
                455                 460                 465
Val Gln His Ile Phe Arg Val Leu Ser Thr Thr Val Lys Ser Ser
                470                 475                 480
Ser Lys Pro Ser Pro Pro Ser Glu Pro Val Gln Leu Leu Glu His
                485                 490                 495
Gly Pro Thr Leu Glu Glu Ala Pro Ala Met Leu Asp Lys Pro Asp
                500                 505                 510
Ile Val Tyr Val Val Glu Gly Gln Pro Ala Ser Val Thr Val Thr
                515                 520                 525
Phe Asn His Val Glu Ala Gln Val Val Trp Arg Ser Cys Arg Gly
                530                 535                 540
Ala Leu Leu Glu Ala Arg Ala Gly Val Tyr Glu Leu Ser Gln Pro
                545                 550                 555
Asp Asp Asp Gln Tyr Cys Leu Arg Ile Cys Arg Val Ser Arg Arg
                560                 565                 570
Asp Met Gly Ala Leu Thr Cys Thr Ala Arg Asn Arg His Gly Thr
                575                 580                 585
Gln Thr Cys Ser Val Thr Leu Glu Leu Ala Glu Ala Pro Arg Phe
                590                 595                 600
Glu Ser Ile Met Glu Asp Val Glu Val Gly Ala Gly Glu Thr Ala
                605                 610                 615
Arg Phe Ala Val Val Val Glu Gly Lys Pro Leu Pro Asp Ile Met
                620                 625                 630
Trp Tyr Lys Asp Glu Val Leu Leu Thr Glu Ser Ser His Val Ser
                635                 640                 645
Phe Val Tyr Glu Glu Asn Glu Cys Ser Leu Val Val Leu Ser Thr
                650                 655                 660
Gly Ala Gln Asp Gly Gly Val Tyr Thr Cys Thr Ala Gln Asn Leu
                665                 670                 675
Ala Gly Glu Val Ser Cys Lys Ala Glu Leu Ala Val His Ser Ala
                680                 685                 690
Gln Thr Ala Met Glu Val Glu Gly Val Gly Glu Asp Glu Asp His
                695                 700                 705
Arg Gly Arg Arg Leu Ser Asp Phe Tyr Asp Ile His Gln Glu Ile
                710                 715                 720
Gly Arg Gly Ala Phe Ser Tyr Leu Arg Arg Ile Val Glu Arg Ser
                725                 730                 735
Ser Gly Leu Glu Phe Ala Ala Lys Phe Ile Pro Ser Gln Ala Lys
                740                 745                 750
Pro Lys Ala Ser Ala Arg Arg Glu Ala Arg Leu Leu Ala Arg Leu
                755                 760                 765
Gln His Asp Cys Val Leu Tyr Phe His Glu Ala Phe Glu Arg Arg
                770                 775                 780
Arg Gly Leu Val Ile Val Thr Glu Leu Cys Thr Glu Glu Leu Leu
                785                 790                 795
Glu Arg Ile Ala Arg Lys Pro Thr Val Cys Glu Ser Glu Ile Arg
                800                 805                 810
Ala Tyr Met Arg Gln Val Leu Glu Gly Ile His Tyr Leu His Gln
```

```
                815                 820                 825
Ser His Val Leu His Leu Asp Val Lys Pro Glu Asn Leu Leu Val
                830                 835                 840
Trp Asp Gly Ala Ala Gly Glu Gln Gln Val Arg Ile Cys Asp Phe
                845                 850                 855
Gly Asn Ala Gln Glu Leu Thr Pro Gly Glu Pro Gln Tyr Cys Gln
                860                 865                 870
Tyr Gly Thr Pro Glu Phe Val Ala Pro Glu Ile Val Asn Gln Ser
                875                 880                 885
Pro Val Ser Gly Val Thr Asp Ile Trp Pro Val Gly Val Val Ala
                890                 895                 900
Phe Leu Cys Leu Thr Gly Ile Ser Pro Phe Val Gly Glu Asn Asp
                905                 910                 915
Arg Thr Thr Leu Met Asn Ile Arg Asn Tyr Asn Val Ala Phe Glu
                920                 925                 930
Glu Thr Thr Phe Leu Ser Leu Ser Arg Glu Ala Arg Gly Phe Leu
                935                 940                 945
Ile Lys Val Leu Val Gln Asp Arg Leu Arg Pro Thr Ala Glu Glu
                950                 955                 960
Thr Leu Glu His Pro Trp Phe Lys Thr Gln Ala Lys Gly Ala Glu
                965                 970                 975
Val Ser Thr Asp His Leu Lys Leu Phe Leu Ser Arg Arg Arg Trp
                980                 985                 990
Gln Arg Ser Gln Ile Ser Tyr Lys Cys His Leu Val Leu Arg Pro
                995                1000                1005
Ile Pro Glu Leu Leu Arg Ala Pro Pro Glu Arg Val Trp Val Thr
               1010                1015                1020
Met Pro Arg Arg Pro Pro Pro Ser Gly Gly Leu Ser Ser Ser Ser
               1025                1030                1035
Asp Ser Glu Glu Glu Glu Leu Glu Glu Leu Pro Ser Val Pro Arg
               1040                1045                1050
Pro Leu Gln Pro Glu Phe Ser Gly Ser Arg Val Ser Leu Thr Asp
               1055                1060                1065
Ile Pro Thr Glu Asp Glu Ala Leu Gly Thr Pro Glu Thr Gly Ala
               1070                1075                1080
Ala Thr Pro Met Asp Trp Gln Glu Gln Gly Arg Ala Pro Ser Gln
               1085                1090                1095
Asp Gln Glu Ala Pro Ser Pro Glu Ala Leu Pro Ser Pro Gly Gln
               1100                1105                1110
Glu Pro Ala Ala Gly Ala Ser Pro Arg Arg Gly Glu Leu Arg Arg
               1115                1120                1125
Gly Ser Ser Ala Glu Ser Ala Leu Pro Arg Ala Gly Pro Arg Glu
               1130                1135                1140
Leu Gly Arg Gly Leu His Lys Ala Ala Ser Val Glu Leu Pro Gln
               1145                1150                1155
Arg Arg Ser Pro Gly Pro Gly Ala Thr Arg Leu Ala Arg Gly Gly
               1160                1165                1170
Leu Gly Glu Gly Glu Tyr Ala Gln Arg Leu Gln Ala Leu Arg Gln
               1175                1180                1185
Arg Leu Leu Arg Gly Gly Pro Glu Asp Gly Lys Val Ser Gly Leu
               1190                1195                1200
Arg Gly Pro Leu Leu Glu Ser Leu Gly Gly Arg Ala Arg Asp Pro
               1205                1210                1215
Arg Met Ala Arg Ala Ala Ser Ser Glu Ala Ala Pro His His Gln
               1220                1225                1230
Pro Pro Leu Glu Asn Arg Gly Leu Gln Lys Ser Ser Ser Phe Ser
```

```
                1235                1240                1245
Gln Gly Glu Ala Glu Pro Arg Gly Arg His Arg Arg Ala Gly Ala
                1250                1255                1260
Pro Leu Glu Ile Pro Val Ala Arg Leu Gly Ala Arg Arg Leu Gln
                1265                1270                1275
Glu Ser Pro Ser Leu Ser Ala Leu Ser Glu Ala Gln Pro Ser Ser
                1280                1285                1290
Pro Ala Arg Pro Ser Ala Pro Lys Pro Ser Thr Pro Lys Ser Ala
                1295                1300                1305
Glu Pro Ser Ala Thr Thr Pro Ser Asp Ala Pro Gln Pro Pro Ala
                1310                1315                1320
Pro Gln Pro Ala Gln Asp Lys Ala Pro Glu Pro Arg Pro Glu Pro
                1325                1330                1335
Val Arg Ala Ser Lys Pro Ala Pro Pro Pro Gln Ala Leu Gln Thr
                1340                1345                1350
Leu Ala Leu Pro Leu Thr Pro Tyr Ala Gln Ile Ile Gln Ser Leu
                1355                1360                1365
Gln Leu Ser Gly His Ala Gln Gly Pro Ser Gln Gly Pro Ala Ala
                1370                1375                1380
Pro Pro Ser Glu Pro Lys Pro His Ala Ala Val Phe Ala Arg Val
                1385                1390                1395
Ala Ser Pro Pro Pro Gly Ala Pro Glu Lys Arg Val Pro Ser Ala
                1400                1405                1410
Gly Gly Pro Pro Val Leu Ala Glu Lys Ala Arg Val Pro Thr Val
                1415                1420                1425
Pro Pro Arg Pro Gly Ser Ser Leu Ser Ser Ser Ile Glu Asn Leu
                1430                1435                1440
Glu Ser Glu Ala Val Phe Glu Ala Lys Phe Lys Arg Ser Arg Glu
                1445                1450                1455
Ser Pro Leu Ser Leu Gly Leu Arg Leu Leu Ser Arg Ser Arg Ser
                1460                1465                1470
Glu Glu Arg Gly Pro Phe Arg Gly Ala Glu Glu Glu Asp Gly Ile
                1475                1480                1485
Tyr Arg Pro Ser Pro Ala Gly Thr Pro Leu Glu Leu Val Arg Arg
                1490                1495                1500
Pro Glu Arg Ser Arg Ser Val Gln Asp Leu Arg Ala Val Gly Glu
                1505                1510                1515
Pro Gly Leu Val Arg Arg Leu Ser Leu Ser Leu Ser Gln Arg Leu
                1520                1525                1530
Arg Arg Thr Pro Pro Ala Gln Arg His Pro Ala Trp Glu Ala Arg
                1535                1540                1545
Gly Gly Asp Gly Glu Ser Ser Glu Gly Gly Ser Ser Ala Arg Gly
                1550                1555                1560
Ser Pro Val Leu Ala Met Arg Arg Arg Leu Ser Phe Thr Leu Glu
                1565                1570                1575
Arg Leu Ser Ser Arg Leu Gln Arg Ser Gly Ser Ser Glu Asp Ser
                1580                1585                1590
Gly Gly Ala Ser Gly Arg Ser Thr Pro Leu Phe Gly Arg Leu Arg
                1595                1600                1605
Arg Ala Thr Ser Glu Gly Glu Ser Leu Arg Arg Leu Gly Leu Pro
                1610                1615                1620
His Asn Gln Leu Ala Ala Gln Ala Gly Ala Thr Thr Pro Ser Ala
                1625                1630                1635
Glu Ser Leu Gly Ser Glu Ala Ser Ala Thr Ser Gly Ser Ser Ala
                1640                1645                1650
Pro Gly Glu Ser Arg Ser Arg Leu Arg Trp Gly Phe Ser Arg Pro
```

1655 1660 1665
Arg Lys Asp Lys Gly Leu Ser Pro Pro Asn Leu Ser Ala Ser Val
1670 1675 1680
Gln Glu Glu Leu Gly His Gln Tyr Val Arg Ser Glu Ser Asp Phe
1685 1690 1695
Pro Pro Val Phe His Ile Lys Leu Lys Asp Gln Val Leu Leu Glu
1700 1705 1710
Gly Glu Ala Ala Thr Leu Leu Cys Leu Pro Ala Ala Cys Pro Ala
1715 1720 1725
Pro His Ile Ser Trp Met Lys Asp Lys Lys Ser Leu Arg Ser Glu
1730 1735 1740
Pro Ser Val Ile Ile Val Ser Cys Lys Asp Gly Arg Gln Leu Leu
1745 1750 1755
Ser Ile Pro Arg Ala Gly Lys Arg His Ala Gly Leu Tyr Glu Cys
1760 1765 1770
Ser Ala Thr Asn Val Leu Gly Ser Ile Thr Ser Ser Cys Thr Val
1775 1780 1785
Ala Val Ala Arg Val Pro Gly Lys Leu Ala Pro Pro Glu Val Pro
1790 1795 1800
Gln Thr Tyr Gln Asp Thr Ala Leu Val Leu Trp Lys Pro Gly Asp
1805 1810 1815
Ser Arg Ala Pro Cys Thr Tyr Thr Leu Glu Arg Arg Val Asp Gly
1820 1825 1830
Glu Ser Val Trp His Pro Val Ser Ser Gly Ile Pro Asp Cys Tyr
1835 1840 1845
Tyr Asn Val Thr His Leu Pro Val Gly Val Thr Val Arg Phe Arg
1850 1855 1860
Val Ala Cys Ala Asn Arg Ala Gly Gln Gly Pro Phe Ser Asn Ser
1865 1870 1875
Ser Glu Lys Val Phe Val Arg Gly Thr Gln Asp Ser Ser Ala Val
1880 1885 1890
Pro Ser Ala Ala His Gln Glu Ala Pro Val Thr Ser Arg Pro Ala
1895 1900 1905
Arg Ala Arg Pro Pro Asp Ser Pro Thr Ser Leu Ala Pro Pro Leu
1910 1915 1920
Ala Pro Ala Ala Pro Thr Pro Pro Ser Val Thr Val Ser Pro Ser
1925 1930 1935
Ser Pro Pro Thr Pro Pro Ser Gln Ala Leu Ser Ser Leu Lys Ala
1940 1945 1950
Val Gly Pro Pro Pro Gln Thr Pro Pro Arg Arg His Arg Gly Leu
1955 1960 1965
Gln Ala Ala Arg Pro Ala Glu Pro Thr Leu Pro Ser Thr His Val
1970 1975 1980
Thr Pro Ser Glu Pro Lys Pro Phe Val Leu Asp Thr Gly Thr Pro
1985 1990 1995
Ile Pro Ala Ser Thr Pro Gln Gly Val Lys Pro Val Ser Ser Ser
2000 2005 2010
Thr Pro Val Tyr Val Val Thr Ser Phe Val Ser Ala Pro Pro Ala
2015 2020 2025
Pro Glu Pro Pro Ala Pro Glu Pro Pro Pro Glu Pro Thr Lys Val
2030 2035 2040
Thr Val Gln Ser Leu Ser Pro Ala Lys Glu Val Val Ser Ser Pro
2045 2050 2055
Gly Ser Ser Pro Arg Ser Ser Pro Arg Pro Glu Gly Thr Thr Leu
2060 2065 2070
Arg Gln Gly Pro Pro Gln Lys Pro Tyr Thr Phe Leu Glu Glu Lys

```
                2075                2080                2085
Ala Arg Gly Arg Phe Gly Val Val Arg Ala Cys Arg Glu Asn Ala
                2090                2095                2100
Thr Gly Arg Thr Phe Val Ala Lys Ile Val Pro Tyr Ala Ala Glu
                2105                2110                2115
Gly Lys Arg Arg Val Leu Gln Glu Tyr Glu Val Leu Arg Thr Leu
                2120                2125                2130
His His Glu Arg Ile Met Ser Leu His Glu Ala Tyr Ile Thr Pro
                2135                2140                2145
Arg Tyr Leu Val Leu Ile Ala Glu Ser Cys Gly Asn Arg Glu Leu
                2150                2155                2160
Leu Cys Gly Leu Ser Asp Arg Phe Arg Tyr Ser Glu Asp Asp Val
                2165                2170                2175
Ala Thr Tyr Met Val Gln Leu Leu Gln Gly Leu Asp Tyr Leu His
                2180                2185                2190
Gly His His Val Leu His Leu Asp Ile Lys Pro Asp Asn Leu Leu
                2195                2200                2205
Leu Ala Pro Asp Asn Ala Leu Lys Ile Val Asp Phe Gly Ser Ala
                2210                2215                2220
Gln Pro Tyr Asn Pro Gln Ala Leu Arg Pro Leu Gly His Arg Thr
                2225                2230                2235
Gly Thr Leu Glu Phe Met Ala Pro Glu Met Val Lys Gly Glu Pro
                2240                2245                2250
Ile Gly Ser Ala Thr Asp Ile Trp Gly Ala Gly Val Leu Thr Tyr
                2255                2260                2265
Ile Met Leu Ser Gly Arg Ser Pro Phe Tyr Glu Pro Asp Pro Gln
                2270                2275                2280
Glu Thr Glu Ala Arg Ile Val Gly Gly Arg Phe Asp Ala Phe Gln
                2285                2290                2295
Leu Tyr Pro Asn Thr Ser Gln Ser Ala Thr Leu Phe Leu Arg Lys
                2300                2305                2310
Val Leu Ser Val His Pro Trp Ser Arg Pro Ser Leu Gln Asp Cys
                2315                2320                2325
Leu Ala His Pro Trp Leu Gln Asp Ala Tyr Leu Met Lys Leu Arg
                2330                2335                2340
Arg Gln Thr Leu Thr Phe Thr Thr Asn Arg Leu Lys Glu Phe Leu
                2345                2350                2355
Gly Glu Gln Arg Arg Arg Arg Ala Glu Ala Ala Thr Arg His Lys
                2360                2365                2370
Val Leu Leu Arg Ser Tyr Pro Gly Gly Pro
                2375                2380

<210> 19
<211> 505
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2190612CD1

<400> 19
Met Glu Gly Gly Pro Ala Val Cys Cys Gln Asp Pro Arg Ala Glu
  1               5                  10                  15
Leu Val Glu Arg Val Ala Ala Ile Asp Val Thr His Leu Glu Glu
                20                  25                  30
```

```
Ala Asp Gly Gly Pro Glu Pro Thr Arg Asn Gly Val Asp Pro Pro
                35                  40                  45
Pro Arg Ala Arg Ala Ala Ser Val Ile Pro Gly Ser Thr Ser Arg
                50                  55                  60
Leu Leu Pro Ala Arg Pro Ser Leu Ser Ala Arg Lys Leu Ser Leu
                65                  70                  75
Gln Glu Arg Pro Ala Gly Ser Tyr Leu Glu Ala Gln Ala Gly Pro
                80                  85                  90
Tyr Ala Thr Gly Pro Ala Ser His Ile Ser Pro Arg Ala Trp Arg
                95                 100                 105
Arg Pro Thr Ile Glu Ser His His Val Ala Ile Ser Asp Ala Glu
               110                 115                 120
Asp Cys Val Gln Leu Asn Gln Tyr Lys Leu Gln Ser Glu Ile Gly
               125                 130                 135
Lys Gly Ala Tyr Gly Val Val Arg Leu Ala Tyr Asn Glu Ser Glu
               140                 145                 150
Asp Arg His Tyr Ala Met Lys Val Leu Ser Lys Lys Lys Leu Leu
               155                 160                 165
Lys Gln Tyr Gly Phe Pro Arg Arg Pro Pro Pro Arg Gly Ser Gln
               170                 175                 180
Ala Ala Gln Gly Gly Pro Ala Lys Gln Leu Leu Pro Leu Glu Arg
               185                 190                 195
Val Tyr Gln Glu Ile Ala Ile Leu Lys Lys Leu Asp His Val Asn
               200                 205                 210
Val Val Lys Leu Ile Glu Val Leu Asp Asp Pro Ala Glu Asp Asn
               215                 220                 225
Leu Tyr Leu Val Phe Asp Leu Leu Arg Lys Gly Pro Val Met Glu
               230                 235                 240
Val Pro Cys Asp Lys Pro Phe Ser Glu Glu Gln Ala Arg Leu Tyr
               245                 250                 255
Leu Arg Asp Val Ile Leu Gly Leu Glu Tyr Leu His Cys Gln Lys
               260                 265                 270
Ile Val His Arg Asp Ile Lys Pro Ser Asn Leu Leu Leu Gly Asp
               275                 280                 285
Asp Gly His Val Lys Ile Ala Asp Phe Gly Val Ser Asn Gln Phe
               290                 295                 300
Glu Gly Asn Asp Ala Gln Leu Ser Ser Thr Ala Gly Thr Pro Ala
               305                 310                 315
Phe Met Ala Pro Glu Ala Ile Ser Asp Ser Gly Gln Ser Phe Ser
               320                 325                 330
Gly Lys Ala Leu Asp Val Trp Ala Thr Gly Val Thr Leu Tyr Cys
               335                 340                 345
Phe Val Tyr Gly Lys Cys Pro Phe Ile Asp Asp Phe Ile Leu Ala
               350                 355                 360
Leu His Arg Lys Ile Lys Asn Glu Pro Val Val Phe Pro Glu Glu
               365                 370                 375
Pro Glu Ile Ser Glu Glu Leu Lys Asp Leu Ile Leu Lys Met Leu
               380                 385                 390
Asp Lys Asn Pro Glu Thr Arg Ile Gly Val Pro Asp Ile Lys Leu
               395                 400                 405
His Pro Trp Val Thr Lys Asn Gly Glu Glu Pro Leu Pro Ser Glu
               410                 415                 420
Glu Glu His Cys Ser Val Val Glu Val Thr Glu Glu Glu Val Lys
               425                 430                 435
Asn Ser Val Arg Leu Ile Pro Ser Trp Thr Thr Val Ile Leu Val
               440                 445                 450
```

```
Lys Ser Met Leu Arg Lys Arg Ser Phe Gly Asn Pro Phe Glu Pro
                455                 460                 465
Gln Ala Arg Arg Glu Glu Arg Ser Met Ser Ala Pro Gly Asn Leu
                470                 475                 480
Leu Val Lys Glu Gly Phe Gly Glu Gly Gly Lys Ser Pro Glu Leu
                485                 490                 495
Pro Gly Val Gln Glu Asp Glu Ala Ala Ser
                500                 505

<210> 20
<211> 1572
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477549CD1

<400> 20
Met Glu Arg Arg Leu Arg Ala Leu Glu Gln Leu Ala Arg Gly Glu
  1                 5                  10                  15
Ala Gly Gly Cys Pro Gly Leu Asp Gly Leu Leu Asp Leu Leu Leu
                 20                  25                  30
Ala Leu His His Glu Leu Ser Ser Gly Pro Leu Arg Arg Glu Arg
                 35                  40                  45
Ser Val Ala Gln Phe Leu Ser Trp Ala Ser Pro Phe Val Ser Lys
                 50                  55                  60
Val Lys Glu Leu Arg Leu Gln Arg Asp Asp Phe Glu Ile Leu Lys
                 65                  70                  75
Val Ile Gly Arg Gly Ala Phe Gly Glu Val Thr Val Val Arg Gln
                 80                  85                  90
Arg Asp Thr Gly Gln Ile Phe Ala Met Lys Met Leu His Lys Trp
                 95                 100                 105
Glu Met Leu Lys Arg Ala Glu Thr Ala Cys Phe Arg Glu Glu Arg
                110                 115                 120
Asp Val Leu Val Lys Gly Asp Ser Arg Trp Val Thr Thr Leu His
                125                 130                 135
Tyr Ala Phe Gln Asp Glu Glu Tyr Leu Tyr Leu Val Met Asp Tyr
                140                 145                 150
Tyr Ala Gly Gly Asp Leu Leu Thr Leu Leu Ser Arg Phe Glu Asp
                155                 160                 165
Arg Leu Pro Pro Glu Leu Ala Gln Phe Tyr Leu Ala Glu Met Val
                170                 175                 180
Leu Ala Ile His Ser Leu His Gln Leu Gly Tyr Val His Arg Asp
                185                 190                 195
Val Lys Pro Asp Asn Val Leu Leu Asp Val Asn Gly His Ile Arg
                200                 205                 210
Leu Ala Asp Phe Gly Ser Cys Leu Arg Leu Asn Thr Asn Gly Met
                215                 220                 225
Val Asp Ser Ser Val Ala Val Gly Thr Pro Asp Tyr Ile Ser Pro
                230                 235                 240
Glu Ile Leu Gln Ala Met Glu Glu Gly Lys Gly His Tyr Gly Pro
                245                 250                 255
Gln Cys Asp Trp Trp Ser Leu Gly Val Cys Ala Tyr Glu Leu Leu
                260                 265                 270
Phe Gly Glu Thr Pro Phe Tyr Ala Glu Ser Leu Val Glu Thr Tyr
```

```
                275                 280                 285
Gly Lys Ile Met Asn His Glu Asp His Leu Gln Phe Pro Pro Asp
                290                 295                 300
Val Pro Asp Val Pro Ala Ser Ala Gln Asp Leu Ile Arg Gln Leu
                305                 310                 315
Leu Cys Arg Gln Glu Glu Arg Leu Gly Arg Gly Gly Leu Asp Asp
                320                 325                 330
Phe Arg Asn His Pro Phe Phe Glu Gly Val Asp Trp Glu Arg Leu
                335                 340                 345
Ala Ser Ser Thr Ala Pro Tyr Ile Pro Glu Leu Arg Gly Pro Met
                350                 355                 360
Asp Thr Ser Asn Phe Asp Val Asp Asp Asp Thr Leu Asn His Pro
                365                 370                 375
Gly Thr Leu Pro Pro Pro Ser His Gly Ala Phe Ser Gly His His
                380                 385                 390
Leu Pro Phe Val Gly Phe Thr Tyr Thr Ser Gly Ser His Ser Pro
                395                 400                 405
Glu Ser Ser Ser Glu Ala Trp Ala Ala Leu Glu Arg Lys Leu Gln
                410                 415                 420
Cys Leu Glu Gln Glu Lys Val Glu Leu Ser Arg Lys His Gln Glu
                425                 430                 435
Ala Leu His Ala Pro Thr Asp His Arg Glu Leu Glu Gln Leu Arg
                440                 445                 450
Lys Glu Val Gln Thr Leu Arg Asp Arg Leu Pro Glu Met Leu Arg
                455                 460                 465
Asp Lys Ala Ser Leu Ser Gln Thr Asp Gly Pro Pro Ala Gly Ser
                470                 475                 480
Pro Gly Gln Asp Ser Asp Leu Arg Gln Glu Leu Asp Arg Leu His
                485                 490                 495
Arg Glu Leu Ala Glu Gly Arg Ala Gly Leu Gln Ala Gln Glu Gln
                500                 505                 510
Glu Leu Cys Arg Ala Gln Gly Gln Gln Glu Glu Leu Leu Gln Arg
                515                 520                 525
Leu Gln Glu Ala Gln Glu Arg Glu Ala Ala Thr Ala Ser Gln Thr
                530                 535                 540
Arg Ala Leu Ser Ser Gln Leu Glu Glu Ala Arg Ala Ala Gln Arg
                545                 550                 555
Glu Leu Glu Ala Gln Val Ser Ser Leu Ser Arg Gln Val Thr Gln
                560                 565                 570
Leu Gln Gly Gln Trp Glu Gln Arg Leu Glu Glu Ser Ser Gln Ala
                575                 580                 585
Lys Thr Ile His Thr Ala Ser Glu Thr Asn Gly Met Gly Pro Pro
                590                 595                 600
Glu Gly Gly Pro Gln Glu Ala Gln Leu Arg Lys Glu Val Ala Ala
                605                 610                 615
Leu Arg Glu Gln Leu Glu Gln Ala His Ser His Arg Pro Ser Gly
                620                 625                 630
Lys Glu Glu Ala Leu Cys Gln Leu Gln Glu Glu Asn Arg Arg Leu
                635                 640                 645
Ser Arg Glu Gln Glu Arg Leu Glu Ala Glu Leu Ala Gln Glu Gln
                650                 655                 660
Glu Ser Lys Gln Arg Leu Glu Gly Glu Arg Arg Glu Thr Glu Ser
                665                 670                 675
Asn Trp Glu Ala Gln Leu Ala Asp Ile Leu Ser Trp Val Asn Asp
                680                 685                 690
Glu Lys Val Ser Arg Gly Tyr Leu Gln Ala Leu Ala Thr Lys Met
```

695 700 705
Ala Glu Glu Leu Glu Ser Leu Arg Asn Val Gly Thr Gln Thr Leu
710 715 720
Pro Ala Arg Pro Leu Lys Met Glu Ala Ser Ala Arg Leu Glu Leu
725 730 735
Gln Ser Ala Leu Glu Ala Glu Ile Arg Ala Lys Gln Gly Leu Gln
740 745 750
Glu Arg Leu Thr Gln Val Gln Glu Ala Gln Leu Gln Ala Glu Arg
755 760 765
Arg Leu Gln Glu Ala Glu Lys Gln Ser Gln Ala Leu Gln Gln Glu
770 775 780
Leu Ala Met Leu Arg Glu Glu Leu Arg Ala Arg Gly Pro Val Asp
785 790 795
Thr Lys Pro Ser Asn Ser Leu Ile Pro Phe Leu Ser Phe Arg Ser
800 805 810
Ser Glu Lys Asp Ser Ala Lys Asp Pro Gly Ile Ser Gly Glu Ala
815 820 825
Thr Arg His Gly Gly Glu Pro Asp Leu Arg Pro Glu Gly Arg Arg
830 835 840
Ser Leu Arg Met Gly Ala Val Phe Pro Arg Ala Pro Thr Ala Asn
845 850 855
Thr Ala Ser Thr Glu Gly Leu Pro Ala Lys Gly Trp Gly Met Gly
860 865 870
Pro Trp Glu Ala Leu Gly Asn Gly Cys Pro Pro Pro Gln Pro Gly
875 880 885
Ser His Thr Leu Arg Pro Arg Ser Phe Pro Ser Pro Thr Lys Cys
890 895 900
Leu Arg Cys Thr Ser Leu Met Leu Gly Leu Gly Arg Gln Gly Leu
905 910 915
Gly Cys Asp Ala Cys Gly Tyr Phe Cys His Thr Thr Cys Ala Pro
920 925 930
Gln Ala Pro Pro Cys Pro Val Pro Pro Asp Leu Leu Arg Thr Ala
935 940 945
Leu Gly Val His Pro Glu Thr Gly Thr Gly Thr Ala Tyr Glu Gly
950 955 960
Phe Leu Ser Val Pro Arg Pro Ser Gly Val Arg Arg Gly Trp Gln
965 970 975
Arg Val Phe Ala Ala Leu Ser Asp Ser Arg Leu Leu Leu Phe Asp
980 985 990
Ala Pro Asp Leu Arg Leu Ser Pro Pro Ser Gly Ala Leu Leu Gln
995 1000 1005
Val Leu Asp Leu Arg Asp Pro Gln Phe Ser Ala Thr Pro Val Leu
1010 1015 1020
Ala Ser Asp Val Ile His Ala Gln Ser Arg Asp Leu Pro Arg Ile
1025 1030 1035
Phe Arg Val Thr Thr Ser Gln Leu Ala Val Pro Pro Thr Thr Cys
1040 1045 1050
Thr Val Leu Leu Leu Ala Glu Ser Glu Gly Glu Arg Glu Arg Trp
1055 1060 1065
Leu Gln Val Leu Gly Glu Leu Gln Arg Leu Leu Leu Asp Ala Arg
1070 1075 1080
Pro Arg Pro Arg Pro Val Tyr Thr Leu Lys Glu Ala Tyr Asp Asn
1085 1090 1095
Gly Leu Pro Leu Leu Pro His Thr Leu Cys Ala Ala Ile Leu Asp
1100 1105 1110
Gln Asp Arg Leu Ala Leu Gly Thr Glu Glu Gly Leu Phe Val Ile

```
                1115                1120                1125
His Leu Arg Ser Asn Asp Ile Phe Gln Val Gly Glu Cys Arg Arg
                1130                1135                1140
Val Gln Gln Leu Thr Leu Ser Pro Ser Ala Gly Leu Leu Val Val
                1145                1150                1155
Leu Cys Gly Arg Gly Pro Ser Val Arg Leu Phe Ala Leu Ala Glu
                1160                1165                1170
Leu Glu Asn Ile Glu Val Ala Gly Ala Lys Ile Pro Glu Ser Arg
                1175                1180                1185
Gly Cys Gln Val Leu Ala Ala Gly Ser Ile Leu Gln Ala Arg Thr
                1190                1195                1200
Pro Val Leu Cys Val Ala Val Lys Arg Gln Val Leu Cys Tyr Gln
                1205                1210                1215
Leu Gly Pro Gly Pro Gly Pro Trp Gln Arg Arg Ile Arg Glu Leu
                1220                1225                1230
Gln Ala Pro Ala Thr Val Gln Ser Leu Gly Leu Leu Gly Asp Arg
                1235                1240                1245
Leu Cys Val Gly Ala Ala Gly Gly Phe Ala Leu Tyr Pro Leu Leu
                1250                1255                1260
Asn Glu Ala Ala Pro Leu Ala Leu Gly Ala Gly Leu Val Pro Glu
                1265                1270                1275
Glu Leu Pro Pro Ser Arg Gly Gly Leu Gly Glu Ala Leu Gly Ala
                1280                1285                1290
Val Glu Leu Ser Leu Ser Glu Phe Leu Leu Leu Phe Thr Thr Ala
                1295                1300                1305
Gly Ile Tyr Val Asp Gly Ala Gly Arg Lys Ser Arg Gly His Glu
                1310                1315                1320
Leu Leu Trp Pro Ala Ala Pro Met Gly Trp Gly Tyr Ala Ala Pro
                1325                1330                1335
Tyr Leu Thr Val Phe Ser Glu Asn Ser Ile Asp Val Phe Asp Val
                1340                1345                1350
Arg Arg Ala Glu Trp Val Gln Thr Val Pro Leu Lys Lys Val Arg
                1355                1360                1365
Pro Leu Asn Pro Glu Gly Ser Leu Phe Leu Tyr Gly Thr Glu Lys
                1370                1375                1380
Val Arg Leu Thr Tyr Leu Arg Asn Gln Leu Ala Glu Lys Asp Glu
                1385                1390                1395
Phe Asp Ile Pro Asp Leu Thr Asp Asn Ser Arg Arg Gln Leu Phe
                1400                1405                1410
Arg Thr Lys Ser Lys Arg Arg Phe Phe Phe Arg Val Ser Glu Glu
                1415                1420                1425
Gln Gln Lys Gln Gln Arg Arg Glu Met Leu Lys Asp Pro Phe Val
                1430                1435                1440
Arg Ser Lys Leu Ile Ser Pro Pro Thr Asn Phe Asn His Leu Val
                1445                1450                1455
His Val Gly Pro Ala Asn Gly Arg Pro Gly Ala Arg Asp Lys Ser
                1460                1465                1470
Pro Ser Gln Pro Leu Arg Thr Val Thr Gln Gln Ala Pro Glu Glu
                1475                1480                1485
Lys Gly Arg Val Ala Arg Gly Ser Gly Pro Gln Arg Pro His Ser
                1490                1495                1500
Phe Ser Glu Ala Leu Arg Arg Pro Ala Ser Met Gly Ser Glu Gly
                1505                1510                1515
Leu Gly Gly Asp Ala Asp Pro Thr Gly Ala Val Lys Arg Lys Pro
                1520                1525                1530
Trp Thr Ser Leu Ser Ser Glu Ser Val Ser Cys Pro Gln Gly Ser
```

1535 1540 1545
Leu Ser Pro Ala Thr Ser Leu Met Gln Val Ser Glu Arg Pro Arg
1550 1555 1560
Ser Leu Pro Leu Ser Pro Glu Leu Glu Ser Ser Pro
1565 1570

<210> 21
<211> 4298
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2564295CB1

<400> 21
gccactgaga ggcccaccag gtcccttctt ctcggatctg gcagaccaag gactagcgta 60
cggacctgcg cttaggggtc tccaagagga caaggagcct cctaggagct gagaggggct 120
cccagaggcc aaggctgtcc acgttctccc gggtcgaggc tgccagaagt taccccgcag 180
atgtcgaggc accgggaagc agaatctaga cacagcgctc cccagaagcc cgggcgcgct 240
ggctgcccct ccggcggtgc agccccactt ggaagaagcc tgtgggctta tcacaccgtt 300
ctccccagag tcaccgggag gagagccggg actggacaca agccagggct gggacaatgg 360
cagtgcctag tctgtggccc tggggagcat gcctgcctgt gatcttcctc tccttgggat 420
ttggcctgga tacagtagag gtgtgcccca gcctggatat tcgctcagag gtggcagagc 480
ttcgtcagct ggagaactgc agcgtggtgg agggccacct gcagatcctg ctcatgttca 540
cagccaccgg ggaggacttc cgcggcctca gcttccctcg cctcacccag gtcaccgact 600
acctgctgct cttccgtgtc tacggactgg agagcctgcg cgacctcttc cccaacctag 660
cagtcatccg cgggacgcgc ctcttcctgg gctatgcact ggtcatcttt gagatgccac 720
atctgcgtga cgtggcactg cctgcacttg gggccgtgct gcgtggggct gtgcgtgtgg 780
agaagaacca ggagctctgc cacctctcca ccattgactg gggactgctg cagccagcac 840
ctggcgccaa ccacatcgtg ggcaacaagc tgggcgagga gtgtgctgac gtgtgccctg 900
gtgtgctggg tgctgctggt gagccctgtg ccaagaccac cttcagcggg cacactgact 960
acagatgctg gacctccagc cactgccaga gagtgtgccc ctgcccccat gggatggctt 1020
gcacagcgag gggcgagtgc tgccacaccg aatgcctggg gggctgcagc cagccagaag 1080
accctcgtgc ctgtgtagct tgccgccacc tctacttcca gggtgcctgc ctgtgggcct 1140
gcccgccagg cacctaccag tatgagtcct ggcgctgtgt cacagctgag cgctgtgcca 1200
gcctgcactc tgtgcccggc cgtgcctcca ccttcggcat acaccagggc agttgcctgg 1260
cccagtgccc ttctggcttc acccgtaata gcagcagcat attctgccac aagtgcgagg 1320
ggctgtgccc taaagagtgc aaggtaggca ccaagaccat cgactccatc caggcggcac 1380
aggatcttgt gggctgcacg catgtggagg gaagcctcat cctcaacctt cgccagggct 1440
acaacctgga gccacagctg cagcacagcc tggggctggt agaaaccatt actggcttcc 1500
tcaaaatcaa gcactccttt gccctcgtgt ccctgggctt tttcaagaac ctcaaactaa 1560
tccggggaga cgccatggtg gatgggaact acactctcta cgtgctggac aaccagaacc 1620
tacaacagct agggtcctgg gtggccgcgg ggctcaccat tcccgtgggc aagatctact 1680
tcgccttcaa cccgcgcctc tgcttggaac acatctaccg actggaggag gtgacaggca 1740
cgcgaggtcg gcagaacaag gctgagatca acccccgcac caacggagac cgcgccgcct 1800
gccagactcg caccctgcgc ttcgtgtcca acgtgacgga ggcagaccgc atcctgctac 1860
gctgggagcg ctatgagcca ctggaggccc gcgacctgct cagcttcatc gtgtactaca 1920
aggagtcccc attccagaac gccacagagc acgtgggtcc agatgcttgt ggaacccaga 1980
gctggaacct gctggatgtg gagctgcccc taagccgcac ccaggagcca ggggtgaccc 2040
tagcctccct caagccttgg acacagtacg cagtgtttgt gcgggccatc acgctaacca 2100
ctgaggagga cagccctcat caaggagccc agagtcccat cgtctacctc cgaacgctgc 2160
ctgcagctcc cacggtgccc caagacgtca tctccacgtc caactcctcc tcccacctcc 2220
tggtgcgctg gaagccaccg acccagcgca atgggaacct cacctactac ctggtgctgt 2280
ggcagcggct ggcagaggac ggcgacctct acctcaatga ctactgccac cgcggcttgc 2340
ggctgcccac cagcaacaac gatccgcgct tcgacggcga agacggggat cctgaggccg 2400

agatggagtc cgactgctgc ccttgccagc acccacctcc tggtcaggtt ctgccccgc 2460
tggaggcgca agaggcctcg ttccagaaga agtttgaaaa ctttctacac aacgcgatca 2520
ccatccccat atccccttgg aaggtgacgt ccatcaacaa gagcccccaa agggactcag 2580
ggcggcaccg ccgggcagct gggcccctcc ggctgggggg caacagctcg gatttcgaga 2640
tccaggagga caaggtgccc cgtgagcgag cggtgctgag cggcctgcgc cacttcacgg 2700
aataccggat cgacatccat gcctgcaacc acgcggcgca caccgtgggc tgcagcgccg 2760
ccaccttcgt ctttgcgcgc accatgcccc acagagaggc tgatggtatt ccaggaaagg 2820
tggcctggga ggcctccagc aagaacagtg tccttctgcg ctggctcgag ccaccagacc 2880
ccaacggact catcctcaag tacgaaatca agtaccgccg cttgggagag gaggccacag 2940
tgctgtgtgt gtcccgtctt cgatatgcga agtttggggg agtccacctg gccctgctgc 3000
cccctggaaa ctactctgcc agggttaggg caacctcact ggctggcaat ggctcttgga 3060
cagacagtgt tgccttctac atccttggcc cagaggagga ggatgctggg gggctgcatg 3120
tcctcctcac tgccaccccc gtggggctca cgctgctcat cgttcttgct gcccttggtt 3180
tcttctacgg caagaagaga aacagaaccc tgtatgcttc tgtgaatcca gagtacttca 3240
gcgcctctga tatgtatgtc cctgatgaat gggaggtgcc tcgggagcag atctcgataa 3300
tccgggaact gggccagggc tcttttggga tggtatatga ggggctggca cgaggacttg 3360
aggctggaga ggagtccaca cccgtggccc tgaagacggt gaatgagctg gccagcccac 3420
gggaatgcat tgagttcctc aaggaagctt ctgtcatgaa agccttcaag tgtcaccatg 3480
tggtgcgtct cctgggtgtg gtatctcagg gccagccaac tctggtcatc atggagttaa 3540
tgacccgtgg ggacctcaag agccatcttc gatctttgcg gcctgaggca gagaacaacc 3600
ctgggctccc acagccagca ttgggggaaa tgatccaaat ggctggtgag attgcagacg 3660
gcatggccta ccttgctgcc aacaagtttg tgcaccgaga tctagcagcc cgcaactgca 3720
tggtgtccca ggacttcacc gtcaagatcg gggacttcgg gatgactcgg gacgtgtatg 3780
agacagacta ttaccgcaag ggtgggaagg ggctgctgcc cgtgcgctgg atggcccccg 3840
agtccctcaa agatgggatc ttcaccaccc actcggatgt ctggtccttt ggcgtggtac 3900
tctgggagat tgtgaccctg gcagaacaac cctaccaggg cctgtccaat gagcaggtgc 3960
tgaagttcgt catggatggc ggggtcctgg aggagctgga gggctgtccc cttcagctgc 4020
aggagctgat gagccgctgc tggcagccga acccacgcct gcgcccatct ttcacacaca 4080
ttctggacag catacaggag gagctgcggc cctccttccg cctcctctcc ttctactaca 4140
gcccggaatg ccgggggggcc cggggctccc tgcctaccac cgatgcagag cctgactcct 4200
cacccactcc aagagactgc agccctcaaa atgggggtcc agggcactga ggggcacctc 4260
attccctggc tggcctccca tggggagaca ggaaggga 4298

<210> 22
<211> 2863
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2837050CB1

<400> 22
atgatggaag aattgcatag cctggaccca cgacggcagg aattattgga ggccaggttt 60
actagagtag gtgttagtaa gggaccactt aatagtgagt cttccaacca gagcttgtgc 120
agcgtcggat ccttgagtga taaagaagta gagactcccg agaaaaagca gaatgaccag 180
cgaaatcgga aaagaaaagc tgaaccatat gaaactagcc aagggaaagg cactcctagg 240
ggacataaaa ttagtgatta ctttgagcga cgagtagaac agcccctcta tggtttagat 300
ggcagtgctg caaaggaggc aacggaggag cagtctgctc tgccaaccct catgtcagtg 360
atgctagcaa aacctcggct tgacacagag cacgtggcgc aaaggggagc tggcctctgc 420
ttcacttttg tttcagctca gcaaaacagt ccctcatcta cgggatctgg caacacagag 480
cattcctgca gctcccaaaa acagatctcc atccagcaca gacagaccca gtccgacctc 540
acaatagaaa aaatatctgc actagaaaac agtaagaatt ctgacttaga gaagaaggag 600
ggaagaatag atgatttatt aagagccaac tgtgatttga gacggcagat tgatgaacag 660
caaaagatgc tagagaaata caaggaacga ttaaatagat gtgtgacaat gagcaagaaa 720
ctccttatag aaaagtcaaa acaagagaag atggcgtgta gagataagag catgcaagac 780

cgcttgagac tgggccactt tactactgtc cgacacggag cctcatttac tgaacagtgg 840
acagatggtt atgcttttca gaatcttatc aagcaacagg aaaggataaa ttcacagagg 900
gaagagatag aaagacaacg gaaaatgtta gcaaagcgga aacctcctgc catgggtcag 960
gcccctcctg caaccaatga gcagaaacag cggaaaagca agaccaatgg agctgaaaat 1020
gaaacgttaa cgttagcaga ataccatgaa caagaagaaa tcttcaaact cagattaggt 1080
catcttaaaa aggaggaagc agagatccag gcagagctgg agagactaga aagggttaga 1140
aatctacata tcagggaact aaaaaggata cataatgaag ataattcaca atttaaagat 1200
catccaacgc taaatgacag atatttgttg ttacatcttt tgggtagagg aggtttcagt 1260
gaagtttaca aggcatttga tctaacagag caaagatacg tagctgtgaa aattcaccag 1320
ttaaataaaa actggagaga tgagaaaaag gagaattacc acaagcatgc atgtagggaa 1380
taccggattc ataaagagct ggatcatccc agaatagtta agctgtatga ttacttttca 1440
ctggatactg actcgttttg tacagtatta gaatactgtg agggaaatga tctggacttc 1500
tacctgaaac agcacaaatt aatgtcagag aaagaggcct ggtccattat catgcagatt 1560
gtgaatgctt taaagtactt aaatgaaata aaacctccca tcatacacta tgacctcaaa 1620
ccaggtaata ttcttttagt aaatggtaca gtgtgtggag agagaaaaat tacagatttt 1680
ggtctttcga agatcatgga tgatgatagc tacaattcag tgggtggcat ggagctgaca 1740
tcacaaggtg ctggcactta ttggtattta ccaccggagt gttttgtggt tgagaaagaa 1800
ccaccaaaga tctcaaataa agttgatgtg tggtcggtgg gtgtgatctt ctatcagtgt 1860
ctttctggag ggaagccttt tggccataac cagtctcagc aagacatcct acaagagaat 1920
actattctta aagctgctga agtgcagttc ccgccaaagc cagtagtaac acctgaagca 1980
aaggcgttta ttcgacgatg cttggcctac cgaaaggagg actgcattga tgcccagcag 2040
ctggcctgtg atccctactt gttgcctcac atccgaaagt cagtctctac aagtagccct 2100
gctggagctg ctattgcatc aacctctggg gcgtccaata acagttcttc taattgagac 2160
tgactccaag gccacaaact gttcaacaca cacaaagtgg acaaatggcg ttcagcagcg 2220
ggtttggaac atagcgaatc tgaatggatc tgatgaaacc tgaaccaggt gcttttattt 2280
tcttgctttt ttcccatcca ctgagcatga cagcatggat tctctttaag gagaaacctt 2340
gggcagctcc agccaggcct cataggaaaa ggcccggcat gaggttctgg cgtcaatggc 2400
cactgtgtat ggctgctctg agtgaggaaa aaactaaaaa gaaaaactgg ttccatgtac 2460
tgtgaacttg aaaacatgca gactcacggg ggttcctgat gcaatgcttc agatgaagat 2520
tgtggacttg aaaatacaga ctagaaggcc gggcacagtg gctcatgcct gtaatctcag 2580
cactttggga ggccaaggaa ggtggatcac aaggtcagga gatcgagacc atcctggcta 2640
acacagtgaa accccgtctc tactaaaaat acaaaaaaat tagccaggct tggtggtggg 2700
cgcctatagt cccagctact tgggagactg aggcaggaga atgtcgtgaa cccgagaggc 2760
ggagcttgca gtgagccgag atcacgccac tgcactccag cctgggcgac agagtgacac 2820
tccgtctcaa aaaataaata tataaataaa taataaaaaa aaa 2863

<210> 23
<211> 1494
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474590CB1

<400> 23
atgtactctg acagcgagga tgagtcatca gagctcagca ctgtgctcag catgtttgag 60
gagaaggagt tcaccaggca gtacaccgtc ctgaagacct tgagccagca tggcactact 120
gaagtgaggc tatgctccca tcacctcaca ggtgtcacag ttgctgtcaa agctctgaag 180
taccagaggt ggtgggagcc aaaggtttca gaagtcgaaa tcatgaagat gctcagccac 240
cctaacattg tttcccttct gcaagtgata gagacagaac agaacattta tctgattatg 300
gaagtggccc aaggcacaca gctacataat cgagtccagg aggctaggtg cctgaaggaa 360
gatgaagcaa gaagcatatt tgttcagttg ctcagtgcca taggctactg tcatggtgaa 420
ggtgttgttc acagagacct aaagcctgac aatgtcatag ttgatgagca tggaaatgtc 480
aaaattgttg actttgggct aggtgccaga ttcatgcctg ggcagaaatt ggaaaggctg 540
tgtggagcct tccagttcat tcctccagag atattcctag ggctcccttа tgatggccca 600

aaagtagaca tatgggcctt gggggttctt ttgtattata tggtgacagg gatttttcca 660
tttgtagggt ccaccttgtc agaaattagc aaggaagttc tacaagggag gtatgaaatt 720
ccttataatc tctctaaaga cttaaggagc atgataggcc tgttattggc aacaaacgca 780
aggcagaggc caactgcaca agacctccta agtcatccat ggcttcagga aggggaaaag 840
actatcacat ttcattccaa tggagacacc agctttccag accctgacat aatggcagcc 900
atgaaaaata ttgggtttca tgtgcaggac attagagaat cattaaaaca cagaaagttc 960
gatgaaacta tggctacata taacttactg agagctgagg catgtcagga tgatggcaat 1020
tatgttcaaa caaagttaat gaatccaggg atgccacctt tcccttcagt aacagactct 1080
ggagcttttt ctctgcctcc taggagaagg gccagtgaac cttcctttaa agtattagtc 1140
tcatctactg aagaacatca attaagacaa actgggggga caaatgcccc ttttccaccc 1200
aagaaaacac ccactatggg cagaagtcag aaacagaaac gtgccatgac tgccccttgt 1260
atttgtttac tgagaaacac ttacatagat acagaagaca gcagcttttg cactagctcc 1320
caggcagaaa agacttcaag tgatccagag aaaagtgaga cttcaacttc atgccctctg 1380
acacctaggg gctggaggaa atggaagaag agaattgtag catgcatcca gacattgtgt 1440
tgctgcacgt tgcctcaaaa aaaatgtccg aggagtgtgc atccccaaaa gtga 1494

<210> 24
<211> 2341
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474594CB1

<400> 24
atgtcagggc tggtgctgat gctggcggcg cggtgcattg tgggcagctc cccgctctgc 60
cgctgccgcc gccgtcgccc aaggaggatc ggggccgggc cgggccggga tgatccgggt 120
cggaaggccg ccgccgccgg agggagcggg tcacccaacg ccgcactgag ccgccccccgc 180
cccgccccgg ccccgggggа tgcgccgccc cgagctgctg cctccgccgc cgccgcagcc 240
gcagccgcag cgggcacaga gcaggtagat ggccccctca gggcaggccc ggcggacacc 300
cctccctctg gctggcggat gcagtgccta gcggccgccc ttaaggacga aaccaacatg 360
agtgggggag gggagcaggc cgacatcctg ccggccaact acgtggtcaa ggatcgctgg 420
aaggtgctga aaaagatcgg gggcgggggc tttggtgaga tctacgaggc catggacctg 480
ctgaccaggg agaatgtggc cctcaaggtg gagtcagccc agcagcccaa gcaggtcctc 540
aagatggagg tggccgtgct caagaagttg caagggaagg accatgtgtg caggttcatt 600
ggctgtggca ggaacgagaa gtttaactat gtagtgatgc agctccaggg ccggaacctg 660
gccgacctgc gccgtagcca gccgcgaggc accttcacgc tgagcaccac attgcggctg 720
ggcaagcaga tcttggagtc catcgaggcc atccactctg tgggcttcct gcaccgtgac 780
atcaagcctt caaactttgc catgggcagg ctgccctcca cctacaggaa gtgctatatg 840
ctggacttcg ggctggcccg gcagtacacc aacaccacgg gggatgtgcg gccccctcgg 900
aatgtggccg ggtttcgagg aacggttcgc tatgcctcag tcaatgccca caagaaccgg 960
gagatgggcc gccacgacga cctgtggtcc ctcttctaca tgctggtgga gtttgcagtg 1020
ggccagctgc cctggaggaa gatcaaggac aaggaacagg tagggatgat caaggagaag 1080
tatgagcacc ggatgctgct gaagcacatg ccgtcagagt tccacctctt cctggaccac 1140
attgccagcc tcgactactt caccaagccc gactaccagt tgatcatgtc agtgtttgag 1200
aacagcatga aggagagggg cattgccgag aatgaggcct ttgactggga gaaggcaggc 1260
accgatgccc tcctgtccac gagcacctct accccgcccc agcagaacac ccggcagacg 1320
gcagccatgt ttggggtggt caatgtgacg ccagtgcctg gggacctgct ccgggagaac 1380
accgaggatg tgctacaggg agagcacctg agtgaccagg agaatgcacc cccaattctg 1440
cccgggaggc cctctgaggg gctgggcccc agtccccacc ttgtccccca ccccgggggt 1500
cctgaggctg aagtctggga ggagacagat gtcaaccgga acaaactccg gatcaacatc 1560
ggcaaagtaa ctgccgccag ggcgaagggc gtgggtggcc ttttctctca cccccgattc 1620
ccagccttgt gcccctgccc tgttcctcct aagcaccctg tccccggcca tctgcctgct 1680
tgccctgcct ctgtttcccg gtccctcccc gcactagcct cgctgtgtct tccatcatca 1740
tcatcctctg tctccttcac cctgaggaga ccatccgccc acagccgcct catcagcccc 1800

agctcatggc actcccctct cctgcagagc ccctgtgtgg aggaggaaca gagccgaggc 1860
atgggggtcc ccagctcccc agtgcgtgcc cccccagact cccccacaac cccagtccgt 1920
tctctgcgct accggagggt gaacagccct gagtcagaaa ggctgtccac ggcggacggg 1980
cgagtggagc tacctgagag gaggtgggtc tggggccagg ggcatggttg gggcccaagg 2040
ccctctccgc cttcacgtgg ctggtctgga ggaaaagtta gatgtgtggc ggaggtgggc 2100
agaccctggg aagtgctgag agggttatac ttgggcctgg ggtcagactc agttggggcc 2160
agagacaggg cctgggagaa ccagtggggg atccagagag gtcccggctc atgccaggaa 2220
acgtaattgg gtgagtgcag gctgcaggag ggacaggtgg ggcgcctggg cccaggaagg 2280
gtgaggggcg agttggttgg tgggtgtgtg tgcttccaga atctcttctc ctagagacta 2340
a 2341

<210> 25
<211> 2552
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477585CB1

<400> 25
cgcggtgtct ggcgctcggt gggtgtggtt gcccctagtt tgaggcctgc ccgattaccc 60
gcaagacttg ggcagccccg ggcgccgctc cgaccacgac agggaaagga accttaatct 120
catctttaaa ataaggagaa ttactgagtg acctgaagga ccctttcag ctggaaagtc 180
tgaactgacc aacactggat gaatttgacc atttcttagg agactggaat gttaagtttc 240
tataaatgaa tgaaccagtt ctctcttgtt tggagcaatg ctgaaattcc aagaggcagc 300
taagtgtgtg agtggatcaa cagccatttc cacttatcca aagaccttga ttgcaagaag 360
atacgtgctt caacaaaaac ttggcagtgg aagttttgga actgtctatc tggtttcaga 420
caagaaagcc aaacgaggag aggaattaaa ggtacttaag gaaatatctg ttggagaact 480
aaatccaaat gaaactgtac aggccaattt ggaagcccaa ctcctctcca agctggacca 540
cccagccatt gtcaagttcc atgcaagttt tgtggagcaa gataatttct gcattatcac 600
ggagtactgt gagggccgag atctggacga taaaattcag gaatataaac aagctggaaa 660
aatctttcca gaaaatcaaa taatagaatg gtttatccag ctgctgctgg gagttgacta 720
catgcatgag aggaggatac ttcatcgaga cttaaagtca aagaatgtat ttctgaaaaa 780
taatctcctt aaaattggag attttggagt ttctcgactt ctaatgggat cctgtgacct 840
ggccacaact ttaactggaa ctccccatta tatgagtcct gaggctctga aacaccaagg 900
ctatgacaca aagtcggaca tctggtcact ggcatgcatt ttgtatgaga tgtgctgcat 960
gaatcatgca ttcgctggct ccaatttctt atccattgtt ttaaaaattg ttgaaggtga 1020
cacaccttct ctccctgaga gatatccaaa agaactaaat gccatcatgg aaagcatgtt 1080
gaacaagaat ccttcattaa gaccatctgc tatcgaaatt ttaaaaatcc cttaccttga 1140
tgagcagcta cagaacctaa tgtgtagata ttcagaaatg actctggaag acaaaaattt 1200
ggattgtcag aaggaggctg ctcatataat taatgccatg caaaaaagga tccacctgca 1260
gactctgagg gcactgtcag aagtacagaa aatgacgcca agagaaagga tgcggctgag 1320
gaagctccag gcggctgatg agaaagccag gaagctgaaa aagattgtgg aagaaaaata 1380
tgaagaaaat agcaaacgaa tgcaagaatt gagatctcgg aactttcagc agctgagtgt 1440
tgatgtactc catgaaaaaa cacatttaaa aggaatggaa gaaaaggagg agcaacctga 1500
gggaagactt tcttgttcac cccaggacga ggatgaagag aggtggcaag gcagggaaga 1560
ggaatctgat gaaccaactt tagagaacct gcctgagtct cagcctattc cttccatgga 1620
cctccacgaa cttgaatcaa ttgtagagga tgccacatct gaccttggat accatgagat 1680
cccagaagac ccacttgtgg ctgaagagta ctacgctgat gcatttgatt cctattgtgt 1740
agagagtgat gaggaggaag aagaaatagc gttagaaaga ccagagaaag aaatcaggaa 1800
tgagggatcc cagcctgctt acagaacaaa ccaacaggac agtgatatcg aagcgttggc 1860
caggtgtttg gaaaatgtcc tgggttgcac ttctctagac acaaagacca tcaccaccat 1920
ggctgaagac atgtccccag gaccaccaat tttcaacagt gtgatggcca ggaccaagat 1980
gaaacgcatg agggaatcag ccatgcagaa gctggggaca gaagtatttg aagaggtcta 2040
taattacctc aagagagcaa ggcatcagaa tgctagcgaa gcagagatcc gcgagtgttt 2100

ggaaaaagtg gtgcctcaag ccagcgactg ttttgaagtg gaccagctcc tgtactttga 2160
agagcagttg ctgatcacga tgggaaaaga acctactctc cagaaccatc tctaggcaac 2220
tatcaaaaag aagcagaagt tcaagtggac aaatttatgt gaaaattcat ttaacatata 2280
agctgaactc tattatgggg aatggataca aaagcagagc tcccatcttg actttcaatt 2340
cctcatcaga agtactggct tctttagaga gtagtaagca tggctgccta tgcttggagt 2400
cataagtgtt atttggacta taccctgaga taagcttata gatcaagttt ggctcccttg 2460
aaaagcattt ctctcatgtg cgccctcagg gcttccagca ggattgagtc accctgacga 2520
tgaccgggga gaagccgtgt gctcttcatt at 2552

<210> 26
<211> 2176
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477587CB1

<400> 26
ctcaccgccc tccccaccag ccccagcatc acaaacgctg ggcttctctg ccgctccgaa 60
ttctgctgtg gctccccagt gcccagggcc atcaagcccc aggttttcat gtgggcccca 120
gggacccgcc agcagggagg acccgaaatg gcacacattc agaacgtcga ggctcatacc 180
tcaagcgcac tgtgggggag aagcccccgg aagcccccaa ccccccacgc gcgagagagc 240
ctcagtttcc cgctcgagcg gccccggagc ggccgcagcg cggtggtctc ggcccggctg 300
cgccagagtc cgcgcatgga gccccggccg cggcggcggc gcaggagtcg ccccctggtc 360
gccgccttcc tgcgagaccc gggctcgggc cgcgtgtaca ggcgcgggaa gctgatcggc 420
aagggcgcct tcagccgctg ctacaagctg acagacatgt ccaccagcgc cgtgttcgcc 480
ctcaaggtgg tgccgtgtgg cggggctggg gccgggtggc ttcgcccgca gggaaaggtg 540
gagcgtgaga ttgccctgca tagccgcctg cgaccccgca acatcgtggc tttccacgga 600
cactttgctg accgcgacca cgtgtacatg gtgctggagt actgcagccg ccagtctttg 660
gcccacgtgc tgagggcgcg gcagatcctg acggagccag aagtgcgcga ctacctgcgg 720
ggcctggtca gcggcctgcg ctacctgcac cagcggtgca tcctgcaccg cgacctgaag 780
ctcagtaact tcttccttaa caagaacatg gaggtgaaga ttggagacct gggactggcg 840
gccaaggtgg ggccaggggg ccgctgccac aggtacacgg tgctgactgg caccccaccc 900
ttcatggcct caccctgtc ggagatgtac caaaacatcc gtgagggcca ctaccccgaa 960
cccgctcacc tgtctgccaa tgcgcgccgc ctcatcgtgc acctcctagc acccaacccg 1020
gccgagcggc ccagcctgga ccacctgctg caggacgact tcttcacaca gggtttcact 1080
ccagaccggc tgccggccca ctcctgccac agtcccccca tcttcgccat acccccgcct 1140
ctgggcagga tcttccggaa ggtgggccag cggctgctca cccagtgccg gccaccctgc 1200
cccttcacgc ctaaagaggc ctcgggtcca ggagaaggtg ggccagaccc tgactccatg 1260
gagtgggacg gcgagagctc cctgtctgcg aaagaggttc cctgcctgga aggccccatc 1320
cacctggtcg cacaagggac cctgcagagt gacctggccg ccacacagga ccccctggga 1380
gagcagcagc ccatcctctg ggcccccaaa tgggtggatt attccagcaa atacggcttt 1440
ggctaccagc tcttggacgg ggggcgcacg ggacggcacc cacatggccc tgcgaccccc 1500
cggaggtatt tattaagcac ctactgtgca cacctacagg tgctccctgc ctgccaagtg 1560
tgctacatgc ccaactgcgg gaggctggaa gccttcgccc tgagggatgt gcccggcctg 1620
ctgggcgcca agctggccgt gctgcagctc tttgccggct gcctgcggcg gcggctgcgg 1680
gaggagggga ccctccccac acctgtgcca cctgctggac ccggcctctg cctcctgcgc 1740
ttcctggcct ctgagcacgc cctgctgctg ctgttcagca atgggatggt gcaggtgagc 1800
ttcagtggag tcccggccca actggtgctg agtggcgagg gtgagggttt gcagctcacc 1860
ctctgggagc aggggtcccc tggcacctcc tactccctgg acgtcccgcg gagccacggc 1920
tgcgccccca ccaccggaca gcaccttcac cacgccctcc gcatgctgca gagtatctag 1980
tgcccctgag ggtcagagtg gacccctgca tggtagtgcc agggacccag gctccatttc 2040
cattcctgtg gctcccccag aggggctgtc ctgggggaga gctgggggcc acacgggagg 2100
tgggttcttg ccttgtggca tgactgttca acccagactt tgctgggatc tcttcctttt 2160
tcattaaaga caattc 2176

<210> 27
<211> 4277
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7594537CB1

<400> 27
tgtgagcaga gttcttgaag ctccactcct cctggggaag ccgagctgtg tgggagcctt 60
cttactgtgc cgggagcgtg tgaattggaa aggatcctga gaactggcta gtcccagttc 120
ctctccggaa aagcagtggc tctcgcttca gagatgcgct cagctttcgc ctgcatcaca 180
ctgcattctt taacacatta ttgaaattac aagcatccaa agcagtttca tgtggacaga 240
ttgcatattt tgaaagcctg aggtatttta tcatgaaaca tgccatgtgg aatctttgaa 300
gcatagacct ctgcgcaaca cctgaataaa gaatctttta cctggtatgt gacagagctt 360
ctcaccacca ccatgacaaa ccaggaaaaa tgggcccacc tcagcccttc ggaattttcc 420
caacttcaga aatatgctga gtattctaca aagaaattaa aggatgttct tgaagaattc 480
catggtaatg gtgtgcttgc aaagtataat cctgaaggga caatagattt tgaaggtttc 540
aaactattca tgaagacatt cctggaagcc gagcttcctg atgatttcac tgcacacctt 600
ttcatgtcat ttagcaacaa gtttcctcat tctagtccaa tggtaaaaag taagcctgct 660
ctcctatcag gcggtctgag aatgaataaa ggtgccatca cccctccccg aactacttct 720
cctgcaaata cgtgttcccc agaagtaatc catctgaagg acattgtctg ttacctgtct 780
ctgcttgaaa gaggaagacc tgaggataag cttgagttta tgtttcgcct ttatgacacg 840
gatgggaatg gcttcctgga cagctcggag ctagaaaata tcatcagtca gatgatgcat 900
gttgcagaat accttgagtg ggatgtcact gaacttaatc caatcctcca tgaaatgatg 960
gaagaaattg actatgatca tgatggaacc gtgtctctgg aggaatggat tcaaggagga 1020
atgacaacga ttccacttct tgtgctcctg ggcttagaaa ataacgtgaa ggatgatgga 1080
cagcacgtgt ggcgactgaa gcactttaac aaacctgcct attgcaacct ttgcctgaac 1140
atgctgattg gcgtggggaa gcagggcctc tgctgttcct tctgcaagta cacagtccat 1200
gagcgctgtg tggctcgagc acctccctct tgcatcaaga cctatgtgaa gtccaaaagg 1260
aacactgatg tcatgcacca ttactgggtt gaaggtaact gcccaaccaa gtgtgataag 1320
tgccacaaaa ctgttaaatg ttaccagggc ctgacaggac tgcattgtgt ttggtgtcag 1380
atcacactgc ataataaatg tgcttctcat ctaaaacctg aatgtgactg tggacctttg 1440
aaggaccata ttttaccacc cacaacaatc tgtccagtgg tactgcagac tctgcccact 1500
tcaggagttt cagttcctga ggaaagacaa tcaacagtga aaaaggaaaa gagtggttcc 1560
cagcagccaa acaaagtgat tgacaagaat aaaatgcaaa gagccaactc tgttactgta 1620
gatggacaag gcctgcaggt cactcctgtg cctggtactc acccactttt agtttttgtg 1680
aaccccaaaa gtggtggaaa acaaggagaa cgaatttaca gaaaattcca gtatctatta 1740
aatcctcgtc aggtttacag tctttctgga aatggaccaa tgccagggtt aaacttttc 1800
cgtgatgttc ctgacttcag agtgttagcc tgtggtggag atggaaccgt gggctgggtt 1860
ttggattgca tagaaaaggc caatgtaggc aagcatcctc cagttgcgat tctgcctctt 1920
gggactggca atgatctagc aagatgcctg cgatggggag gaggttacga aggtgagaat 1980
ctgatgaaaa ttctaaaaga cattgaaaac agcacagaaa tcatgttgga caggtggaag 2040
tttgaagtca tacctaatga caaagatgag aaaggagacc cagtgcctta cagtatcatc 2100
aataattact tttccattgg cgtggatgcc tccattgcac acagattcca catcatgaga 2160
gaaaaacacc cagagaaatt caacagtaga atgaagaaca aattttggta ttttgagttt 2220
ggcacatctg aaactttctc agccacctgc aagaagctac atgaatctgt agaaatagaa 2280
tgtgatggag tacagataga tttaataaac atctctctgg aaggaattgc tattttgaat 2340
ataccaagca tgcatggagg atccaatctt tggggagagt ctaagaaaag acgaagccat 2400
cgacgaatag agaaaaaagg gtctgacaaa aggaccaccg tcacagatgc caaagagttg 2460
aagtttgcaa gtcaagatct cagtgaccag ctgctggagg tggtcggctt ggaaggagcc 2520
atggagatgg ggcaaatata cacaggcctg aaaagtgctg gccggcggct ggctcagtgc 2580
tcctgcgtgg tcatcaggac gagcaagtct ctgccaatgc aaattgatgg ggagccatgg 2640
atgcagaccc catgcacaat aaaaattaca cacaagaacc aagccccaat gctgatgggc 2700
ccgcctccaa aaaccggttt attctgctcc ctcgtcaaaa ggacaagaaa ccgaagcaag 2760

gaataatcct gtgttgtttc actcttagaa attgaattag cataattggg ccatggaaca 2820
catatgctgg aaatctttga accatttcaa gtctcctgct catgcaaaat catggaagtg 2880
gtttaacagt ttttgttact aagctaatgt aaaattcagc tattagaaaa tttattgtct 2940
cagtttttat aggcatcttt gcatgaagaa agcagaagtt tacctgaagt gatactgcat 3000
atttttggtg catgcattcc catagatttt tacatctccc acccaactct tccccaattt 3060
ccttttacta acctgtgaga aaaacccgtg aaacatgaaa aaggaaatac catgggaaac 3120
gtgattctca gtgtgattcc aattattacg aagcactaat cagtaacgct acaatgatca 3180
taattgcaga ttgctatacg tttccctttt agaatcagtg tatcagtgac ctatgacttg 3240
aggagaaact tttaattcga agattttatt aaatagttga ctacaatacc ttgctatata 3300
tacatagttt ttcttcaaca tcttaactct tctgagtgga aataaaaata tcaggcataa 3360
ggtttttctca tgctgaaaaa tagaacgcgg tttttatttt gcttagtttt ctttttaatt 3420
ccagaaataa gtgaaaacat gttacttgac agtcaagtgt ggtaatatgg caagccttgt 3480
tcctttctgc atgagaatct aggagagaat tcataaccac accaataacg aaatagaagt 3540
tttaaactat gtgcctaatc aatgtgtttc ccaccaaaga ttcagaaaac aatgcttgag 3600
agaaatgggt taatgcataa ttaattaagc attgtggagc aaatttaggg ttcctgtgat 3660
taattttgtg atgactaaaa tgctggaaag caagtgagtt gcccattaat tatgattaaa 3720
attctcacct ttcacagaca gacaataagc cagacaacac aatcaaagct caatagatga 3780
tttcttgctt ttttcagtca tttataaata taggtgtaat ttttcatgga tcagttaagt 3840
acacttgaag gaagtaaatg attgtatcag tttatttcta gtataaatgg gtacctgtaa 3900
taatactgag ctcttggaag cgaatcatgc atgcaattag ctccctcctc ctcacctact 3960
ccactcccat ctttatgaca tttcaaatgt ttatttggaa acaacagcct agatcactgt 4020
tgaaggtgtt catggcatag ttggagtctc tgactgttta aagaaatcac agaacagtac 4080
ttttctttta gtgtttcatt aagcctatga tgtaaaatga aatgcttctg agcagtcttg 4140
taatattgtt cattcatatt gacctgcatc tcatcattgc atgttttatg ttttcaaaca 4200
tgccataagg aaaacgagtg cctgaactgc atgatttatt agtttctctc cactctgcat 4260
taaagtgcta atgattt 4277

<210> 28
<211> 2616
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 70467491CB1

<400> 28
atgtccacta ggaccccatt gccaacggtg aatgaacgag acactgaaaa cgctgtattg 60
ccgcacacgt cacatggaga tgggcgtcaa gaagttacct ctcgtaccag ccgctcagga 120
gctcggtgta gaaactctat agcctcctgt gcagatgaac aacctcacat cggaaactac 180
agactgttga aaacaatcgg caaggggaat tttgcaaaag taaaattggc aagacatatc 240
cttacaggca gagagaaaaa tgttagaata tccaaagaaa ttgataattt tctaggaaaa 300
catgacttac caaaattaac tctagaaaag aatcgataca catcagtaac aacagaagtt 360
gagaaagtag ttaacatatt gccaaacctg gaattcatga ttgaattctt tgagatctac 420
tctataggtg aagtatttga ctatttggtt gcacatggca ggatgaagga aaaagaagca 480
agatctaaat ttagacagat tgtgtctgca gttcaatact gccatcagaa acggatcgta 540
catcgagacc tcaaggctga aaatctattg ttagatgccg atatgaacat taaaatagca 600
gatttcggtt ttagcaatga atttactgtt ggcggtaaac tcgacacgtt ttgtggcagt 660
cctccatacg cagcacctga gctcttccag ggcaagaaat atgacgggcc agaagtggat 720
gtgtggagtc tgggggtcat tttatacaca ctagtcagtg gctcacttcc ctttgatggg 780
caaaacctaa aggaactgag agagagagta ttaagaggga aatacagaat tcccttctac 840
atgtctacag actgtgaaaa ccttctcaaa cgtttcctgg tgctaaatcc aattaaacgc 900
ggcactctag agcaaatcat gaaggacagg tggatcaatg cagggcatga agaagatgaa 960
ctcaaaccat ttgttgaacc agagctagac atctcagacc aaaaaagaat agatattatg 1020
gtgggaatgg gatattcaca agaagaaatt caagaatctc ttagtaagat gaaatacgat 1080
gaaatcacag ctacatattt gttattgggg agaaaatctt cagagctgga tgctagtgat 1140

tccagttcta gcagcaatct ttcacttgct aaggttaggc cgagcagtga tctcaacaac 1200
agtactggcc agtctcctca ccacaaagtg cagagaagtg tttcttcaag ccaaaagcaa 1260
agacgctaca gtgaccatgc tggaccagct attccttctg ttgtggcgta tccgaaaagg 1320
agtcagacca gcactgcaga tagtgacctc aaagaagatg gaatttcctc ccggaaatca 1380
agtggcagtg ctgttggagg aaagggaatt gctccagcca gtcccatgct tgggaatgca 1440
agtaatccta ataaggcgga tattcctgaa cgcaagaaaa gctccactgt ccctagtagt 1500
aacacagcat ctggtggaat gacacgacga aatacttatg tttgcagtga gagaactaca 1560
gctgatagac actcagtgat tcagaatggc aaagaaaaca gcactattcc tgatcagaga 1620
actccagttg cttcaacaca cagtatcagt agtgcagcca ccccagatcg aatccgcttc 1680
ccaagaggca ctgccagtcg tagcactttc cacggccagc cccgggaacg gcgaaccgca 1740
acatataatg gccctcctgc ctctcccagc ctgtcccatg aagccacacc attgtcccag 1800
actcgaagcc gaggctccac taatctcttt agtaaattaa cttcaaaact cacaaggagg 1860
cttccaactg aatatgagag gaacgggaga tatgagggct caagtcgcaa tgtatctgct 1920
gagcaaaaag atgaaaacaa agaagcaaag cctcgatccc tacgcttcac ctggagcatg 1980
aaaaccacta gttcaatgga tcccggggac atgatgcggg aaatccgcaa agtgttggac 2040
gccaataact gcgactatga gcagagggag cgcttcttgc tcttctgcgt ccacggagat 2100
gggcacgcgg agaacctcgt gcagtgggaa atggaagtgt gcaagctgcc aagactgtct 2160
ctgaacgggg tccggtttaa gcggatatcg gggacatcca tagccttcaa aaatattgct 2220
tccaaaattg ccaatgagct aaagctgtaa cccagtgatt atgatgtaaa ttaagtagca 2280
attaaagtgt tttcctgaac actgatggaa atgtatagaa taatatttag gcaataacgt 2340
ctgcatcttc taaatcatga aattaaagtc tgaggacgag agcaaaaaaa aaaaaaaagg 2400
gcggccctcg agccgctcga gccgaattcg gctcgaggat tcagtgggtg agagggaaga 2460
aggggaggtt ggggggctcc ttcccttcag aacttgaagt ttctcccact gcctcctctc 2520
cagtggtctc ccaggtgcca gacccaaaag cttttcctac agtgataccc ttatattttt 2580
acttcccctt gactcatatg ttttaacatg aatttt 2616

<210> 29
<211> 1253
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7478559CB1

<400> 29
ctggcccctc ctctaccact cccactccct cgccggaccc ccccgccggg gctagcgtct 60
gccgcggctc cgagggggtg gggctgctgg gaatggctgt gccccccttcg gcccctcagc 120
cgcgcgcgtc ctttcacctg aggaggcaca cgccttgccc gcagtgctca tggggcatgg 180
aggagaaggc ggcggccagc gccagctgcc gggagccgcc gggcccccccg agggccgccg 240
ccgtcgcgta cttcggcatt tccgtggacc cggacgacat ccttcccggg gccctgcgcc 300
tcatccagga gctgcggccg cattggaaac ccgagcaagt tcggaccaag cgcttcatgg 360
atggcatcac caacaagctg gtggcctgct atgtggagga ggacatgcag gactgcgtgc 420
tggtccgggt gtatggggag cggacggagc tgctggtgga ccgggagaat gaggtcagaa 480
acttccagct gctgcgagca cacagctgtg cccccaaact ctactgcacc ttccagaatg 540
ggctgtgcta tgagtacatg cagggtgtgg ccctggagcc tgagcacatc cgtgagcccc 600
ggcttttcag gttaatcgcc ttagaaatgg caaagattca tactatccac gccaacggca 660
gcctgcccaa gcccatcctc tggcacaaga tgcacaatta tttcacgctt gtgaagaacg 720
agatcaaccc cagcctttct gcagatgtcc ctaaggtaga ggtgttggaa cgggagctgg 780
cctggctgaa ggagcatctg tcccagctgg agtcccctgt ggtgttttgt cacaatgacc 840
tgctctgcaa gaatatcatc tatgacagca tcaaaggtca cgtgcggttc attgactatg 900
aatatgctgg ctacaactac caagcttttg acattggcaa ccatttcaat gagtttgcag 960
gcgtgaatga ggtggattac tgcctgtacc cggcgcggga gacccagctg cagtggctgc 1020
actactacct gcaggcacaa aaggggatgg ccgtgacccc cagggaggtg caaaggctct 1080
acgtgcaagt caacaagttt gccctggcgt ctcacttctt ctgggctctc tgggccctca 1140
tccagaacca gtactccacc atcgactttg atttcctcag gtacgcagtg atccgattca 1200

accagtactt caaggtgaag cctcaagcgt cagccttgga gatgccaaag tga 1253

<210> 30
<211> 1790
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1698381CB1

<400> 30
tttaagaagg agttccctta taggagatgg aagaaacggc cattaatccg gggacttttt 60
atgctggaaa caaacctgaa ggtacaggtt cggcccggaa gttataccca ccaagagaag 120
tatgtccgga attgtgggtt ctgcagtcac tgacttcaag aatgaagccg cggaccctcg 180
cggtgcagca ttgtactgca agtcaatcga tacaataatt taagtcactt cagctataat 240
ggaaaagtat gaaaaattag ctaagactgg agaagggtct tatggggttg tattcaaatg 300
cagaaacaaa acctctggac aagtagtagc tgttaaaaaa tttgtggaat ctgaagatga 360
tcctgttgtt aagaaaatag cactaagaga aatacgtatg ttgaagcaat taaaacatcc 420
aaatcttgtg aacctcatcg aggtgttcag gagaaaaagg aaaatgcatt tagtttttga 480
atactgtgat catacacttt taaatgagct ggaaagaaac ccaaatggag ttgctgatgg 540
agtgatcaaa agcgtattat ggcaaacact tcaagctctt aatttctgtc atatacataa 600
ctgtattcac agagatataa aacctgaaaa tattctaata actaagcaag gaataatcaa 660
gatttgtgac ttcgggtttg cacaaattct gattccagga gatgcctaca ccgattatgt 720
agctacgaga tggtaccgag ctcctgaact tcttgtggga gatactcagt atggttcttc 780
agtcgatata tgggctattg gttgtgtttt tgcagagctc ctgacaggcc agccactgtg 840
gcctggaaaa tcagatgtgg accaacttta tctgataatc agaacactag gaaaattaat 900
cccaagacat caatcaatct ttaaaagtaa cgggtttttc catggcatca gtatacctga 960
gccagaagac atggaaactc ttgaggaaaa gttctcagat gttcatcctg tggctctgaa 1020
cttcatgaag gggtgtctga agatgaatcc agatgacaga ttaacctgtt cccaactcct 1080
ggagagctcc tactttgatt cttttcaaga ggcccaaatt aaaagaaaag cacgtaatga 1140
aggaagaaac agaagacgcc aacagaatca actgttgcct ctcataccag gaagccacat 1200
ctcccccaca cctgatggaa gaaaacaagt cctccagtta aaatttgatc accttccaaa 1260
catttaggaa aatgttcttt caagtgcaaa gtaatttaat atgtacacat tttgtacaag 1320
tgagatagga attctcagtg tttcaaatgc aaatgagcca tatgaaaatt aagatgcctt 1380
ctagaattgt tttggctctg atcattgctg attcctttcc ccatgctttt acatgccaac 1440
tttatctttt agaatatttt ctttaaatgt tataaagcct aaaactgcac atatggaaga 1500
gacattttca atttcatcag agcagcccct cccgaggcta tctatatgga gaatttgtga 1560
gcttatactt ggatttatga aaaagattta catgtgtcat cttgcttcag ctgaccacat 1620
aatttcttaa agcaatatca aatagcctgc ctcactgttt gtgtaagaaa tgacatatgt 1680
tcctgcatgt gtaattcata cttattgtaa ccaggtctgt tgagtattgc tggtatctta 1740
tactgagtaa atatggtgta gaaagggaac tttgaagggc tgcagattcg 1790

<210> 31
<211> 4132
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474637CB1

<400> 31
cccccgactg tcttggtggc agaggggact tttattcagc tggaaccgcg cggcgaggcc 60
caagtgtctc tggagagatt cggggttcag gaggtggcgg gtgcacccaa gggtgctggg 120
aggaagctcc aggttcccat tcttccccag ggatcggcgt tgcccctgct cgcgggggta 180

gtctagggca acggaagatg gcggcggcgg ccgggcacgg ggttccgggc tccgctcggg 240
cagagcccac ccgctgacca actccgccgc ccccgccggg cggtgctgtg tccccgcagg 300
agtcggagag gatggcaggg gccggaggcc agcaccaccc tccgggcgcc gctggaggag 360
cggccgccgg agccggcgcc gcggtcacct ccgccgctgc ctcggcgggg ccgggagagg 420
attcgtctga cagcgaagcg gagcaagagg gaccccagaa actgatccgc aaagtgtcta 480
cctcggggca gatccggacc aagaccagta ttaaagaggg acagctattg aagcaaacca 540
gttctttcca aaggtggaaa aagcgatact tcaaacttcg aggccgcacc ctttactatg 600
caaaggactc aaagtctctg atatttgatg aagttgacct ctcagatgct agtgtagctg 660
aagcaagcac gaaaaatgct aacaacagct tcacgatcat cactccattc agaaggctaa 720
tgctgtgtgc tgagaacaga aaggagatgg aggattggat cagctcactg aagtctgtac 780
agaccagaga accctacgag gtggcccagt ttaatgtgga acatttctca gggatgcaca 840
actggtacgc ctgctcccac gcccgaccca ccttctgtaa cgtgtgcaga gagagtcttt 900
ctggagtcac ctcccatggc ctgtcctgcg aagtgtgtaa attcaaggct cacaaaagat 960
gtgcagtgag agcaacaaat aactgtaaat ggactaccct ggcctccatc gggaaggaca 1020
ttatagaaga tgaagatggc gtcgcgatgc ctcaccagtg gcttgagggc aacctgcctg 1080
taagtgccaa gtgtgctgtc tgcgacaaaa catgtggcag tgttctccgt ctacaggatt 1140
ggaaatgcct ttggtgtaag acaatggtac acactgcctg caaagattta taccatccaa 1200
tatgtccact tggtcaatgt aaagtatcta tcatacctcc aattgcacta aacagcaccg 1260
attccgatgg tttctgtaga gcaacatttt cgttctgtgt tagtcctcta ttggtttttg 1320
tcaattctaa gagtggagat aatcagggag taaagttcct ccgtcgcttt aaacagttgc 1380
taaatccggc tcaggtgttt gatttaatga atggaggtcc tcatttaggt ttaagattat 1440
ttcagaagtt tgacaatttc cggattcttg tatgtggagg cgatggaagt gtaggttggg 1500
ttttgtcaga aatcgataag ctcaacttga ataaacagtg tcagctggga gtgttgcctt 1560
tgggtacagg aaatgacctt gcccgagttc ttggctgggg aggttcatat gacgatgaca 1620
cccagcttcc tcagatccta gagaaactgg aacgagccag taccaaaatg ttggacaggt 1680
ggagtataat gacatatgaa ctcaaattgc caccaaaagc ttccctactt ccaggacctc 1740
cagaagcatc tgaagaattt tatatgacga tttatgaaga ctcagttgca acgcatctta 1800
caaaaatcct caattctgat gaacatgcag tggtcatatc ttctgccaag acgctatgtg 1860
aaactgtaaa ggacttcgtt gccaaagtag aaaagacgta tgacaaaacc ttggaaaatg 1920
ccgttgtagc tgatgccgtg gccagtaaat gttcagtcct aaacgagaag ctcgaacaac 1980
tgctgcaggc tttgcacaca gattcccagg ctgcgcctgt tctccctggc ctcagccctc 2040
tcattgtgga agaagatgct gtggaatcgt ccagtgaaga gtccctgggt gaaagcaaag 2100
agcagcttgg ggatgacgtt acaaaacctt cctcccagaa agccgtcaaa ccaagggaaa 2160
tcatgttgcg ggcaaatagt ttaaagaaag cagtgaggca agtcattgag gaagccggaa 2220
aagttatgga tgacccgaca gttcacccct gtgaaccagc taatcagtcc tctgattatg 2280
acagcacaga aacagatgaa tctaaggagg aagctaaaga tgatggtgcc aaagaatcaa 2340
taactgttaa aactgcacct cggtctccag atgcccgggc aagttatggc cattcccaaa 2400
ctgattctgt ccctggtcca gctgtggcag ccagcaaaga aaacctccct gtgctcaata 2460
ccagaataat ctgcccaggt ttaagagcag gactggctgc ctcaattgct gggagttcga 2520
ttatcaacaa aatgttactg gcaaacattg atccttttgg tgccacgccg tttattgacc 2580
ctgatctaga ttccgtagat ggatattcag aaaaatgtgt catgaacaat tactttggga 2640
ttggattaga tgcaaaaatt tcattagaat ttaataataa aagagaggag caccctgaaa 2700
aatgcaggag ccgaactaaa aacttgatgt ggtatggagt ccttggaacc cgggagttat 2760
tacagagatc gtacaagaat ttagaacaaa gggttcaact tgagtgtgat gggcagtata 2820
ttcctcttcc cagcttgcaa ggcatagccg tgttgaacat tcccagctat gctggaggca 2880
ctaacttttg gggtggaact aaagaggatg atatatttgc tgcaccatcc tttgatgaca 2940
agatcctgga agttgtagca atatttgata gcatgcaaat ggcagtttca agggtcatta 3000
aactgcagca tcatcgaata gcccagtgcc gtacagtgaa aatcactata tttggtgacg 3060
aaggagtccc agtgcaagtg gatggtgaag cgtgggttca gcctccaggg attatcaaaa 3120
ttgtgcacaa aaacagagca caaatgctaa caagggacag agcctttgag agcactctga 3180
aatcttggga agataagcag aagtgtgatt ctggtaaacc agttctccga acccatttgt 3240
acatccatca cgccattgac ttggcaacag aagaggtgtc gcagatgcag ctatgctccc 3300
aggctgcaga ggagctcatt actaggatat gtgacgcagc cacaattcac tgtcttttgg 3360
agcaagaact ggcccatgct gtgaatgcct gctcccatgc cctgaataaa gccaacccaa 3420
ggtgcccgga gagtcttaca agagacactg ccactgaaat agccatcaat gtgaaggcgc 3480
tgtataatga aacagaatct ttgctagttg gcagggttcc tttgcagctg gaatcgccac 3540

atgaagagcg agtatccaat gccttacact ctgtggaggt ggaattacag aaactgacag 3600
agattccttg gctttattat atcttacacc caaatgaaga tgaggaacct cctatggatt 3660
gcaccaaaag gaacaacaga agcaccgtat ttcgaatagt gccaaagttt aaaaaggaaa 3720
aggttcagaa gcagaagaca agttcacagc ctggatctgg ggataccgaa agtgggtcat 3780
gtgaagcgaa ttctccaggg aattaaagag cttggaagga gcactccaca gtcggaggtg 3840
taatcatatt ggtgctattc cttggaagag aagttattgc cacttaatac aaagtccttg 3900
gaagcaagtg gctgttcttg tagttttctg catagataag taagcaccac tgaagcacct 3960
ctgtggcttg atattttgct gtgggtgaaa ttttgatttg aggtattaga aaatattttt 4020
gtgccgaaca atacattcca cgaagccatt ttctttttgt gcaaacctga catgttcaaa 4080
tatattcaca atggtaataa ggtaggagga atctgagacg attgcattgt ct 4132

<210> 32
<211> 1137
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7170260CB1

<400> 32
atggaggact ttctgctctc caatgggtac cagctgggca agaccattgg ggaagggacc 60
tactcaaaag tcaaagaagc attttccaaa aaacaccaaa gaaaagtggc aattaaagtt 120
atagacaaga tgggagggcc agaagagttt atccagagat tcctccctcg ggagctccaa 180
atcgtccgta ccctggacca caagaacatc atccaggtgt atgagatgct ggagtctgcc 240
gacgggaaaa tctgcctggt gatggagctc gctgagggag gggatgtctt tgactgcgtg 300
ctgaatgggg ggccactgcc tgaaagccgg gccaaggccc tcttccgtca gatggttgag 360
gccatccgct actgccatgg ctgtggtgtg gcccaccggg acctcaaatg tgagaacgcc 420
ttgttgcagg gcttcaacct gaagctgact gactttggct ttgccaaggt gttgcccaag 480
tcacaccggg agctgagcca gaccttctgc ggcagtacag cctatgctgc ccccgaggtg 540
ctgcagggca ttccccacga tagcaaaaaa ggtgatgtct ggagcatggg tgtggtcctg 600
tatgtcatgc tctgtgccag cctacctttt gacgacacag acatccccaa gatgctgtgg 660
cagcagcaga agggggtgtc cttccccact catctgagca tctcggccga ttgccaggac 720
ctgctcaaga ggctcctgga acccgatatg atcctccggc cttcaattga agaagttagt 780
tggcatccat ggctagcaag cacttgataa aagcaatggc aagtgctctc caataaagta 840
gggggagaaa gcaaacccaa aaacccgctt ctaaaatggt gatatatatt ttacgcttta 900
agtttactta tcctaaaact tacctacatc taccccagcc ttactactac tctttccttt 960
tagagatctt catggaatca aagggcctca ttcagacttc ctttttttt ttaagagtct 1020
tgctctgtcg cccaggctgg aatgcagtgg cacgattcca gttcactgca actctgcttc 1080
ccaggttcaa gcgattctcc tgcctcagcc tccccagtag ctggctttcc agcacac 1137

<210> 33
<211> 3365
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1797506CB1

<400> 33
atgagaaggg cggggatcgg cgaggactcc aggctggggt tgcaggccca gccaggggcg 60
gagccttctc cgggtcgggc ggggacagag cgctcccttg gaggcaccca gggacctggc 120
cagccgtgca gctgcccagg cgctatggcg agtgcggtca gggggtcgag gccgtggccc 180
cggctggggc tccagctcca gttcgcggcg ctgctgctcg ggacgctgag tccacaggtt 240
catactctca ggccagagaa cctcctgctg gtgtccacct tggatggaag tctccacgca 300

ctaagcaagc agacagggga cctgaagtgg actctgaggg atgatcccgt catcgaagga 360
ccaatgtacg tcacagaaat ggcctttctc tctgacccag cagatggcag cctgtacatc 420
ttggggaccc aaaaacaaca gggattaatg aaactgccat tcaccatccc tgagctggtt 480
catgcctctc cctgccgcag ctctgatggg gtcttctaca caggccggaa gcaggatgcc 540
tggtttgtgg tggaccctga gtcaggggag acccagatga cactgaccac agagggtccc 600
tccacccccc gcctctacat tggccgaaca cagtatacgg tcaccatgca tgacccaaga 660
gccccagccc tgcgctggaa caccacctac cgccgctact cagcgccccc catggatggc 720
tcacctggga aatacatgag ccacctggcg tcctgcggga tgggcctgct gctcactgtg 780
gacccaggaa gcgggacggt gctgtggaca caggacctgg gcgtgcctgt gatgggcgtc 840
tacacctggc accaggacgg cctgcgccag ctgccgcatc tcacgctggc tcgagacact 900
ctgcatttcc tcgccctccg ctggggccac atccgactgc ctgcctcagg cccccgggac 960
acagccaccc tcttctctac cttggacacc cagctgctaa tgacgctgta tgtggggaag 1020
gatgaaactg gcttctatgt ctctaaagca ctggtccaca caggagtggc cctggtgcct 1080
cgtggactga ccctggcccc cgcagatggc cccaccacag atgaggtgac actccaagtc 1140
tcaggagagc gagagggctc acccagcact gctgttagat acccctcagg cagtgtggcc 1200
ctcccaagcc agtggctgct cattggacac cacgagctac ccccagtcct gcacaccacc 1260
atgctgaggg tccatcccac cctggggagt ggaactgcag agacaagacc tccagagaat 1320
acccaggccc cagccttctt cttggagcta ttgagcctga gccgagagaa actttgggac 1380
tccgagctgc atccagaaga aaaaactcca gactcttact tggggctggg accccaagac 1440
ctgctggcag ctagcctcac tgctgtcctc ctgggagggt ggattctctt tgtgatgagg 1500
cagcagcagg agacccccct ggcacctgca gactttgctc acatctccca ggatgcccag 1560
tccctgcact cgggggccag ccggaggagc cagaagaggc ttcagagtcc ctcacctgag 1620
tcaccaccct cctctccccc agctgagcaa ctcaccgtag tggggaagat ttccttcaat 1680
cccaaggacg tgctgggccg cggggcaggc gggactttcg ttttcagggg acagtttgag 1740
ggacgggcag tggctgtcaa gcggctcctc cgcgagtgct ttggcctggt tcggcgggaa 1800
gttcaactgc tgcaggagtc tgacaggcac cccaacgtgc tccgctactt ctgcaccgag 1860
cggggacccc agttccacta cattgccctg gagctctgcc gggcctcctt gcaggagtac 1920
gtagaaaacc cggacctgga tcgcgggggt ctggagcccg aggtcgtgct gcagcagctg 1980
atgtctggcc tggcccacct gcactcttta cacatagtgc accgggacct gaagccagga 2040
aatattctca tcaccgggcc tgacagccag ggcctgggca gagtggtgct ctcagacttc 2100
ggcctctgca agaagctgcc tgctggccgc tgtagcttca gcctccactc cggcatcccc 2160
ggcacggaag gctggatggc gcccgagctt ctgcagctcc tgccaccaga cagtcctacc 2220
agcgctgtgg acatcttctc tgcaggctgc gtgttctact acgtgctttc tggtggcagc 2280
cacccctttg gagacagtct ttatcgccag gcaaacatcc tcacaggggc tccctgtctg 2340
gctcacctgg aggaagaggt ccacgacaag gtggttgccc gggacctggt tggagccatg 2400
ttgagcccac tgccgcagcc acgcccctct gccccccagg tgctggccca ccccttcttt 2460
tggagcagag ccaagcaact ccagttcttc caggacgtca gtgactggct ggagaaggag 2520
tccgagcagg agcccctggt gagggcactg gaggcgggag gctgcgcagt ggtccgggac 2580
aactggcacg agcacatctc catgccgctg cagacagatc tgagaaagtt ccggtcctat 2640
aaggggacat cagtgcgaga cctgctccgt gctgtgagga acaagaagca ccactacagg 2700
gagctcccag ttgaggtgcg acaggcactc ggccaagtcc ctgatggctt cgtccagtac 2760
ttcacaaacc gcttcccacg gctgctcctc cacacgcacc gagccatgag gagctgcgcc 2820
tctgagagcc tcttcctgcc ctactacccg ccagactcag aggccaggag gccatgccct 2880
ggggccacag ggaggtgagg tgggctggat gccacacaga tggtctccgt gctggctcac 2940
tgaagagctg agcctgtggc tggcctcaga atcaggctgg gtgcagtggc tcacacctgt 3000
aatcccagca ttttgggagg ctgagtgaga ggatcacttg agctcaggag ttcgagacca 3060
gcctggccaa catggcaaca ccccatttct acaaaaaatt tgtaaaatta gccaggcatg 3120
gtggcgcacg cctgtagtcc cagctgcttg ggaggctgag gtgggagaat cacttgagcc 3180
caggagttcg aggctgcagt gagccaggat catgccactg cactccagcc tggtccacag 3240
agagacactg tcacccccct tcccccacaa gactggcaga ggctgggcag cctggggctg 3300
atgaagcaga gatgttcgct ggatcccagc tcctggcaca ctgtaaggaa atacaacgaa 3360
gaggt 3365

<210> 34
<211> 2049
<212> DNA

<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1851973CB1

<400> 34
gcgttctttc ccgcggaagt agttgacatt tacaaggagc agcgccccca aaggtcttta 60
gctgtttttt aaggggagaa cagcctttac cctctttgga ctttttcttc gttttttttt 120
tttttggaga cggagtttcg ttctttcgcc caggctggcg tacagtggcg cgatctcggc 180
tcactgcaac ctctgctccc cgggttcaag cgattctcct gcctcagcct ccggagtagc 240
tgggattaca ggtgcccgcc accacgcccg gctgatttcc tcttaagact ttctacagct 300
tccttatgaa atcttctgac tgggccttga gcaataaggt cttttgctac aatttagtgc 360
tcttttcctc acactaaatc gaaaactctc cctgttggtc ctgatctgtt tcagtcaggc 420
aaattacatc ctgggaaaac gtcagatgac aggggaggcc actcgcttcc tgctcatcca 480
gtttcgacac tttctgtgct ttcattagct tccagacctc agccctggcc ctcgctttac 540
tgtacagtca gaactggttt ctacgcctcg cgagggtggg aggtcgtgta tgggaggagg 600
accgcttccc accagcctcg ttgggaagcc aggagaaatc tcttcaaatc ctgcgattca 660
gagtcaagtc ccagtcgtcc tttttctggt cggcccagaa ctgtttgtgc ctcctccctc 720
atgaggaatg atgtcagtgg ggccgcggtc gccgcccacg aagagtgtaa ggctgcgaag 780
tcggggcttt cccgacgccc cctccgtccg cgtctgcgta ggggaggtga cgagggcggg 840
gcgcggcggc ggggtgacgt cacggccgcg cgcggcgtgg gcggagcctc actttgaacc 900
cagttggcgg gaatggctgc tcgcggaggg gcagtgtacg cggggccgct gtaggctgtc 960
cagcgatgga tcccaccgcg ggaagcaaga aggagcctgg aggaggcgcg gcgactgagg 1020
agggcgtgaa taggatcgca gtgccaaaac cgccctccat tgaggaattc agcatagtga 1080
agcccattag ccggggcgcc ttcgggaaag tgtatctggg gcagaaaggc ggcaaattgt 1140
atgcagtaaa ggttgttaaa aaagcagaca tgatcaacaa aaatatgact catcaggtcc 1200
aagctgagag agatgcactg gcactaagca aaagcccatt cattgtccat ttgtattatt 1260
cactgcagtc tgcaaacaat gtctacttgg taatggaata tcttattggg ggagatgtca 1320
agtctctcct acatatatat ggttattttg atgaagagat ggctgtgaaa tatatttctg 1380
aagtagcact ggctctagac taccttcaca gacatggaat catccacagg gacttgaaac 1440
cggacaatat gcttatttct aatgagggtc atattaaact gacggatttt ggcctttcaa 1500
aagttacttt gaatagagat attaatatga tggatatcct tacaacacca tcaatggcaa 1560
aacctagaca agattattca agaaccccag gacaagtgtt atcgcttatc agctcgttgg 1620
gatttaacac accaattgca gaaaaaaatc aagaccctgc aaacatcctt tcagcctgtc 1680
tgtctgaaac atcacagctt tctcaaggac tcgtatgccc tatgtctgta gatcaaaagg 1740
acactacgcc ttattctagc aaattactaa aatcatgtct tgaaacagtt gcctccaacc 1800
caggaatgcc tgtgaagtgt ctaacttcta atttactcca gtctaggaaa aggctggcca 1860
catccagtgc cagtagtcaa tcccacacct tcatatccag tgtggaatca gaatgccaca 1920
gcagtcccaa atgggaaaaa gattgccagg tttgagggac atttatctta atgaaaatca 1980
attatgtatg tcaaatgaat gtgagaaata ttataccttt tcatataaat tccataaaga 2040
aatgaaagg 2049

<210> 35
<211> 2962
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474604CB1

<400> 35
accactcgtg cccactgatt atcagcatct tttactttca ccagcgtttc tgggtgtcca 60
cctcctgcgg ccgcggcgga aaacatgacg aaaagcgagg agcagcagcc tctgagtttg 120
caaaaagcct tacagcagtg cgaactggtc caaaacatga tagacttgag catctccaac 180

ctggaagggc ttaggaccaa atgtgctacc tccaacgacc tcacacaaaa agaaatccgg 240
accctggaga gcaagctggt gaagtacttc agccggcagc tgtcctgcaa aaagaaggta 300
gccttgcagg agcgcaacgc ggagctggac ggcttccccc agctacggca ctggttccga 360
atcgtcgatg tgcgcaagga ggtcctggag gaaatctccc ccggccagct gagcctggag 420
gacctcttgg agatgacgga tgaacaggtg tgcgagactg tggagaaata cggagccaac 480
cgggaggagt gtgcccgcct caacgcctcc ctctcctgcc tcaggaatgt ccacatgtca 540
ggaggcaacc tttccaaaca agactggacc atccagtggc ccaccacaga gacggggaag 600
gagaacaatc ccgtgtgccc cccggagccc accccgtgga tccgcaccca tctctcccag 660
agccccaggg tcccgtccaa gtgcgtccag cactattgtc acaccagccc cactcccggg 720
gcccctgtgt acacccacgt ggacaggctt accgtggacg cctacccggg cttgtgcccg 780
cccccgccac tggagtcggg ccaccgttcc ctgcccccat cgccccggca gcggcacgcg 840
gtccgcaccc cgccgcgcac ccccaacatc gtcaccaccg tgaccccgcc gggcacgccg 900
cccatgagga agaagaacaa gctgaagccc ccggggaccc caccgccctc ctcccgaaaa 960
ctgatacact tgatcccggg attcaccgcg ctgcatcgga gcaaatccca cgagttccag 1020
ctggggcacc gcgtggacga ggcccacacg cccaaagcca agaagaagag caaacccttg 1080
aacctcaaga tccacagcag cgtaggcagc tgcgagaaca tcccctctca gcagcgctcc 1140
ccgctgctgt ccgagcgctc cctccgctcc ttctttgtgg gacacgcacc tttcctgcct 1200
tccacccctc ctgttcacac tgaggccaac ttctctgcaa acacactgtc agtgccacgc 1260
tggtccccgc agatccctcg cagagatctt ggcaactcca tcaagcacag gttttccacc 1320
aagtactgga tgtctcagac gtgcacagtc tgtgggaaag ggatgctttt tggcctcaag 1380
tgtaaaaact gcaagttaaa gtgccacaac aaatgcacca aagaagcccc accctgtcat 1440
cttctgatca tccaccgagg agatccagca aggttagtcc ggacagagtc cgttccgtgt 1500
gacatcaaca accctctacg gaagccacct cgctattcag acctgcacat cagtcagacg 1560
ctccccaaaa ccaacaaaat caacaaggac cacatccctg tcccttacca gccagactcc 1620
agcagcaacc cctcctccac gacgtcctcc acgccctcct cgccagcacc ccccctccct 1680
cctagtgcca cgccgccttc tcccctacac ccttccccac agtgcacacg gcagcagaag 1740
aacttcaacc tgccagcatc ccactactac aaatacaagc agcagttcat cttcccagat 1800
gtggtgccgg tgccggagac gccgacccgg gcgccccagg tcatcctgca tccggtgacc 1860
tcgaatccaa tcttggaagg aaatccatta cttcaaattg aagtggagcc aacgtcggag 1920
aatgaagagg tccatgatga ggccgaagag tcagaggatg acttcgagga gatgaacctg 1980
tccctcctct cggcccggag cttcccacgc aaggccagcc agaccagcat cttccttcag 2040
gagtgggaca tccccttga gcagctggag atcggcgagc tcattggaaa gggccgcttt 2100
gggcaagtgt accacggccg ctggcatggc gaggtggcca tccggctgat tgacattgag 2160
agggacaacg aggaccagct caaggccttc aagcgggagg tgatggccta caggcagaca 2220
cggcatgaga acgtggtgct tttcatgggt gcctgcatga gcccgcctca cctggccatc 2280
atcaccagcc tctgtaaggg acggacgctc tattccgttg tgagggatgc caaaatcgtt 2340
ttggatgtca acaaaaccag gcagattgct caagaaattg tgaagggcat gggctacctc 2400
cacgccaagg gaatcctaca caaggacctc aagtcaaaga acgtcttcta tgacaacggc 2460
aaagtggtca tcacggactt tggactcttc agcatttctg gggtgctgca ggctggcagg 2520
cgggaggaca aactgcgcat ccagaatggc tggctatgcc acctggcacc agagatcatc 2580
cgccagctgt cccccgacac agaggaggat aagctccct tctccaagca ctctgacgtc 2640
tttgcccttg gcacaatctg gtatgaactc cacgccaggg aatggccttt caagacccaa 2700
ccagcagagg caataatctg gcaaatgggc acaggcatga aacccaacct cagccagatt 2760
ggcatgggaa aagaaatctc ggacattctt ctcttctgct gggcctttga acaagaagag 2820
agacctacct tcaccaagct catggacatg ctggagaaac tgccaaagcg aaaccgtcgc 2880
ctgtctcacc ctggacattt ctggaagtct gcagagctgt gacctttgga catcgggacg 2940
gcgcccagct gcctgggctc cc 2962

<210> 36
<211> 3112
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7474721CB1

<400> 36
ggggggcattg ctcagcggtg ctaggctggc gcggcttgag ccgccgccgg actgacagct 60
cggtctgcgg accatggaga cctgcgccgg tccacacccg ctgcgcctct tcctctgccg 120
gatgcagctc tgtctcgcgc tgcttttggg accctggcgg cctgggaccg ccgaggaagt 180
tatcctcctg gattccaaag cctcccaggc cgagctgggc tggactgcac tgccaagtaa 240
tgggtgggag gagatcagcg gcgtggatga acacgaccgt cccatccgca cgtaccaagt 300
gtgcaatgtg ctggagccca accaggacaa ctggctgcag actggctgga taagccgtgg 360
ccgcgggcag cgcatcttcg tggaactgca gttcacactc cgtgactgca gcagcatccc 420
tggcgccgcg ggtacctgca aggagacctt caacgtctac tacctggaaa ctgaggccga 480
cctgggccgt gggcgtcccc gcctaggcgg cagccggccc cgcaaaatcg acacgatcgc 540
ggcggacgag agcttcacgc agggcgacct gggtgagcgc aagatgaagc tgaacacaga 600
ggtgcgcgag atcggaccgc tcagccggcg gggtttccac ctggcctttc aggacgtggg 660
cgcatgcgtg gcgcttgtct cggtgcgcgt ctactacaag cagtgccgcg ccaccgtgcg 720
gggcctggcc acgttcccag ccaccgcagc cgagagcgcc ttctccacac tggtggaagt 780
ggccggaacg tgcgtggcgc actcggaagg ggagcctggc agccccccac gcatgcactg 840
cggcgccgac ggcgagtggc tggtgcctgt gggccgctgc agctgcagcg cgggattcca 900
ggagcgtggt gacatctgcg aagcctgtcc cccagggttt tacaaggtgt ccccgcggcg 960
aagggtctgc tcaccgtgcc cagagcacag ccgggccctg gaaaacgcct ccaccttctg 1020
cgtgtgccag gacagctatg cgcgctcacc caccgacccg ccctcggctt cctgcacccg 1080
tgggccgccg tcggcgccgc gggacctgca gtacagcctg agccgctcgc cgctggtgct 1140
gcgactgcgc tggctgccgc cggccgactc gggaggccgc tcggacgtca cctactcgct 1200
gctgtgcctg cgctgcggcc gcgagggccc ggcgggcgcc tgcgagccgt gcgggccgcg 1260
cgtggccttc ctaccgcgcc aggcagggct gcgggagcga gccgccacgc tgctgcacct 1320
gcggcccggg gcgcgctaca ccgtgcgcgt ggccgtgctc aacggcgtct cgggcccggc 1380
ggccgccctg gttccggttg gcgctgtttc aattaaccct ggtacggttg gccctgttcc 1440
tgttgccggg gttatccgcg accgagtgga accccagagc gtgtccctgt cgtggcggga 1500
gcccatccct gccggagccc ctggggccaa tgacacggag tacgagatcc gatactacga 1560
gaaggtgcag agtgagcaga cttactccat ggtgaagaca ggggcgccca cagtcaccgt 1620
caccaacctg aagccggcta cccgctacgt ctttcagatc cgggccgctt ccccggggcc 1680
atcctgggag gcccagagtt ttaaccccag cattgaagta cagaccctgg gggaggctgc 1740
ctcagggtcc agggaccaga gccccgccat tgtcgtcacc gtagtgacca tctcggccct 1800
cctcgtcctg ggctccgtga tgagtgtgct ggccatttgg aggaggccct gcagctatgg 1860
caaaggagga ggggatgccc atgatgaaga ggagctgtat ttccacttca aagtcccaac 1920
acgtcgcaca ttcctggacc cccagagctg tggggacctg ctgcaggctg tgcatctgtt 1980
cgccaaggaa ctggatgcga aaagcgtcac gctggagagg agccttggag gagggcggtt 2040
tggggagctg tgctgtggct gcttgcagct ccccggtcgc caggagctgc tcgtagccgt 2100
gcacatgctg agggacagcg cctccgactc acagaggctc ggcttcctgg ccgaggccct 2160
cacgctgggc cagtttgacc atagccacat cgtgcggctg gagggcgttg ttacccgagg 2220
aagcaccttg atgattgtca ccgagtacat gagccatggg gccctggacg gcttcctcag 2280
gcggcacgag gggcagctgg tggctgggca actgatgggg ttgctgcctg ggctggcatc 2340
agccatgaag tatctgtcag agatgggcta cgttcaccgg ggcctggcag ctcgccatgt 2400
gctggtcagc agcgaccttg tctgcaagat ctctggcttc gggcggggcc cccgggaccg 2460
atcagaggct gtctacacca ctatgagtgg ccggagccca gcgctatggg ccgctcccga 2520
gacacttcag tttggccact tcagctctgc cagtgacgtg tggagcttcg gcatcatcat 2580
gtgggaggtg atggcctttg gggagcggcc ttactgggac atgtctggcc aagacgtgat 2640
caaggctgtg gaggatggct tccggctgcc acccccccagg aactgtccta accttctgca 2700
ccgactaatg ctcgactgct ggcagaagga cccaggtgag cggcccaggt tctcccagat 2760
ccacagcatc ctgagcaaga tggtgcagga cccagagccc cccaagtgtg ccctgactac 2820
ctgtcccagg cctcccaccc cactagcgga ccgtgccttc tccaccttcc cctcctttgg 2880
ctctgtgggc gcgtggctgg aggccctgga cctgtgccgc tacaaggaca gcttcgcggc 2940
tgctggctat gggagcctgg aggccgtggc cgagatgact gcccagaggg acctggtgag 3000
cctaggcatc tctttggctg aacatcgaga ggccctcctc agcgggatca gcgccctgca 3060
ggcacgagtg ctccagctgc agggccaggg ggtgcaggtg tgagtggacc cc 3112

<210> 37
<211> 3650

<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7478815CB1

<400> 37
caacactcca gagtcgtagg agtgaacact gcacaggaat ctctgcccat ctcaggagaa 60
accaaacttg gggaaaatgt ttgcggtcca cttgatggca ttttacttca gcaagctgaa 120
ggaggaccag atcaagaagg tggacaggtt cctgtatcac atgcggctct ccgatgacac 180
ccttttggac atcatgaggc ggttccgggc tgagatggag aagggcctgg caaaggacac 240
caaccccacg gctgcagtga agatgttgcc caccttcgtc agggccattc ccgatggttc 300
cgaaaatggg gagttccttt ccctggatct cggagggtcc aagttccgag tgctgaaggt 360
gcaagtcgct gaagagggga agcgacacgt gcagatggag agtcagttct acccaacgcc 420
caatgaaatc atccgcggga acggcacaga gctgtttgaa tatgtagctg actgtctggc 480
agatttcatg aagaccaaag atttaaagca taagaaattg ccccttggcc taacttttc 540
tttcccctgt cgacagacta aactggaaga gggtgtccta ctttcgtgga caaaaaagtt 600
taaggcacga ggagttcagg acacggatgt ggtgagccgt ctgaccaaag ccatgagaag 660
acacaaggac atggacgtgg acatcctggc cctggtcaat gacaccgtgg ggaccatgat 720
gacctgtgcc tatgacgacc cctactgcga agttggtgtc atcatcggaa ctggcaccaa 780
tgcgtgttac atggaggaca tgagcaacat tgacctggtg gagggcgacg agggcaggat 840
gtgcatcaac acagagtggg gggccttcgg ggacgacggg gccctggagg acattcgcac 900
tgagttcgac agggagctgg acctcggctc tctcaaccca ggaaagcaac tgttcgagaa 960
gatgatcagt ggcctgtacc tgggggagct tgtcaggctt atcttgctga agatggccaa 1020
ggctggcctc ctgtttggtg gtgagaaatc ttctgctctc cacactaagg gcaagatcga 1080
aacacggcac gtggctgcca tggagaagta taaagaaggc cttgctaata caagagagat 1140
cctggtggac ctgggtctgg aaccgtctga ggctgactgc attgccgtcc agcatgtctg 1200
taccatcgtc tccttccgct cggccaatct ctgtgcagca gctctggcgg ccatcctgac 1260
acgcctccgg gagaacaaga aggtggaacg gctccggacc acagtgggca tggacggcac 1320
cctctacaag atacaccctc agtacccaaa acgcctgcac aaggtggtga ggaaactggt 1380
cccaagctgt gatgtccgct tcctcctgtc agagagtggc agcaccaagg gggccgccat 1440
ggtgaccgcg gtggcctccc gcgtgcaggc ccagcggaag cagatcgaca gggtgctggc 1500
tttgttccag ctgacccgag agcagctcgt ggacgtgcag gccaagatgc gggctgagct 1560
ggagtatggg ctgaagaaga agagccacgg gctggccacg gtcaggatgc tgcccaccta 1620
cgtctgcggg ctgccggacg gcacagagaa aggaaagttt ctcgccctgg atcttggggg 1680
aaccaacttc cgggtcctcc tggtgaagat cagaagtgga cggaggtcag tgcgaatgta 1740
caacaagatc ttcgccatcc ccctggagat catgcagggc actggtgagg agctctttga 1800
tcacattgtg cagtgcatcg ccgacttcct ggactacatg ggcctcaagg gagcctccct 1860
acctttgggc ttcacattct catttccctg caggcagatg agcattgaca agggaacact 1920
catagggtgg accaaaggtt tcaaggccac tgactgtgaa ggggaggacg tggtggacat 1980
gctcagggaa gccatcaaga ggagaaacga gtttgacctg gacattgttg cagtcgtgaa 2040
tgatacagtg gggaccatga tgacctgtgg ctatgaagat cctaattgtg agattggcct 2100
gattgcagga acaggcagca acatgtgcta catggaggac atgaggaaca tcgagatggt 2160
ggaggggggt gaagggaaga tgtgcatcaa tacagagtgg ggaggatttg gagacaatgg 2220
ctgcatagat gacatccgga cccgatacga cacggaggtg gatgaggggt ccttgaatcc 2280
tggcaagcag agatacgaga aaatgaccag tgggatgtac ttgggggaga ttgtgcggca 2340
gatcctgatc gacctgacca agcagggtct cctcttccga gggcagattt cagagcgtct 2400
ccggaccagg ggcatcttcg aaaccaagtt cctgtcccag atcgaaagcg atcggctggc 2460
ccttctccag gtcaggagga ttctgcagca gctgggcctg gacagcacgt gtgaggacag 2520
catcgtggtg aaggaggtgt gcggagccgt gtcccggcgg gcggcccagc tctgcggtgc 2580
tggcctggcc gctatagtgg aaaaaaggag agaagaccag gggctagagc acctgaggat 2640
cactgtgggt gtggacggca ccctgtacaa gctgcaccct cacttttcta gaatattgca 2700
ggaaactgtg aaggaactag cccctcgatg tgatgtgaca ttcatgctgt cagaagatgg 2760
cagtggaaaa ggggcagcac tgatcactgc tgtggccaag aggttacagc aggcacagaa 2820
ggagaactag gaacccctgg gattggacct gatgcatctt ggatactgaa cagcttttcc 2880

tctggcagat cagttggtca gagaccaatg ggcaccctcc tggctgacct caccttctgg 2940
atggccgaaa gagaacccca ggttctcggg tactcttagt atcttgtact ggatttgcag 3000
tgacattaca tgacatctct atttggtata tttgggccaa aatgggccaa cttatgaaat 3060
caaagtgtct gtcctgagag atccccttc aacacattgt tcaggtgagg cttgagctgt 3120
caattctcta tggctttcag tcttgtggct gcgggacttg gaaatatata gaatctgccc 3180
atgtggctgg caggctgttt ccccattggg atgcttaagc catctcttat aggggattgg 3240
accctgtact tgtggatgaa cattggagag caagaggaac tcacgttatg aactaggggg 3300
atctcatcta acttgtcctt aacttgccat gttgacttca aacctgttaa gagaacaaag 3360
actttgaagt atccagcccc agggtgcaga gaggttgatt gccagggagc actgcaggaa 3420
tcattgcatg cttaaagcga gttatgtcag caccctgtag gattttgttc cttattaagt 3480
gtgtgccatg tggtggggtg ctgtctgggg catctgtttt tcattttgcc tgtggtttgt 3540
gttgcaggtg ttgatagttg ttttaaggat tgttaggtat aggaaatcca gtaaattaat 3600
aaaaaaattt tgattttcca ataaaaaaaa aaaaaaaaaa aaaaaaaaaa 3650

<210> 38
<211> 7789
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477141CB1

<400> 38
cacaccctga aagccggtcc ctggccgtgc tggcccccct gcaggacgtg gacgtggggg 60
ccggggagat ggcgctgttt gagtgcctgg tggcggggcc cactgacgtg gaggtggatt 120
ggctgtgccg tggccgcctg ctgcagcctg cactgctcaa atgcaagatg catttcgatg 180
gccgcaaatg caagctgcta cttacatctg tacatgagga cgacagtggc gtctacacct 240
gcaagctcag cacggccaaa gatgagctga cctgcagtgc ccggctgacc gtgcggccct 300
cgttggcacc cctgttcaca cggctgctgg aagatgtgga ggtgttggag ggccgagctg 360
cccgtttcga ctgcaagatc agtggcaccc cgccccctgt tgttacctgg actcattttg 420
gctgccccat ggaggagagt gagaacttgc ggctgcggca ggacgggggt ctgcactcac 480
tgcacattgc ccatgtgggc agcgaggacg aggggctcta tgcggtcagt gctgttaaca 540
cccatggcca ggcccactgc tcagcccagc tgtatgtaga agagccccgg acagccgcct 600
caggccccag ctcgaagctg gagaagatgc catccattcc cgaggagcca gagcagggtg 660
agctggagcg gctgtccatt cccgacttcc tgcggccact gcaggacctg gaggtgggac 720
tggccaagga ggccatgcta gagtgccagg tgaccggcct gccctacccc accatcagct 780
ggttccacaa tggccaccgc atccagagca gcgacgaccg gcgcatgaca cagtacaggg 840
atgtccatcg cttggtgttc cctgccgtgg ggcctcagca cgccggtgtc tacaagagcg 900
tcattgccaa caagctgggc aaagctgcct gctatgccca cctgtatgtc acagatgtgg 960
tcccaggccc tccagatggc gccccgcagg tggtggctgt gacggggagg atggtcacac 1020
tcacatggaa ccccccccagg agtctggaca tggccatcga cccggactcc ctgacgtaca 1080
cagtgcagca ccaggtgctg ggctcggacc agtggacggc actggtcaca ggcctgcggg 1140
agccagggtg ggcagccaca gggctgcgta agggggtcca gcacatcttc cgggtcctca 1200
gcaccactgt caagagcagc agcaagccct cacccccttc tgagcctgtg cagctgctgg 1260
agcacggccc aaccctggag gaggcccctg ccatgctgga caaaccagac atcgtgtatg 1320
tggtggaggg acagcctgcc agcgtcaccg tcacattcaa ccatgtggag gcccaggtcg 1380
tctggaggag ctgccgaggg gccctcctag aggcacgggc cggtgtgtac gagctgagcc 1440
agccagatga tgaccagtac tgtcttcgga tctgccgggt gagccgccgg gacatggggg 1500
ccctcacctg caccgcccga aaccgtcacg gcacacagac ctgctcggtc acattggagc 1560
tggcagaggc ccctcggttt gagtccatca tggaggacgt ggaggtgggg gctggggaaa 1620
ctgctcgctt tgcggtggtg gtcgagggaa aaccactgcc ggacatcatg tggtacaagg 1680
acgaggtgct gctgaccgag agcagccatg tgagcttcgt gtacgaggag aatgagtgct 1740
ccctggtggt gctcagcacg ggggcccagg atggaggcgt ctacacctgc accgcccaga 1800
acctggcggg tgaggtctcc tgcaaagcag agttggctgt gcattcagct cagacagcta 1860
tggaggtcga gggggtcggg gaggatgagg accatcgagg aaggagactc agcgactttt 1920

atgacatcca ccaggagatc ggcaggggtg ctttctccta cttgcggcgc atagtggagc 1980
gtagctccgg cctggagttt gcggccaagt tcatccccag ccaggccaag ccaaaggcat 2040
cagcgcgtcg ggaggcccgg ctgctggcca ggctccagca cgactgtgtc ctctacttcc 2100
atgaggcctt cgagaggcgc cggggactgg tcattgtcac cgagctctgc acagaggagc 2160
tgctggagcg aatcgccagg aaacccaccg tgtgtgagtc tgagatccgg gcctatatgc 2220
ggcaggtgct agagggaata cactacctgc accagagcca cgtgctgcac ctcgatgtca 2280
agcctgagaa cctgctggtg tgggatggtg ctgcgggcga gcagcaggtg cggatctgtg 2340
actttgggaa tgcccaggag ctgactccag gagagcccca gtactgccag tatggcacac 2400
ctgagtttgt agcacccgag attgtcaatc agagccccgt gtctggagtc actgacatct 2460
ggcctgtggg tgttgttgcc ttcctctgtc tgacaggaat ctccccgttt gttggggaaa 2520
atgaccggac aacattgatg aacatccgaa actacaacgt ggccttcgag gagaccacat 2580
tcctgagcct gagcagggag gcccggggct tcctcatcaa agtgttggtg caggaccggc 2640
tgagacctac cgcagaagag accctagaac atccttggtt caaaactcag gcaaagggcg 2700
cagaggtgag cacggatcac ctgaagctat tcctctcccg gcggaggtgg cagcgctccc 2760
agatcagcta caaatgccac ctggtgctgc gccccatccc cgagctgctg cgggcccccc 2820
cagagcgggt gtgggtgacc atgcccagaa ggccaccccc cagtgggggg ctctcatcct 2880
cctcggattc tgaagaggaa gagctggaag agctgccctc agtgccccgc ccactgcagc 2940
ccgagttctc tggctcccgg gtgtccctca cagacattcc cactgaggat gaggccctgg 3000
ggaccccaga gactggggct gccacccccа tggactggca ggagcaggga agggctccct 3060
ctcaggacca ggaggctccc agcccagagg ccctcccctc cccaggccag gagcccgcag 3120
ctggggctag ccccaggcgg ggagagctcc gcaggggcag ctcggctgag agcgccctgc 3180
cccgggccgg gccgcgggag ctgggccggg gcctgcacaa ggcggcgtct gtggagctgc 3240
cgcagcgccg gagccccggc ccgggagcca cccgcctggc ccggggaggc ctgggtgagg 3300
gcgagtatgc ccagaggctg caggccctgc gccagcggct gctgcgggga ggccccgagg 3360
atggcaaggt cagcggcctc aggggtcccc tgctggagag cctgggggggc cgtgctcggg 3420
acccccggat ggcacgagct gcctccagcg aggcagcgcc ccaccaccag cccccactcg 3480
agaaccgggg cctgcaaaag agcagcagct tctcccaggg tgaggcggag ccccggggcc 3540
ggcaccgccg agcgggggcg cccctcgaga tccccgtggc caggcttggg gcccgtaggc 3600
tacaggagtc tccttccctg tctgccctca gcgaggccca gccatccagc cctgcacggc 3660
ccagcgcccc caaacccagt acccctaagt ctgcagaacc ttctgccacc acacctagtg 3720
atgctccgca gccccccgca ccccagcctg cccaagacaa ggctccagag cccaggccag 3780
aaccagtccg agcctccaag cctgcaccac ccccccaggc cctgcaaacc ctagcgctgc 3840
ccctcacacc ctatgctcag atcattcagt ccctccagct gtcaggccac gcccagggcc 3900
cctcgcaggg ccctgccgcg ccgccttcag agcccaagcc ccacgctgct gtctttgcca 3960
gggtggcctc cccacctccg ggagcccccg agaagcgcgt gccctcagcc gggggtcccc 4020
cggtgctagc cgagaaagcc cgagttccca cggtgccccc caggccaggc agcagtctca 4080
gtagcagcat cgaaaacttg gagtcggagg ccgtgttcga ggccaagttc aagcgcagcc 4140
gcgagtcgcc cctgtcgctg gggctgcggc tgctgagccg ttcgcgctcg gaggagcgcg 4200
gcccccttccg tggggccgag gaggaggatg gcatataccg gcccagcccg gcgggggaccc 4260
cgctggagct ggtgcgacgg cctgagcgct cacgctcggt gcaggacctc agggctgtcg 4320
gagagcctgg cctcgtccgc cgcctctcgc tgtcactgtc ccagcggctg cggcggaccc 4380
ctcccgcgca gcgccacccg gcctgggagg cccgcggcgg ggacggagag agctcggagg 4440
gcgggagctc ggcgcggggc tccccggtgc tggcgatgcg caggcggctg agcttcaccc 4500
tggagcggct gtccagccga ttgcagcgca gtggcagcag cgaggactcg gggggcgcgt 4560
cgggccgcag cacgccgctg ttcggacggc ttcgcagggc cacgtccgag ggcgagagtc 4620
tgcggcgcct tggccttccg cacaaccagt tggccgccca ggccggcgcc accacgcctt 4680
ccgccgagtc cctgggctcc gaggccagcg ccacgtcggg ctcctcagcc ccaggggaaa 4740
gccgaagccg gctccgctgg ggcttctctc ggccgcggaa ggacaagggg ttatcgccac 4800
caaacctctc tgccagcgtc caggaggagt tgggtcacca gtacgtgcgc agtgagtcag 4860
acttcccccc agtcttccac atcaaactca aggaccaggt gctgctggag ggggaggcag 4920
ccaccctgct ctgcctgcca gcggcctgcc ctgcaccgca catctcctgg atgaaagaca 4980
agaagtcctt gaggtcagag ccctcagtga tcatcgtgtc ctgcaaagat gggcggcagc 5040
tgctcagcat cccccgggcg ggcaagcggc acgccggtct ctatgagtgc tcggccacca 5100
acgtactggg cagcatcacc agctcctgta ccgtggctgt ggcccgagtc ccaggaaagc 5160
tagctcctcc agaggtaccc cagacctacc aggacacggc gctggtgctg tggaagccgg 5220
gagacagccg ggcaccttgc acgtatacgc tggagcggcg agtggatggg gagtctgtgt 5280

ggcaccctgt gagctcaggc atccccgact gttactacaa cgtgacccac ctgccagttg 5340
gcgtgactgt gaggttccgt gtggcctgtg ccaaccgtgc tgggcagggg cccttcagca 5400
actcttctga gaaggtcttt gtcaggggta ctcaagattc ttcagctgtg ccatctgctg 5460
cccaccaaga ggcccctgtc acctcaaggc cagccagggc ccggcctcct gactctccta 5520
cctcactggc cccaccccta gctcctgctg cccccacacc cccgtcagtc actgtcagcc 5580
cctcatctcc ccccacacct cctagccagg ccttgtcctc gctcaaggct gtgggtccac 5640
caccccaaac ccctccacga agacacaggg gcctgcaggc tgcccggcca gcggagccca 5700
ccctacccag tacccacgtc accccaagtg agcccaagcc tttcgtcctt gacactggga 5760
ccccgatccc agcctccact cctcaagggg ttaaaccagt gtcttcctct actcctgtgt 5820
atgtggtgac ttcctttgtg tctgcaccac cagcccctga gcccccagcc cctgagcccc 5880
ctcctgagcc taccaaggtg actgtgcaga gcctcagccc ggccaaggag gtggtcagct 5940
cccctgggag cagtccccga agctctccca ggcctgaggg taccactctt cgacagggtc 6000
cccctcagaa accctacacc ttcctggagg agaaagccag gggccgcttt ggtgttgtgc 6060
gagcgtgccg ggagaatgcc acggggcgaa cgttcgtggc caagatcgtg ccctatgctg 6120
ccgagggcaa gcggcgggtc ctgcaggagt acgaggtgct gcggaccctg caccacgagc 6180
ggatcatgtc cctgcacgag gcctacatca cccctcggta cctcgtgctc attgctgaga 6240
gctgtggcaa ccgggaactc ctctgtgggc tcagtgacag gttccggtat tctgaggatg 6300
acgtggccac ttacatggtg cagctgctac aaggcctgga ctacctccac ggccaccacg 6360
tgctccacct agacatcaag ccagacaacc tgctgctggc ccctgacaat gccctcaaga 6420
ttgtggactt tggcagtgcc cagccctaca acccccaggc ccttaggccc cttggccacc 6480
gcacgggcac gctggagttc atggctccgg agatggtgaa gggagaaccc atcggctctg 6540
ccacggacat ctggggagcg ggtgtgctca cttacattat gctcagtgga cgctccccgt 6600
tctatgagcc agacccccag gaaacggagg ctcggattgt gggggccgc tttgatgcct 6660
tccagctgta ccccaataca tcccagagcg ccaccctctt cttgcgaaag gttctctctg 6720
tacatccctg gagccggccc tccctgcagg actgcctggc ccacccatgg ttgcaggacg 6780
cctacctgat gaagctgcgc cgccagacgc tcaccttcac caccaaccgg ctcaaggagt 6840
tcctgggcga gcagcggcgg cgccgggctg aggctgccac ccgccacaag gtgctgctgc 6900
gctcctaccc tggcggcccc tagaggcacg gaccacagcc aggcctcggg cttcaactgg 6960
ggttcccacc aatgccacgg gacattccag ggcccacgct gagccaggcg ggcctggggc 7020
ttcggttacc accagcagca acatctggct gggctcttac ctcatagacc ttcaaggaca 7080
gagacccccag ggcctggacc tgatgccacc ccaggccaaa gccagagtgg gagacccatt 7140
ggtcaggctc agcagggtgg gaacaggcag agggacaaga ggggaatgga gaagtggaga 7200
ggaaaaggaa tcgagggaca ggaaggggga ggctctagga aggttctggg ttgggggtca 7260
gtgcatctca gggagaacca aggaaggtgg gcatggctgg agaggaggaa aaggaaggag 7320
ccccaggtgt cagggcagta ggctgggagt cagtgtggca aagcgggggc aggacacaga 7380
tacagtggca ggggcccagg gctgggacat gagagaaggc agcgaggcgg cagagggaga 7440
agagaggact caggtggagg tggggtgggt cagctgtcag catccctcag aggagaaatg 7500
tggagagctg gaggccagca gtcactcaca ctcgctctgt cctcctgtcc agtggataca 7560
gccctgggcg ctctgctggc ccaaggatgt ccccactgcc cctccatggc ctttggcctt 7620
cttcccattc atatttattt atttattgac ttttatgaag tttccccttc catccgatcc 7680
ctactgccca tgttgtcctg accatccctc ccagccatcc agctgtctgt ctgtctgcca 7740
caaggaaata aaaatggcaa gcagcataaa aaaaaaaaaa aaaaaaaaa 7789

<210> 39
<211> 1937
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2190612CB1

<400> 39
gtggtgtggc tgcagtggag agttcccaac aaggctacgc agaagaaccc ccttgactga 60
agcaatggag gggggtccag ctgtctgctg ccaggatcct cgggcagagc tggtagaacg 120
ggtggcagcc atcgatgtga ctcacttgga ggaggcagat ggtggcccag agcctactag 180

aaacggtgtg gacccccac cacgggccag agctgcctct gtgatccctg gcagtacttc 240
aagactgctc ccagcccggc ctagcctctc agccaggaag ctttccctac aggagcggcc 300
agcaggaagc tatctggagg cgcaggctgg gccttatgcc acggggcctg ccagccacat 360
ctccccccgg gcctggcgga ggcccaccat cgagtcccac cacgtggcca tctcagatgc 420
agaggactgc gtgcagctga accagtacaa gctgcagagt gagattggca agggtgccta 480
cggtgtggtg aggctggcct acaacgaaag tgaagacaga cactatgcaa tgaaagtcct 540
ttccaaaaag aagttactga agcagtatgg ctttccacgt cgccctcccc cgagagggtc 600
ccaggctgcc cagggaggac cagccaagca gctgctgccc ctggagcggg tgtaccagga 660
gattgccatc ctgaagaagc tggaccacgt gaatgtggtc aaactgatcg aggtcctgga 720
tgacccagct gaggacaacc tctatttggt gtttgacctc ctgagaaagg ggcccgtcat 780
ggaagtgccc tgtgacaagc ccttctcgga ggagcaagct cgcctctacc tgcgggacgt 840
catcctgggc ctcgagtact tgcactgcca gaagatcgtc cacagggaca tcaagccatc 900
caacctgctc ctgggggatg atgggcacgt gaagatcgcc gactttggcg tcagcaacca 960
gtttgagggg aacgacgctc agctgtccag cacggcggga accccagcat tcatggcccc 1020
cgaggccatt tctgattccg gccagagctt cagtgggaag gccttggatg tatgggccac 1080
tggcgtcacg ttgtactgct ttgtctatgg gaagtgcccg ttcatcgacg atttcatcct 1140
ggccctccac aggaagatca agaatgagcc cgtggtgttt cctgaggagc cagaaatcag 1200
cgaggagctc aaggacctga tcctgaagat gttagacaag aatcccgaga cgagaattgg 1260
ggtgccagac atcaagttgc acccttgggt gaccaagaac ggggaggagc cccttccttc 1320
ggaggaggag cactgcagcg tggtggaggt gacagaggag gaggttaaga actcagtcag 1380
gctcatcccc agctggacca cggtgatcct ggtgaagtcc atgctgagga agcgttcctt 1440
tgggaacccg tttgagcccc aagcacggag ggaagagcga tccatgtctg ctccaggaaa 1500
cctactggtg aaagaagggt ttggtgaagg gggcaagagc ccagagctcc ccggcgtcca 1560
ggaagacgag gctgcatcct gagcccctgc atgcacccag ggccacccgg cagcacactc 1620
atcccgcgcc tccagaggcc cacccctcat gcaacagccg cccccgcagg caggggggctg 1680
gggactgcag ccccactccc gcccctcccc catcgtgctg catgacctcc acgcacgcac 1740
gtccagggac agactggaat gtatgtcatt tggggtcttg ggggcagggc tcccacgagg 1800
ccatcctcct cttcttggac ctccttggcc tgagccattc tgtggggaaa ccgggtgccc 1860
atggagcctc agaaatgaca cccggctggt tggcatggcc tggggcagga ggcagaggca 1920
ggagaccaag atggcag 1937

<210> 40
<211> 5373
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 7477549CB1

<400> 40
atggagcggc ggctgcgcgc gctggagcag ctggcgcggg gcgaggccgg cggctgcccg 60
gggctcgacg gcctcctaga tctgctgctg gcgctgcacc acgagctcag cagcggcccc 120
ctacggcggg agcgcagcgt ggcgcagttc ctgagctggg ccagcccctt cgtatcaaag 180
gtgaaagaac tgcgtctgca gagagatgac tttgagatct tgaaggtgat cggccgagga 240
gcctttgggg aggtcaccgt ggtgaggcag agggacactg ggcagatttt tgccatgaaa 300
atgctgcaca agtgggagat gctgaagagg gctgagacag cctgtttccg ggaggagcgg 360
gatgtgctcg tgaaagggga cagccgttgg gtgaccactc tgcactatgc cttccaagac 420
gaggagtacc tgtaccttgt gatggactac tatgctggtg gggacctcct gacgctgctg 480
agccgcttcg aggaccgtct cccgcccgag ctggcccagt tctacctggc tgagatggtg 540
ctggccatcc actcgctgca ccagctgggt tatgtccaca gggatgtcaa gccagacaac 600
gtcctgctgg atgtgaacgg gcacattcgc ctggctgact tcggctcctg cctgcgtctc 660
aacaccaacg gcatggtgga ttcatcagtg gcagtaggga cgccggacta tatctccct 720
gagatcctgc aggccatgga ggagggcaag ggccactacg gcccacagtg tgactggtgg 780
tcgcttggag tctgcgccta tgagctgctc tttggggaga cgcccttcta tgctgagtcc 840
ttggtggaaa cctacggcaa gatcatgaac cacgaggacc acctgcagtt ccccccggac 900.

gtgcctgacg tgccagccag cgcccaagac ctgatccgcc agctgctgtg tcgccaggaa 960
gagcggctag gccgtggtgg gctggatgac ttccggaacc atcctttctt cgaaggcgtg 1020
gactgggagc ggctggcgag cagcacggcc ccctatattc ctgagctgcg ggggcccatg 1080
gacacctcca actttgatgt ggatgacgac accctcaacc atccagggac cctgccaccg 1140
ccctcccacg gggccttctc cggccatcac ctgccattcg tgggcttcac ctacacctca 1200
ggcagtcaca gtcctgagag cagctctgag gcttgggctg ccctggagcg gaagctccag 1260
tgtctggagc aggagaaggt ggagctgagc aggaagcacc aagaggccct gcacgccccc 1320
acagaccatc gggagctgga gcagctacgg aaggaagtgc agactctgcg ggacaggctg 1380
ccagagatgc tgagggacaa ggcctcattg tcccagacgg atgggccccc agctggtagc 1440
ccaggtcagg acagtgacct acggcaggag cttgaccgac ttcaccggga gctggccgag 1500
ggtcgggcag ggctgcaggc tcaggagcag gagctctgca gggcccaggg gcagcaggag 1560
gagctgcttc agaggctaca ggaggcccag gagagagagg cggccacagc tagccagacc 1620
cgggccctga gctcccagct ggaggaagcc cgggctgccc agagggagct ggaggcccag 1680
gtgtcctccc tgagccggca ggtgacgcag ctgcagggac agtgggagca acgccttgag 1740
gagtcgtccc aggccaagac catccacaca gcctctgaga ccaacgggat gggacccccc 1800
gagggtgggc ctcaggaggc ccaactgagg aaggaggtgg ccgccctgcg agagcagctg 1860
gagcaggccc acagccacag gccgagtggt aaggaggagg ctctgtgcca gctgcaggag 1920
gaaaaccgga ggctgagccg ggagcaggag cggctagaag cagagctggc ccaggagcag 1980
gagagcaagc agcggctgga gggtgagcgg cgggagacgg agagcaactg ggaggcccag 2040
ctcgccgaca tcctcagctg ggtgaatgat gagaaggtct caagaggcta cctgcaggcc 2100
ctggccacca agatggcaga ggagctggag tccttgagga acgtaggcac ccagacgctc 2160
cctgcccggc cactgaagat ggaggcctcg gccaggctgg agctgcagtc agcgctggag 2220
gccgagatcc gcgccaagca gggcctgcag gagcggctga cacaggtgca ggaggcccag 2280
ctgcaggctg agcgccgtct gcaggaggcc gagaagcaga gccaggccct gcaacaggag 2340
ctcgccatgc tgcgggagga gctgcgggcc cgagggccag tggacaccaa gccctcaaac 2400
tccctgattc ccttcctgtc cttccggagc tcagagaagg attctgccaa ggaccctggc 2460
atctcaggag aggccacaag gcatggagga gagccagatc tgaggccgga gggccgacgc 2520
agcctgcgca tgggggctgt gttccccaga gcacccactg ccaacacagc ctctacagaa 2580
ggtcttcctg ctaagggatg gggcatgggg ccctgggagg ccttgggtaa tggctgtccc 2640
cctccccggc ccggctcaca cacgctgcgc ccccggagct tcccatcccc gaccaagtgt 2700
ctccgctgca cctcgctgat gctgggcctg ggccgccagg gcctgggttg tgatgcctgc 2760
ggctactttt gtcacacaac ctgtgcccca caggccccac cctgccccgt gccccctgac 2820
ctcctccgca cagccctggg agtacacccc gaaacaggca caggcactgc ctatgagggc 2880
tttctgtcgg tgccgcggcc ctcaggtgtc cggcggggct ggcagcgcgt gtttgctgcc 2940
ctgagtgact cacgcctgct gctgtttgac gcccctgacc tgaggctcag cccgcccagt 3000
ggggccctcc tgcaggtcct agatctgagg gacccccagt tctcggctac ccctgtcctg 3060
gcctctgatg ttatccatgc ccaatccagg gacctgccac gcatctttag ggtgacaacc 3120
tcccagctgg cagtgccgcc caccacgtgc actgtgctgc tgctggcaga gagcgagggg 3180
gagcgggaac gctggctgca ggtgctgggt gagctgcagc ggctgctgct ggacgcgcgg 3240
ccaagacccc ggcccgtgta cacactcaag gaggcttacg acaacgggct gccgctgctg 3300
cctcacacgc tctgcgctgc catcctcgac caggatcgac ttgcgcttgg caccgaggag 3360
gggctctttg tcatccatct gcgcagcaac gacatcttcc aggtggggga gtgccggcgc 3420
gtgcagcagc tgaccttgag ccccagtgca ggcctgctgg tcgtgctgtg tggccgcggc 3480
cccagcgtgc gtctctttgc cctggcggag ctggagaaca tagaggtagc aggtgccaag 3540
atccccgagt ctcgaggctg ccaggtgctg gcagctggaa gcatcctgca ggcccgcacc 3600
ccggtgctct gtgtagccgt caagcgccag gtgctctgct accagctggg cccgggccct 3660
gggccctggc agcgccgcat ccgtgagctg caggcacctg ccactgtgca gagcctgggg 3720
ctgctgggag accggctatg tgtgggcgcc gccggtggct ttgcactcta cccgctgctc 3780
aacgaggctg cgccgttggc gctgggggcc ggtttggtgc ctgaggagct gccaccatcc 3840
cgcgggggcc tgggtgaggc actgggtgcc gtggagctta gcctcagcga gttcctgcta 3900
ctcttcacca ctgctggcat ctacgtggat ggcgcaggcc gcaagtctcg tggccacgag 3960
ctgttgtggc cagcagcgcc catgggctgg gggtatgcgg ccccctacct gacagtgttc 4020
agcgagaact ccatcgatgt gtttgacgtg aggagggcag aatgggtgca gaccgtgccg 4080
ctcaagaagg tgcggccccc caatccagag ggctccctgt tcctctacgg caccgagaag 4140
gtccgcctga cctacctcag gaaccagctg gcagagaagg acgagttcga catcccggac 4200
ctcaccgaca acagccggcg ccagctgttc cgcaccaaga gcaagcgccg cttctttttc 4260

```
cgcgtgtcgg aggagcagca gaagcagcag cgcagggaga tgctgaagga ccctttgtg 4320
cgctccaagc tcatctcgcc gcctaccaac ttcaaccacc tagtacacgt gggccctgcc 4380
aacgggcggc ccggcgccag ggacaagtcc ccgtcccagc ccctccgcac tgtcacccaa 4440
caggctcccg aagagaaggg ccgagttgcc cgcggctccg gcccacagcg gccccacagc 4500
ttctccgagg cgttgcggcg cccagcctcc atgggcagcg aaggcctcgg tggagacgca 4560
gaccccactg gagcagtgaa gaggaaaccc tggacatccc tgtccagcga gtctgtgtcc 4620
tgcccccagg gatcgctgag ccctgcaacc tccctaatgc aggtctcaga acggccccga 4680
agcctccccc tgtcccctga attggagagc tctccttgat gccctctgtt agggcccacc 4740
ccaatcccag ggcagaagga catgagggag caaagagctt gaggaatgcc atactccggc 4800
tggtccggga catggaaatt cggactcagg gaggacccgg gctgggcaat gactgggaga 4860
cttgcctggg ttcccaggac ttgggggtcc tgactcccag ccctcatcct gccttacccc 4920
tctgttccca gccccagcct ttctaagcca ttgggaatag aatggcccct tttgttctgg 4980
tgtccagggg tgattgtgcc aaagctctta tttccagtgc caagccccca gaggcttgta 5040
agagttggga tgagggatgg agagggactg ggtctctggg aacaggttgg aggtcttatc 5100
tgtggactgt ctgactccca gctgaggcca agatggggca tgtccccgtc tctgcttagc 5160
gtctgggtga gaaaaacagg ctgtgatcca gaagaaggga agatagagaa ggagggaaag 5220
gatgtaggcg aaggaggtga gagacaggat aggaggaagg aagtggagga ggaggtggta 5280
ggaattggaa ggaggtagaa gccgtgcaga ggaagagggg agagggacga aggaggagcg 5340
atgaagaaga ggagggagac aaaaaaaggg aag                              5373
```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/008399 A3

(51) International Patent Classification[7]: C12N 15/00, 15/54, C07K 16/40, C12N 15/63, 9/12, A61K 38/45, C12Q 1/48, 1/68

(21) International Application Number: PCT/US01/23092

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/220,038	21 July 2000 (21.07.2000)	US
60/222,112	28 July 2000 (28.07.2000)	US
60/222,831	4 August 2000 (04.08.2000)	US
60/224,729	11 August 2000 (11.08.2000)	US

(71) Applicant *(for all designated States except US)*: **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(71) Applicant and
(72) Inventor: **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **KHAN, Farrah, A.** [IN/US]; 3617 Central Road #102, Glenview, IL 60025 (US). **GURURAJAN, Rajagopal** [IN/US]; 5591 Dent Avenue, San Jose, CA 95118 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **CHAWLA, Naribder K.** [US/US]; 33 Union Square, #712, Union City, California 94587 (US). **ARVIZU, Chandra S.** [US/US]; 1706 Morocco Drive, San Jose, California 95125 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue, #1, Menlo Park, CA 94025 (US). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **TRIBOULEY, Catherine, M.** [US/US]; 1121 Tennessee Street, #5, San Francisco, CA 94107 (US). **BANDMAN, Olga** [US/US]; 366 Anna Avenue, MT. View, CA 94043 (US). **NGUYEN, Danniel, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **BURFORD, Neil** [US/US]; 105 Wildwood Circle, Durham, CT 06422 (US). **LAL, Preeti** [US/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **DING, Li** [CN/US]; 3353 Alma Street #146, Palo Alto, CA 94306 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). **RECIPON, Shirley, A.** [US/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). **KEARNEY, Liam** [IE/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **GREENWALD, Sara, R.** [US/US]; 21 Bucareli Drive, San Francisco, CA 94132 (US). **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **XU, Yuming** [US/US]; 1739 Walnut Drive, Mountain View, CA 94040 (US). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB). **GIETZEN, Kimberly, J.** [US/US]; 691 Los Huecos Drive, San Jose, CA 95123 (US). **YANG, Junming** [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). **JACKSON, Jennifer, L.** [US/US]; 1826 Rina Court, Santa Cruz, California 95062 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
28 August 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN KINASES

(57) Abstract: The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associatedd withd abberant expression of PKIN.

WO 02/008399 A3

INTERNATIONAL SEARCH REPORT

International Application No	PCT/US 01/23092

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/00 C12N15/54 C07K16/40 C12N15/63 C12N9/12
A61K38/45 C12Q1/48 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHIER P AND WATT V M: "Primary structure of a putative receptor for a ligand of the insulin family" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, 'Online! vol. 264, no. 25, 5 September 1989 (1989-09-05), pages 14605-14608, XP002154780 ISSN: 0021-9258 page 14607; figure 1 -& DATABASE EMBL 'Online! "insulin receptor-related receptor" Database accession no. p14616 XP002213066	1-19,21, 22, 24-45,65

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
11 September 2002	07.03.03

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Seroz, T

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HAENZE J ET AL: "CLONING AND SEQUENCING OF THE COMPLETE CDNA ENCODING THE HUMAN INSULIN RECEPTOR RELATED RECEPTOR" HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 31, no. 2/3, 1999, pages 77-79, XP000944669 ISSN: 0018-5043 page 77, right-hand column, last paragraph -page 78, left-hand column, paragraph 1 page 78, left-hand column, line 10-13,32-34	1-19,21, 22, 24-45,65
X	WO 00 14212 A (ACTON SUSAN ;MILLENNIUM PHARM INC (US)) 16 March 2000 (2000-03-16) page 42, line 11 -page 43, line 20 page 56, line 14-17 page 62, line 24-29 page 63, line 28 -page 91, line 16; claims 1-26; examples 1-5	1-19,21, 22, 24-45,65
X	SCHULTZ S J ET AL: "IDENTIFICATION OF 21 NOVEL HUMAN PROTEIN KINASES, INCLUDING 3 MEMBERS OF A FAMILY RELATED TO THE CELL CYCLE REGULATOR NIMA OF ASPERGILLUS NIDULANS" CELL GROWTH AND DIFFERENTIATION, THE ASSOCIATION, PHILADELPHIA, PA, US, vol. 4, 1 October 1993 (1993-10-01), pages 821-830, XP000564042 ISSN: 1044-9523 the whole document	1-19,21, 22, 24-45,65

INTERNATIONAL SEARCH REPORT

...ational application No.
PCT/US 01/23092

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. [X] Claims Nos.: 20, 23
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [X] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19(partially),21(partially),22(partially),24-44(partially),45(completely),65(completely)

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 45 (completely), 65 (completely)

Human kinase comprising SEQ ID No 1 and a polynucleotide comprising SEQ ID No 21 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

2. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 46 (completely), 66 (completely)

Human kinase comprising SEQ ID No 2 and a polynucleotide comprising SEQ ID No 22 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

3. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 47 (completely), 67 (completely)

Human kinase comprising SEQ ID No 3 and a polynucleotide comprising SEQ ID No 23 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

4. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 48 (completely), 68 (completely)

Human kinase comprising SEQ ID No 4 and a polynucleotide comprising SEQ ID No 24 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 49 (completely), 69 (completely)

Human kinase comprising SEQ ID No 5 and a polynucleotide comprising SEQ ID No 25 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

6. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 50 (completely), 70 (completely)

Human kinase comprising SEQ ID No 6 and a polynucleotide comprising SEQ ID No 26 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

7. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 51 (completely), 71 (completely)

Human kinase comprising SEQ ID No 7 and a polynucleotide comprising SEQ ID No 27 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

8. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 52 (completely), 72 (completely)

Human kinase comprising SEQ ID No 8 and a polynucleotide comprising SEQ ID No 28 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 53 (completely), 73 (completely)

Human kinase comprising SEQ ID No 9 and a polynucleotide comprising SEQ ID No 29 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

10. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 54 (completely), 74 (completely)

Human kinase comprising SEQ ID No 10 and a polynucleotide comprising SEQ ID No 30 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

11. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 55 (completely), 75 (completely)

Human kinase comprising SEQ ID No 11 and a polynucleotide comprising SEQ ID No 31 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

12. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 56 (completely), 76 (completely)

Human kinase comprising SEQ ID No 12 and a polynucleotide comprising SEQ ID No 32 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the

activity of the kinase.

13. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 57 (completely), 77 (completely)

Human kinase comprising SEQ ID No 13 and a polynucleotide comprising SEQ ID No 33 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

14. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 58 (completely), 78 (completely)

Human kinase comprising SEQ ID No 14 and a polynucleotide comprising SEQ ID No 34 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

15. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 59 (completely), 79 (completely)

Human kinase comprising SEQ ID No 15 and a polynucleotide comprising SEQ ID No 35 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

16. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 60 (completely), 80 (completely)

Human kinase comprising SEQ ID No 16 and a polynucleotide comprising SEQ ID No 36 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of

PKIN. Method for screening compounds that modulates the activity of the kinase.

17. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 61 (completely), 81 (completely)

Human kinase comprising SEQ ID No 17 and a polynucleotide comprising SEQ ID No 37 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

18. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 62 (completely), 82 (completely)

Human kinase comprising SEQ ID No 18 and a polynucleotide comprising SEQ ID No 38 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

19. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 63 (completely), 83 (completely)

Human kinase comprising SEQ ID No 19 and a polynucleotide comprising SEQ ID No 39 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

20. Claims: 1-19 (partially), 21 (partially), 22 (partially), 24-44 (partially), 64 (completely), 84 (completely)

Human kinase comprising SEQ ID No 20 and a polynucleotide comprising SEQ ID No 40 which encodes and identifies said kinase. Expression vectors, host cells, antibodies. Methods for diagnosing and treating or

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

preventing disorders associated with aberrant expression of PKIN. Method for screening compounds that modulates the activity of the kinase.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 32, 34 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound.

Although claim 18, 21, 24, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

Continuation of Box I.2

Claims Nos.: 20, 23

Present claims 20, 23 relate to a compound defined by reference to a desirable characteristic or property, namely agonist and antagonist. The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for those claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 01/23092

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0014212 A	16-03-2000	US 6183962 B	06-02-2001
		AU 5817799 A	27-03-2000
		CA 2342311 A	16-03-2000
		EP 1112354 A	04-07-2001
		JP 2002524073 T	06-08-2002
		US 6043040 A	28-03-2000
		US 6146841 A	14-11-2000
		US 6180358 B	30-01-2001
		US 6153417 A	28-11-2000
		US 6146832 A	14-11-2000
		US 6190874 B	20-02-2001
		US 6121030 A	19-09-2000
		US 6200770 B	13-03-2001
		US 2002094559 A	18-07-2002
		US 6214597 B	10-04-2001

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11					Phorbol esters/diacylglycerol binding domain proteins BL00479: H176-G198, H202-C217, L415-L427	BLIMPS_BLOCKS
					Diacylglycerol kinase catalytic domain (presumed) PF00781: K278-K283, P332-F363, R384-L398, C410-Y433, Q441-T461, N772-Y808, L848-G861, V919-Q930	BLIMPS_PFAM
					Diacylglycerol/phorbol-ester binding signature PR00008: H202-A213, H214-K226	BLIMPS_PRINTS
					KINASE PROTEIN DOMAIN PD00584: K74-K84, L386-G395, L466-L473	BLIMPS_PRODOM
					Phorbol esters/diacylglycerol binding domain: H176-C225	MOTIFS
12	7170260CD1	268	S161 S188 S255 S29 T15 Y124 Y21		Eukaryotic protein kinase domain pkinase: Y10-L265	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyrosine: G82-H162	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|P27448|58-297: K14-I256	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|I48609|55-294: K14-S255	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|Q05512|55-294: K14-S255	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|JC1446|20-261: Q11-I256	BLAST_DOMO
					Tyrosine kinase catalytic domain signature PR00109: Y124-L142	BLIMPS_PRINTS
					Protein kinases ATP-binding region signature: I16-K39	MOTIFS
13	1797506CD1	965	S234 S326 S527 S530 S607 S636 S741 S841 S879 S884 S92 T111 T143 T155 T174 T202 T215 T229 T29 T372 T619 T685 T82 T922 T932 T963 Y173	N227	Eukaryotic protein kinase domain pkinase:F559-F820,	HMMER_PFAM
					Protein kinases signatures and profile protein_kinase_tyr.prf:E652-G709	PROFILESCAN
					PROTEIN KINASE DOMAIN DM00004|Q09499|536-784: P561-A811	BLAST_DOMO
					PROTEIN KINASE DOMAIN DM00004|P32361|676-970: V564-Q732, T740-A811	BLAST_DOMO
					KINASE; THREONINE; ATP; SERINE; DM06305|Q09499|786-924: V814-Y949	BLAST_DOMO